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ABSTRACT 
INTRODUCTION: Asthma is a chronic inflammatory disorder of the airways 
punctuated by acute exacerbations.  Coagulation and fibrinolysis pathways are 
increasingly recognised in the asthmatic inflammatory milieu and markers of fibrin 
turnover represent potential asthma biomarkers targets.  A biomarker in plasma or 
urine predicting exacerbation could enable early intervention to attenuate or 
prevent exacerbation.   
STUDY DESIGN: A study in 2 parts comparing exacerbation and stable asthma was 
performed.  Part 1 compared adults with exacerbations requiring hospital 
treatment to clinical recovery.  Part 2 prospectively followed a cohort of adult 
moderate to severe asthmatics when well until exacerbation and through to clinical 
recovery.  
METHODS: Plasma was analysed by ELISA for markers of fibrin turnover alongside 
inflammatory and cellular markers, and comparison was made between 
exacerbation and recovery.  Urine was analysed by latex agglutination for 
fibrin(ogen) degradation products (FDPs).  Symptoms were recorded and a score 
was derived to distinguish asthma exacerbation from baseline and recovery states.  
Comparison was made between exacerbation and recovery using multivariate 
statistical analysis. 
KEY FINDINGS: Prospectively, the detection of FDP in urine significantly increased 
the likelihood of subsequent asthma exacerbation in the following 7-14 days 
between 4 and 6 times that of a negative urine FDP test.  FDP +7 days (OR 4.35 
(95% CI 1.12, 16.9) p=0.03), FDP +10 days (OR 5.50 (95% CI 1.38, 21.9) p=0.02), FDP 
+14 days (OR 6.07 (95% CI 1.43, 25.8) p=0.02).  Plasma D-dimer was significantly 
increased from baseline to exacerbation (median 0.07 µgFEU/ml (95% CI -0.01, 
0.15) p=0.02).  Plasma eosinophils (median 10*9/l (95% CI 0.10, 0.29) p=0.02) and 
eotaxin (median 12 pg/ml (95% CI 3, 22) p<0.001) increased significantly from 
exacerbation to recovery, and PF4 significantly increased from exacerbation to 
follow up (median 9 µg/ml (95 % CI 2, 17), p=0.002).  Positive correlations were 
observed at exacerbation between eosinophils and eotaxin (p<0.001), platelets and 
PF4 (p=0.02) and platelets and eosinophils (p=0.01).  Clinical symptoms and reliever 
use increased in the 10 days preceding exacerbation and reduced during recovery 
(p<0.001). 
CONCLUSIONS:  This is the largest study to date examining coagulation and 
fibrinolysis in acute exacerbation of asthma.  Detection of urine FDP in moderate to 
severe asthma suggests up to 6-fold increased exacerbation risk in the subsequent 
14 days.  The potential to translate these findings into a point-of-care test for use 
by patients at home warrants further study.  Positive correlations between 
eosinophils, eotaxin, platelets and platelet factor 4 (PF4) alongside increased PF4, 
eosinophils and eotaxin in plasma after a period of recovery and treatment support 
eosinophil and platelet migration into the lung during asthma exacerbation.  The 
symptom score used in this study provides a simple objective measure of asthma 
exacerbation for use in future research or clinical practice but requires prospective 
validation.  
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1.0 INTRODUCTION 
 
1.1 Asthma 
 
1.1.1 Definition 
Asthma is a chronic inflammatory disorder of the airways in which many cells and 
cellular elements play a role: in particular, mast cells, eosinophils, neutrophils, T 
lymphocytes, macrophages, epithelial cells and airway smooth muscle.  In 
susceptible individuals, this inflammation causes recurrent episodes of coughing 
(particularly at night or early in the morning), wheezing, breathlessness, and chest 
tightness.  These episodes are usually associated with widespread but variable 
airflow obstruction that is often reversible either spontaneously or with treatment 
(1). 
 
Although often thought of as one disease, asthma is really a spectrum of clinical and 
inflammatory phenotypes that affect individual asthma sufferers in dramatically 
different ways.  The severity of asthma varies greatly from mild disease that causes 
little in the way of symptoms and can be well controlled with minimal intervention, 
to severe disease causing daily debilitating symptoms and frequent life threatening 
exacerbations despite extensive therapy and polypharmacy.   
 
1.1.2 The burden of asthma 
300 million people worldwide suffer from asthma and its prevalence increases by 
50% every decade (2).  In the UK,  5.1 million people have asthma and over half (2.6 
million) suffer serious symptoms, including debilitating breathlessness, attacks so 
bad they cannot speak, fear that they may die and emergency hospital admissions 
(3).   Worldwide, 180,000 deaths each year are attributable to asthma (2).  In 2004 
the British Thoracic Society (BTS) reported 1381 deaths from asthma across the 
whole of the UK (4). 
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The financial burden of asthma is enormous and it is estimated that developed 
countries will spend between 1 and 2% of their healthcare budget treating the 
condition (2).  Not surprisingly, more severe disease consumes a larger proportion 
of the expenditure than mild disease and 80% of asthma expenditure goes on the 
20% of sufferers with more severe disease.  In the UK over £45.8 million are spent 
on emergency hospital admissions for asthma and for every 2 people admitted to 
hospital, 5 more are treated in the Emergency Department.  Asthma that is difficult 
to control costs the National Health Service (NHS) £680 million every year, and 
results in 18 million lost working days to the UK economy (3). 
 
1.1.3 Asthma exacerbation 
The term asthma exacerbation is commonly used, yet poorly defined.  International 
guidelines refer to a progressive increase in shortness of breath, cough, wheezing, 
or chest tightness, or some combination of these symptoms.  They are further 
characterised by decreases in expiratory airflow measured by spirometry or peak 
expiratory flow rate (PEFR) (1, 5).  The Global Initiative for Asthma (GINA) guideline 
(5) also refers to a requirement for symptoms sufficient to require a change in 
treatment.  BTS (4), GINA (5) and National Heart Lung and Blood Institute (NHLBI) 
(1) guidelines all give definitions of exacerbation severity based on physiological 
parameters such as PEFR, heart rate, oxygen saturation, arterial partial pressure of 
carbon dioxide (PaCO2), in combination with clinical parameters such as the ability 
to complete a sentence, auscultatory findings and clinical exhaustion.  However, 
these definitions are applicable to an established exacerbation, which we can see 
from the above definition is somewhat nebulous. 
 
Historically from a research perspective, the definition of an exacerbation has 
varied greatly from one study to the next.  The American Thoracic Society (ATS) and 
European Respiratory Society (ERS) recently jointly set up a task force to agree 
definitions for different aspects of asthma which included exacerbation (6).  They 
define a severe exacerbation as events that require urgent action on the part of the 
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patient and physician to prevent a serious outcome such as hospitalisation or death 
from asthma.  Furthermore, a severe exacerbation should include at least 3 days of 
oral corticosteroid use. 
 
For an asthma patient, an exacerbation may range from a mild increase in 
symptoms, to a life threatening episode of breathlessness.  Unsurprisingly, 
exacerbations are one of the most frightening and dangerous aspects of asthma 
and sufferers fear for their lives.  In a recent publication by Asthma UK, patients 
describe asthma as “living with a time bomb”, and exacerbations as “like I’m going 
to die”.  One father explained “I simply had no idea asthma could be that serious, 
not until the day my daughter died in my arms” (3). 
 
Taking both clinical guidelines and research definitions into account, whether an 
asthma exacerbation has occurred remains subjective on the part of both patient 
with respect to symptoms, and clinician with respect to whether treatment is 
warranted.  Although quantifiable parameters such as PEFR or forced expiratory 
volume in 1 second (FEV1) are more objective, in the absence of symptoms, 
worsening airflow alone does not mean an exacerbation is occurring.  The use of 
percentage change in PEFR from baseline as a marker of exacerbation has been 
comprehensively reviewed by the ATS/ERS task force and is not currently 
recommended as a marker of severe exacerbation (6). 
 
1.1.4 Recovery from exacerbation 
Although attempts have been made to define an exacerbation, neither clinical nor 
research guidelines define subsequent recovery from an exacerbation.  As 
recognised by the ATS/ERS task force, exacerbations are identified as events 
characterised by a change from the patient’s previous status, a concept that should 
be applied in clinical trials (6).  BTS guidance describes the key event in recovery 
with respect to criteria and timing for hospital discharge, as being improved 
symptoms and PEFR rather than a complete return to normality (4). 
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Although there is a paucity of guidance in this area, the inference from these 
statements is that recovery from exacerbation is a return to the patient’s previous 
status of “normality”.  This does not take into account previous asthma control, 
which may be poor, rather recovery is a return to the patient’s pre-exacerbation 
state. 
 
1.1.5 Asthma control  
From a clinical perspective it is useful to think of asthma control and exacerbation 
as separate entities, accepting that poor asthma control is likely to result in more 
frequent exacerbation. 
 
Good asthma control may require significant medications to maintain, and may not 
be achieved in every case.  GINA determines asthma control using the following 
criteria (5): 
 
 Asthma symptoms 
 Limitations of activities 
 Nocturnal symptoms/awakening 
 Need for reliever/rescue medication 
 Exacerbations 
 Lung function (PEFR or FEV1) 
 
GINA defines controlled asthma as having normal lung function with none of the 
other criteria above. 
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1.1.6 Classification of asthma 
The classification of asthma has been the subject of much debate in the past.  A 
variety of terms are in use and although they help to define certain disease 
characteristics, they are not always helpful in disease management.  “Atopic 
asthma” for example, may be useful to describe an individual who demonstrates 
sensitisation to common aeroallergens, however allergen avoidance may have no 
impact on their disease and may not be practical.  Asthma is often termed 
“difficult” or “difficult-to-control” but this definition has no agreed parameters.   
 
With regard to asthma severity, the ATS/ERS task force (6) agreed to classify asthma 
in terms of the difficulty of controlling symptoms, i.e. how much treatment is 
required, or not controlled despite significant treatment.  Although not explicitly 
stated in the past, this has been implied for a number of years from treatment 
guidance in American and British asthma guidelines.  GINA guidance now adopts a 
similar approach but their previous classification based on symptoms prior to 
treatment is still recognised as having a potential role for research purposes (7). 
 
The BTS and Scottish Intercollegiate Guidelines Network (SIGN) asthma guidelines 
(4) have, for a number of years, recommended a stepwise approach to therapy 
[Figure 1], adding or subtracting medication to achieve asthma control. 
 
A similar approach is recognised by the latest GINA and NHLBI guidelines (1, 5), 
albeit with minor differences in inhaled steroid dose brackets and the order in 
which drugs are stepped in.  A further criteria was published in 2000 by the ATS 
defining severe refractory asthma by a combination of treatment required to 
achieve control and criteria similar to those used by the 2008 GINA guidelines, 
however this criteria is not commonly used in clinical practice (8). 
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Figure 1 - BTS stepwise management of asthma in adults 
Adapted from BTS asthma guideline 2011 – summary of stepwise management in 
adults 
Step 1  
Mild intermittent asthma 
Inhaled short-acting beta2 agonist (SABA) as required 
Step 2  
Regular preventer therapy 
Add inhaled corticosteroid (ICS) 200-800mcg/day 
 400mcg/day is an appropriate starting dose for many 
patients 
 Start at dose of ICS appropriate to severity of disease 
Step 3 
Initial add-on therapy 
1. Add inhaled long-acting beta2 agonist (LABA) 
2. Assess control of asthma: 
 Good response to LABA – continue LABA 
 Benefit from LABA but control still inadequate – continue 
LABA and increase ICS to 800mcg/day 
 No response to LABA – stop LABA and increase ICS to 
800mcg/day. If control still inadequate, institute 
leukotriene receptor antagonist (LTRA) or slow-release (SR) 
theophylline 
Step 4 
Persistent poor control 
Consider trials of: 
 Increasing ICS up to 2000mcg/day 
 Addition of a 4
th
 agent – e.g. LTRA, SR theophylline, β2 
agonist tablet 
Step 5 
Continuous or frequent 
use of oral steroids 
Use daily steroid tablet: 
 In lowest dose providing adequate control 
 Maintain high dose ICS at 2000mcg/day 
 Consider other treatments to minimise the use of steroid 
tablets 
 Refer patient to specialist care 
Note all doses refer to BDP (beclomethasone dipropionate) or equivalent – see appendix 1 
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1.1.7 Brittle asthma 
There is a subset of patients who are said to have “brittle” asthma due to the 
rapidity of deterioration when exacerbation occurs.  Type I brittle asthma is 
determined by persistent diurnal variation of airflow limitation of >40% for >50% of 
the time over a period of 150 days despite multiple drug therapies, i.e. poor control 
measured by airway hyperresponsiveness despite treatment.  Patients with type II 
brittle asthma are usually well controlled but once exacerbation occurs, deteriorate 
rapidly and very severely (9).  It is important to highlight that while such subtypes 
are described, they rarely occur as an isolated clinical phenomenon and do not 
always align with recognised inflammatory phenotypes. 
 
1.2 Asthma pathophysiology 
Here is described the pathology and key inflammatory events in asthma, in order to 
discuss how they may be implicated in the coagulation cascade, which forms the 
basis of the hypothesis tested in this thesis.  
 
1.2.1 Asthma development and onset 
Asthma is long established as an inflammatory disorder, particularly characterised 
by a type II T helper lymphocyte (Th2) inflammatory profile.  However, not all atopic 
individuals develop asthma and asthma occurs in the absence of atopy.  Other 
factors must therefore be present for asthma to occur.  A family history of asthma 
is recognised as a risk for disease development (10) however, numerous candidates 
exist for asthma susceptibility genes (e.g. ADAM 33) and their roles and complex 
interactions remain incompletely understood (11).  The observation that basement 
membrane thickening is present in the airways of asthmatic children in the absence 
of prolonged inflammation (12) has opened the possibility that existing structural 
alterations may precede and even be a prerequisite for the inflammatory response.  
This model proposes the “soil” of structural abnormality enabling the “seed” of 
airway injury to result in chronic inflammation and subsequent remodelling (13).  
Basement membrane thickening occurs in children in the absence of inflammation 
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and before clinical onset of asthma.  Furthermore, this airway remodelling does not 
occur with childhood wheeze alone (14). 
 
1.2.2 Epithelial fragility 
The bronchial epithelium forms a protective barrier against inhaled agents.  In 
asthma the epithelium demonstrates increased fragility (15), possibly by reduced 
desmosomal contact in this group (16, 17).  Once columnar epithelium is denuded, 
basal cells rapidly flatten and spread to cover the basement membrane, 
accompanied by plasma exudation that results in a gel-like network of fibrin and 
plasma as well an inflammatory cell infiltration (18).   The normal epithelial barrier 
is rapidly reformed by migration and proliferation of existing epithelial cells which 
then undergo apoptosis to restore cell numbers and proportion of cell types (19). 
 
1.2.3 Epithelial injury 
There is an exaggerated epithelial inflammatory response to insult in asthma 
resulting from a range of stimuli including allergens and viruses.  Once sensitised to 
an allergen, the production of specific immunoglobulin E (IgE) enhances the 
inflammatory response to subsequent exposure through mast cell degranulation 
(20).  In the case of viral pathogens, asthmatic airway epithelium not only produces 
inflammatory cytokines but undergoes apoptosis as a defence mechanism to 
reduce virus replication in infected cells (21).  Recurrent epithelial damage resulting 
from these multiple hits induces a state of chronic inflammation in the asthmatic 
airway (22). 
 
1.2.4 Airway remodelling 
As described above, structural airway abnormalities in the form of thickened 
basement membrane occur in asthma but not wheezy bronchitis in children (14).  
Recurrent inflammatory insults and the chronic inflammatory state that ensues, 
result in a process of airway remodelling.  This consists of thickening of the 
basement membrane, smooth muscle hypertrophy and hyperplasia, and vascular 
proliferation.  However, this is not explained entirely by inflammation as 
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demonstrated by progressive airway remodelling in more severe asthma despite 
high-dose corticosteroids.  In fact, airway remodelling may be a protective measure 
as individuals with more extensive remodelling, display less bronchial 
hyperreactivity (13). 
 
The epithelial mesenchymal trophic unit (EMTU) is a term used to describe the 
interaction of the epithelium with underlying mesenchymal tissue.  This 
communication is observed in embryology during lung development (23), it is 
proposed that reactivation of the EMTU occurs in asthma and mediates airway 
remodelling (14).  Injury to the asthmatic epithelium results in release of pro-
fibrogenic growth factors including fibroblast growth factor (FGF)-2, insulin-like 
growth factor (IGF)-1, platelet-derived growth factor (PDGF) and transforming 
growth factor β (TGF-β) 2 (13).  In response to profibrogenic stimuli, subepithelial 
fibroblasts undergo transformation to a myofibroblast phenotype with resulting 
alterations in extracellular matrix deposition and airway remodelling (24).   
 
1.2.5 Inflammatory phenotypes 
Increasingly, there is recognition that the heterogeneity of asthma is, in part, due to 
differences in inflammatory phenotype.  The use of bronchoalveolar lavage, 
bronchial biopsy and sputum induction enables examination of the cellular 
inflammation within the airway lumen.  Four cellular phenotypes are now 
recognised; eosinophilic, neutrophilic, paucicellular and mixed (25).  Sputum 
induction has certain advantages over bronchoscopic evaluation in that it is less 
invasive, requires less personnel and equipment, and repeat examination can be 
performed with relative ease enabling comparison after intervention. 
 
Looking solely at airway luminal inflammation has its limitations e.g. mast cells in 
asthma are usually located in the airway smooth muscle, mucous glands and 
epithelium (26) but not readily found in the airway lumen.  Nonetheless, 
relationships between inflammatory and clinical phenotypes are recognised and 
useful in practice (27). 
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1.2.6 Eosinophils 
Eosinophils derive from CD34+ bone marrow precursors in response to Th2 
cytokines including GM-CSF (granulocyte macrophage colony stimulating factor), 
interleukin (IL)-3 and IL-5.  IL-5 and eotaxin have chemoattractant effects on 
eosinophils and IL-4 and IL-13 generated in target organs increase eosinophil 
adhesiveness (28).  Eosinophils have numerous roles including antigen 
presentation, regulation of T cell function and granulocytes, and storage of 
numerous preformed cytokines (29, 30).  Eosinophils are also a source of TGF-β and 
may play a role in airway remodelling (31). 
 
Much of the recent focus on eosinophils stems from studies demonstrating 
successful outcomes from intervention to reduce eosinophilia.  Green and 
colleagues (32) studied the use of sputum eosinophilia to guide corticosteroid 
therapy compared with standard guideline treatment.  They demonstrated that by 
increasing steroids and reducing eosinophilia there was a reduction in asthma 
exacerbations and hospital admissions compared with standard treatment.  
Moreover, no adverse outcomes were observed when steroids were reduced in the 
absence of eosinophilia. 
 
Steroids, however, affect not only eosinophils and initial studies of the anti-IL-5 
monoclonal antibody mepolizumab showed a lack of significant clinical outcomes 
despite reducing eosinophils (33, 34).  More recent studies have demonstrated 
positive outcomes using mepolizumab.  In subjects with persistent eosinophilia 
despite corticosteroids, eosinophils were significantly reduced, as were 
exacerbation rates (35, 36).  These observations demonstrate that the eosinophil is 
an important player in the inflammatory milieu, but to be effective, treatments 
must also affect other aspects of the inflammatory process.  
 
1.2.7 Neutrophils 
The role of the neutrophil in asthma is less clear.  A neutrophil predominance in 
asthmatic airways is associated with steroid resistance (37), and is observed in 
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acute and chronic infection, smoking, obesity and with exposure to occupational 
antigens, endotoxin exposure and environmental pollutants (38).  There is some 
evidence that macrolides may be of benefit in this group via an anti-inflammatory 
mechanism that is independent of their antibiotic effect (39). 
 
1.2.8 Inflammatory cytokines 
The balance of inflammatory and inhibitory cytokines determines the cell types 
present in the airways and therefore certain characteristics of an individual’s 
disease.  Th2 cytokine predominance promotes IgE production (IL-4), eosinophil 
maturation and survival (IL-5) and airway hyper-responsiveness (AHR) (IL-13) (40).  
Viral infection is thought to be the trigger for asthma exacerbation in around 70% 
of cases (41) and is associated with increased IL-8 (a neutrophil chemoattractant), 
RANTES (regulation on activation normal T-cell expressed) (a T-cell 
chemoattractant) and pro-inflammatory cytokines such as TNFα (tumour necrosis 
factor) (21, 42).  Inhibitory cytokines such as IL-12 suppress Th2 responses and may 
shift the balance in favour of the Th1/neutrophilic inflammation associated with 
steroid-resistant refractory asthma (43).  There is also emerging evidence to 
support a role for Th17 cells and their cytokines including IL-17a in severe steroid-
resistant asthma, a T cell bias mediated via IL-6 (40). 
 
1.2.9 Immunoglobulin E (IgE) 
IgE mediates allergic reactions and sensitisation to allergens with the development 
of specific IgE to aeroallergens such as pollen, hastens this effect.  IgE attaches to 
cell surfaces via high-affinity receptors on mast cells, basophils, dendritic cells and 
lymphocytes.  Exposure to specific allergen induces crosslinking of IgE on the cell 
surface and degranulation results in the release of inflammatory cytokines that 
perpetuate inflammation and induce bronchospasm (44).  Targeted therapy with 
monoclonal antibodies against IgE (omalizumab) has been shown to be effective in 
reducing exacerbations and corticosteroid requirements (45). 
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1.2.10 Exhaled nitric oxide 
Nitric oxide (NO) has vasodilator, bronchodilator, neurotransmitter and 
inflammatory mediator roles and is detectable at high levels in exhaled breath in 
asthma (46).  The fractional exhaled nitric oxide (FeNO) is considered as a surrogate 
marker of eosinophilic airway inflammation (47).  Although studies examining 
clinical outcomes based on treatment in response to serial FeNO measurements 
have so far been disappointing (48), it is considered a useful and non-invasive 
measure in the management of asthma.  Recent ATS guidance on the use of FeNO 
recommends it is used in the diagnosis of eosinophilic airway inflammation, 
determination of steroid-responsiveness and in support of an asthma diagnosis 
where objective evidence is required (49).  The National Institute of Health and 
Care Excellence have also recently approved it for diagnosis and treatment of 
asthma (50). 
 
1.2.11 Mechanical stimulation 
Epithelial damage results not only from inflammatory insult but also mechanical 
stimulation as occurs during bronchospasm.  Communication between the 
epithelium and extra cellular matrix (ECM) occurs under such circumstances as 
demonstrated in experimental models (51, 52), and impaired wound repair has also 
been demonstrated (53).  Recent biopsy studies have demonstrated that this also 
occurs in vivo in the absence of an inflammatory stimulus to bronchoconstriction 
(54). 
 
1.2.12 Plasma exudation 
The airway mucosa encompasses an extensive microvascular network which is 
highly responsive to inflammatory vasopermeability agents including histamine, 
bradykinins, leukotrienes, platelet-activating factor (PAF), eosinophilic cationic 
protein (ECP), tryptase and TNFα (55).  In response to such stimuli, gaps appear 
between endothelial cells of venules allowing plasma exudation into the lamina 
propria (56).  Under normal conditions, a minor baseline transfer of plasma occurs 
that selectively favours smaller proteins, however, under exudative conditions 
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plasma is transferred in bulk with no filtration of plasma.  Furthermore, the bulk 
plasma proceeds across the epithelium into the airway lumen without significant 
filtration.  In plasma, the ratio of albumin (60kDa) to α2-macroglobulin (700kDA) is 
20:1, in resting nasal lavage this ratio is 40:1 indicating retention of larger proteins 
within the plasma. Under exudative conditions the albumin (60kDa) to α2-
macroglobulin (700kDA) ratio in nasal lavage is equal to that of plasma (20:1) 
demonstrating the passage of unfiltered plasma into the lamina propria and across 
the respiratory epithelium (57). 
 
It is important to highlight that although plasma exudation occurs in response to 
inflammatory stimuli, the passage of bulk plasma into the airway lumen occurs 
across an intact epithelium.  Plasma proteins pass between the epithelial cell-cell 
junctions onto the luminal surface in response to elevated pressure in the lamina 
propria and the resulting transepithelial pressure gradient (58).  This transepithelial 
passage is unidirectional and mucosal permeability is not affected under these 
conditions (57). 
 
This exudation of plasma into the airway lumen is thought to transport cytokines, 
immunoglobulins and plasma proteins, including coagulation factors. 
 
1.2.13 Matrix metalloproteinases 
The matrix metalloproteinase (MMP) family are a group of enzymes involved in 
extracellular matrix remodelling, cellular migration and are implicated in lung 
epithelial repair mechanisms (59).  In the asthmatic airway, MMPs are thought to 
be involved in airway remodelling but may have differing roles.  MMP-2 and MMP-3 
have been implicated as promoters of airway remodelling (60), whereas MMP-9 
may have a protective effect (61).  Suppression of MMP-9 activity by plasminogen 
activator inhibitor-1 (PAI-1) is associated with increased ECM deposition (62). 
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1.2.14 Glycosaminoglycans 
The glycosaminoglycans (GAGs) are a family of carbohydrates that include 
anticoagulants such as heparin and the naturally-occurring heparan sulphate, and 
extracellular matrix components such as hyaluronan.  Fibroblasts in the asthmatic 
airway produce increased hyaluronan, implicating this protein in asthmatic airway 
remodelling (63).  Heparin, usually considered an anticoagulant is known to possess 
anti-inflammatory properties, possibly mediated via the coagulation cascade.  
Furthermore, it is highly sulphated and therefore highly negatively charged allowing 
it to bind to a wide range of biological materials.  These include TGF-β, ECP, 
cytokines and chemokines, and heparin binding can inhibit many of these factors 
(64).  Endogenous heparin levels are low in asthma implying these anti-
inflammatory properties are absent in asthma (65).  However, in a murine model of 
airway inflammation, defective production of heparan sulphate resulted in reduced 
airway inflammation, possibly via reduced eosinophil migration, implying a dual role 
for these proteins (66). 
 
1.2.15 Transforming growth factor beta-1 and vascular endothelial growth factor 
Transforming growth factor beta-1 (TGF-β1) is one isoform of the TGF-β superfamily 
of profibrotic cytokines.  It is expressed by bronchial epithelium in the lung and 
from the majority of inflammatory cells involved in the asthmatic response 
including eosinophils (67).  TGF-β1 promotes airway remodelling in asthma, 
probably via epithelial mesenchymal transition (EMT), an embryonic developmental 
process reactivated in wound healing and repair (68, 69).  The observation that 
there is a positive correlation with plasma levels of TGF-β1 and uncontrolled 
asthma suggests it may be a marker of asthma control (70).  Furthermore, TGF-β1 
stimulates lung fibroblasts to produce vascular endothelial growth factor (VEGF) 
(71).   
 
VEGF has effects on angiogenesis, vascular permeability, leukocyte migration and 
proliferation of smooth muscle and endothelial cells (72).  With this in mind, it is 
perhaps unsurprising that elevated sputum (73), serum and plasma levels of VEGF 
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are observed in stable asthma when compared with healthy controls, and that 
these levels rise during exacerbation (74). 
 
1.3 Therapeutic goals 
It is clear that reducing asthma symptoms and exacerbations would be beneficial to 
patients by improving quality of life and reducing morbidity and mortality.  
Furthermore, there are significant societal gains to be made in terms of direct and 
indirect financial cost.  The translation of cellular and inflammatory phenotype into 
personalised titration of corticosteroids or, monoclonal antibody therapy, is a 
significant step towards achieving these gains from the historical perspective of 
blind steroid prescribing supported by beta agonists.  There are, however, still a 
significant number of individuals who continue to suffer unpredictable and life-
threatening exacerbations despite these interventions. 
 
By definition asthma symptoms and airflow limitation are variable and there must 
be sufficient increase in symptoms or decrease in markers such as PEFR for patients 
to seek medical help or commence treatment as per self-management plans.  
Tattersfield and colleagues (75)  investigated acute asthma exacerbation and 
observed that five days prior to commencing treatment for exacerbation when 
symptoms peak and PEFR levels trough, patients experience a gradual increase in 
symptoms accompanied by a gradual decline in PEFR which accelerates over these 
five days.  This phenomenon has been utilised by treatment strategies such as 
Symbicort SMART (symbicort maintenance and reliever therapy) whereby the use 
of ICS combined with a LABA as preventer and reliever can reduce the frequency 
and severity of exacerbation (76, 77).  However, for those with more severe and 
brittle disease, once the symptoms of an exacerbation have begun it is too late to 
prevent an exacerbation.   
 
The detection of inflammatory changes occurring pre-exacerbation could enable 
intervention in even the most severe asthmatic with the goal of moderating or even 
preventing exacerbation. Existing inflammatory indices such as sputum eosinophilia 
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are not practical for the frequent, possibly daily monitoring that would be required, 
whereas modification of a marker such as FeNO that might be practical has not 
been shown to affect exacerbations. 
 
A biomarker is a characteristic that is objectively measured and evaluated as an 
indicator of normal biological processes, pathogenic processes or pharmacological 
responses to a therapeutic intervention.  In clinical terms this is a laboratory 
measurement or physical sign used as a surrogate marker of clinical meaningful 
outcome (78).  A successful biomarker requires sufficient sensitivity, specificity, 
positive predictive value and negative predictive value to identify a predetermined 
clinical state in the absence of established diagnostic criteria with sufficient 
accuracy to delineate presence and absence of that clinical state (79).  Applying this 
to asthma exacerbation, an effective biomarker would need to predict an 
exacerbation of asthma prior to development of clinical signs or symptoms with 
sufficient accuracy to justify intervention and its inherent complications balanced 
against the risks of exacerbation occurring. 
 
A suitable biomarker of asthma exacerbation that is safe, easily measured, cost 
effective and enables successful intervention and outcomes is yet to be found.  
Testing such a biomarker would need to be possible by patients themselves, similar 
to a capillary blood glucose monitor for diabetes, or a urinary pregnancy test.  In 
line with the changes in lung function observed by Tattersfield and colleagues 5 
days before an exacerbation (75), Brims et al observed a dramatic increase in 
coagulation markers in the sputum of an asthmatic displaying no signs or 
symptoms, who five days later suffered an exacerbation of his asthma (80).  The 
coagulation cascade is therefore a promising target for such a biomarker and is 
discussed in detail below. 
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1.4 Haemostasis 
In order to understand the roles of fibrinogenesis and fibrinolysis in the lung one 
must first understand coagulation in the more familiar setting of haemostasis. 
 
Haemostasis describes several processes which occur in response to endothelial 
injury resulting in the formation of a clot that temporarily plugs the area of damage, 
allowing repair and restoration of the endothelium.  Once the endothelial barrier is 
restored, the clot is removed by fibrinolysis restoring vessel patency and integrity.  
In reality haemostatic and fibrinolytic mechanisms occur simultaneously and it is 
the balance of clotting factors that determines which is the dominant process at 
any particular time.  For the purposes of understanding it is useful to separate each 
process before looking at the complex interactions that continuously occur 
between them. 
 
1.4.1 Platelets 
The first response to endothelial damage is platelet adhesion to exposed 
extracellular matrix at the site of injury, followed by platelet aggregation and 
subsequent activation.  Activated platelets release the contents of cytoplasmic 
alpha granules which include coagulation factors, cytokines, chemokines, growth 
factors involved in the inflammatory response and platelet factor 4 (PF4) (81).  
Furthermore, the platelet surface acts as a platform for certain coagulation factors 
to bind in a configuration that optimises their enzymatic action (82) as described 
below.   
 
1.4.2 Coagulation 
The process of coagulation, or fibrinogenesis, is an enzymatic cascade that results in 
the generation of a stable cross-linked fibrin clot.  It encompasses the intrinsic and 
extrinsic cascades and final common pathway.  The term extrinsic arises because 
tissue factor (TF), the initiator of this pathway is not expressed on cells exposed to 
circulating blood, whereas the intrinsic cascade consists entirely of factors within 
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the circulation.  This division is far less straightforward in reality as will be seen, but 
is nevertheless useful in describing and understanding fibrinogenesis (see Figure 2). 
 
 
1.4.3 The extrinsic pathway 
TF is not present on vascular endothelium, but is widely expressed on extravascular 
cell surfaces.  TF is expressed in a pattern that envelopes the vascular tree, 
however, the density of expression is variable and represents a response to the 
differential importance of bleeding in different anatomical sites (83).  Endothelial 
damage exposes extravascular TF which binds with circulating activated factor VII 
(FVIIa).  FVII is activated by proteolytic cleavage by TF dependence or downstream 
serine protease inhibitors (serpins) including FXa, FIXa, FXIa, FXIIa, thrombin and 
plasmin (84).  The TF-FVIIa complex cleaves factor X (FX) and is known as the 
extrinsic “tenase” (Xase).  The resulting FXa is the beginning of the common 
pathway and in turn activates prothrombin by further enzymatic cleavage to form 
thrombin.   
 
1.4.4 The intrinsic pathway 
The intrinsic pathway begins with factor XII (FXII) which undergoes autoactivation 
when exposed to the anionic surface of ECM.  FXIIa formation leads to prekallikrein 
(PK) activation in the presence of high molecular weight kininogens (HK) and it is 
this interaction that gives rise to the pseudonym “contact pathway” (85).  
Importantly this provides an alternative activator of coagulation and hence 
complimentary mechanisms of action.  FXIIa in turn cleaves FXI, FXIa in the 
presence of Ca2+ activates FIX which combines with its co-factor FVIIIa to form the 
FIXa-FVIIIa complex known as the intrinsic Xase, which in turn activates FX to FXa 
beginning the final common pathway (86). 
 
1.4.5 The final common pathway 
Both the extrinsic and intrinsic pathways result in the production of FXa, then 
follows the final common pathway.  FXa binds with its co-factor factor Va and the 
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resultant FXa-FVa complex, also known as the pro-thrombinase complex, more 
effectively cleaves prothrombin to thrombin.  Following this model, thrombin now 
cleaves fibrinogen forming fibrin monomers which are then crosslinked by activated 
factor XIII (FXIIIa) producing the final product, a stable polymerised fibrin clot (86). 
 
1.4.6 Fibrinogenesis in vivo 
This division into extrinsic, intrinsic and common is useful for understanding 
coagulation in vitro and is the basis of the laboratory tests for Prothrombin Time 
(PT; tests extrinsic and common) and Activated Partial Thromboplastin Time (APTT; 
tests intrinsic and common).  However, in vivo, the extrinsic Xase is only capable of 
producing a small amount of thrombin which is not sufficient to cleave enough 
fibrinogen to form a fibrin clot.  This thrombin acts as a primer which in turn can 
directly activate FXI without the need for FXII (87).  The primer also activates FV and 
FVIII, without which the intrinsic pathway could not progress, and FXIII which 
completes fibrinogenesis by crosslinking fibrin monomers (86).   It is the intrinsic 
pathway that produces thrombin in sufficient quantity to cleave enough fibrinogen 
to form a fibrin clot.  To do this, it utilises the phospholipid surface of platelets as a 
platform to assemble and align the intrinsic Xase and prothrombinase complexes so 
as to maximise their enzymatic capabilities.  Although the extrinsic pathway via TF is 
the main initiator of coagulation, it is the intrinsic pathway that has the greatest 
influence on clot propagation (88).  
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1.4.7 Control and termination of coagulation 
Coagulation is a rapid process that requires regulation to prevent disseminated 
thrombus formation and damage to the vascular system.  Various mechanisms 
contribute to the control of fibrinogenesis including the dilution of procoagulants in 
flowing blood, removal of activated factors by the reticuloendothelial system and 
the control of activated procoagulants and platelets by antithrombotic pathways.  
Antithrombotic pathways are anchored to vascular endothelial cells ensuring clot 
propagation is limited to areas of damaged endothelium. 
 
1.4.8 Antithrombin (AT) 
Antithrombin (AT) or antithrombin III is a serpin that circulates in plasma.  It 
neutralises thrombin, FXa, FIXa, FVIIa-TF, FXIIa and FXIa by binding with them to 
form irreversible complexes.  It has 2 functional sites, the reactive centre and a 
heparin binding site.  The inactivation rate of AT is increased up to 10,000 fold by 
binding to heparins (86).  Furthermore, heparan sulphate, a glycosaminoglycan 
found on endothelial surfaces, can also bind activated AT producing an endothelial 
surface coated in AT which mops up excess circulating coagulation factors (89). 
 
1.4.9 Activated protein C (APC), protein S and thrombomodulin 
Thrombomodulin is a transmembrane protein synthesised by and localised to 
endothelial cells that binds and inactivates thrombin.  The thrombin-
thrombomodulin complex activates protein C, then APC with its cofactor protein S 
inactivates FVa and FVIIa, and hence the intrinsic and extrinsic Xase complexes 
respectively.  Protein S circulates in its free form or bound to C4b binding protein.  
In its free form it is a naturally occurring anticoagulant but is inactivated when 
bound to C4b (90).  In the setting of inflammation, C4b is an acute phase reactant 
resulting in a reduction of free protein S, which may in part explain the pro-
thrombotic nature of inflammatory states. 
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1.4.10 Tissue factor pathway inhibitor (TFPI) 
TFPI is synthesised by endothelial cells.  90% of circulating TFPI is bound to low-
density lipoproteins.  TFPI directly inhibits FXa in a slow reaction then forms a 
complex with FXa and inhibits the TF-FVIIa complex.  TFPI is the principal regulator 
of the initiation phase of thrombin generation (86).  One of the effects of heparin is 
to release endothelium-bound TFPI into the circulation. 
 
1.4.11 Fibrinolysis 
Once endothelial repair is complete, the fibrin clot formed through coagulation is 
no longer required and must be removed to restore vessel patency and vascular 
function.  Clot removal occurs through the process of fibrinolysis.  Although 
described as discrete phenomena, fibrinogenesis and fibrinolysis occur 
simultaneously and regulate each other through inhibitory feedback.  The 
fluctuation of fibrinolytic versus fibrinogenic factors and their inhibitory proteases 
determines which cascade dominates at any point in this process. 
 
Fibrinolysis begins with the cleavage of plasminogen to plasmin by plasminogen 
activators.  There are 2 types of plasminogen activator, tissue-type plasminogen 
activator (tPA) and urokinase-type plasminogen activator (uPA), the latter named 
for its abundance in urine (86).  tPA has its main role in dispersing thrombus within 
the circulation whereas uPA has a more extravascular inflammatory role.   
 
The activity of both tPA and uPA on plasminogen is relatively poor until fibrin is 
present when enzymatic activity is enhanced.  Both tPA and plasminogen are 
adsorbed onto the surface of fibrin clot localising the production of plasmin to the 
site of clot and protecting it from inhibition by circulating α2-antiplasmin.  α2-
antiplasmin inactivates plasmin by irreversibly binding with it to form an inactive 
complex and in the circulation, rapidly mops up free plasmin.  Within a clot, FXIIIa 
not only stabilises fibrin monomers but also incorporates α2-antiplasmin into the 
clot structure.  α2-antiplasmin not only binds plasmin at the site of thrombus, but 
competes with plasminogen for binding sites on fibrin.  However, plasminogen 
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concentration exceeds that of α2-antithrombin therefore depletion will occur if 
plasmin continues to be generated and fibrinolysis will eventually occur (86). 
 
1.4.12 Plasminogen activator inhibitor-1 (PAI-1) 
PAI-1 is the primary physiologic inhibitor of plasminogen activation in blood, 
targeting uPA and tPA.  The major fraction of PAI-1 present in blood is from 
platelets where it is stored in α granules, but it is also synthesised in endothelial 
cells, smooth muscle cells and macrophages.  Alongside its role as inhibitor of 
plasminogen activators, PAI-1 has a regulatory role for cell adhesion and migration 
(86). 
 
1.4.13 Thrombin-activatable fibrinolysis inhibitor (TAFI) 
TAFI circulates in the blood in complex with plasminogen and is activated by the 
thrombin-thrombomodulin complex.  It cleaves plasminogen binding sites on fibrin 
clot thus reducing the efficacy of clot lysis by plasmin (86). 
 
1.4.14 Fibrin(ogen) degradation products (FDPs) 
A fibrinogen molecule is composed of 3 pairs of protein chains, (α, β and γ) in a 
dimeric structure bound via the γ chains.  Thrombin cleaves a segment from each α 
and β chain resulting in the formation of fibrinopeptide A (FPA) and B (FPB) 
respectively.  Thrombin cleavage of each fibrinogen molecule forms two FPAs, two 
FPBs and one fibrin monomer [see figure 3a].   Although adjacent fibrin monomers 
will polymerise to form a fibrin clot, the monomeric structure is less stable, and 
vulnerable to enzymatic breakdown by fibrinolysis.  Crosslinking of adjacent D 
domains by FXIIIa increases structural integrity and reduces vulnerability to 
premature proteolysis (86) [see figure 3b]. 
 
When present in sufficient concentrations, plasmin can cleave polymerised fibrin, 
however, the crosslinked D domains remain joined and the adjacent E domains are 
cleaved [see figure 3b].  The resulting fibrin degradation products are one E 
fragment and one D-dimer.  Plasmin can also degrade fibrinogen, and cleavage 
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occurs in an asymmetrical manner resulting in the formation of two D fragments 
and one E fragment, or intermediate breakdown products known as fragments X 
and Y (91). 
 
The only unique fibrin degradation product is the D-dimer, as individual D domains 
and E domains may be the result of fibrin or fibrinogen breakdown.  The presence 
of FPA and FPB indicate fibrinogen cleavage by thrombin has taken place but do not 
indicate successful fibrin clot formation.  However, the presence of D-dimer not 
only indicates successful fibrin clot formation and conclusion of fibrinogenesis by 
FXIIIa crosslinking of fibrin monomers, but also subsequent fibrinolysis. 
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1.5 Coagulation beyond haemostasis 
Coagulation is traditionally taught as a mechanism for haemostasis, however it has 
wider roles in innate immunity and epithelial repair outside the vascular tree.  In 
part, extravascular coagulation occurs due to plasma exudation in inflammatory 
states, however, extravascular tissues in some settings are capable of fibrinogenesis 
in the absence of plasma-derived clotting factors (92). 
 
1.5.1 Innate immunity 
The innate immune system consists of the complement system and cellular 
defences including, macrophages, neutrophils, eosinophils, mast cells and dendritic 
cells.  The origins of innate immunity go hand-in-hand with coagulation, and 
clotting mechanisms may in fact be an evolutionary product of the innate immune 
system (93).  As discussed above, coagulation is taught in terms of haemostasis, but 
if a fibrin clot is considered not only as a plug to prevent further bleeding but also a 
barrier to keep out injurious agents, many of its roles become clear.  It is also no 
coincidence that the cells that play a central role in the pathogenesis of asthma 
derive from innate immunity.  Furthermore, while the Th2 response key to atopy is 
part of adaptive immunity, it is the innate system that orchestrates and directs the 
balance between Th1/Th2 (94). 
 
The fact that pathogens such as group A Streptococci and Staphylococci have 
developed strategies to disrupt and utilise coagulation to increase their 
pathogenicity further illustrates the link between coagulation and immunity.  Group 
A Streptococci produce the plasminogen activator streptokinase enabling tissue 
invasion by fibrinolysis (95).  The production of coagulase by Staphylococci results 
in fibrin formation and defence against phagocytosis and the production of 
staphylokinase, a plasminogen activator, reduces Staphylococcal virulence (96). 
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1.5.2 Protease-activated receptors (PARs) 
Proteases such as those involved in coagulation function by cleavage of inactive 
zymogens which cascade as described above.  These proteases have cellular actions 
beyond coagulation and it is the protease-activated receptors or PARs that enable 
these actions.  PARs are transmembrane G protein-coupled receptors that carry 
their own tethered ligand that is revealed when proteolytic cleavage occurs (97).  
For example, thrombin activates lung fibroblasts to produce procollagen via PAR-1 
(98) a mechanism that is involved in lung fibrosis.  FXa can also stimulate fibroblasts 
to produce procollagen and proliferate (99). 
 
Idiopathic pulmonary fibrosis (IPF) is a devastating condition with an average 2-3 
year survival from diagnosis.  In bronchoalveolar lavage fluid (BALF) specimens from 
patients with IPF, there is increased procoagulant activity and fibroblast survival via 
PAR-2 upregulation.  Furthermore, in bleomycin-induced fibrosis, a model used to 
replicate IPF, PAR-2 knockout mice demonstrate reduced fibrosis, less 
myofibroblast differentiation and collagen expression is decreased (100).  These 
mechanisms involving coagulation have implications for airway remodelling in 
asthma. 
 
1.5.3 Acute lung injury/acute respiratory distress syndrome 
Acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) is a spectrum of 
lung disease arising in response to local and systemic pulmonary insult resulting in 
rapid respiratory failure that carries a mortality of 40-60% (101).  Increased capillary 
and epithelial permeability results in pulmonary oedema alongside increased 
pulmonary vascular resistance due to microemboli and microthrombosis, surfactant 
inactivation, loss of pulmonary compliance and ventilation/perfusion mismatch 
(102).  The recognition that coagulation is activated in the lung in the condition is 
widespread and has been the subject of significant research. 
 
Alveolar fibrin deposition occurs in ALI/ARDS resulting from enhanced coagulation 
and suppressed fibrinolysis (103).  TF mediates enhanced intra-alveolar 
28 
 
fibrinogenesis in this setting (104), possibly stimulated by elevated levels of FVII 
activating protein (105).  TF is increased in ALI/ARDS through plasma exudation and 
cellular sources including alveolar macrophages (106), neutrophils (107) and the 
alveolar epithelium itself (108).  Mature neutrophils do not usually express TF (109), 
however stimulation with complement protein C5a or TNFα results in neutrophil 
expression of TF in this setting (107).  Alveolar microparticles with TF activity are 
also present in ARDS, possibly of alveolar cell origin (108).  Although TF is the major 
initiator of coagulation, clot propagation and production of thrombin in sufficient 
quantities to produce fibrin, requires the intrinsic cascade (88).  Formation of the 
intrinsic Xase and prothrombinase complexes requires a plasma phospholipid 
surface, usually that of the platelet, however, platelets are not usually present in 
BALF (110).  Plasma microparticles can serve this purpose (88), and the alveolar 
microparticles observed by Bastarache and colleagues (111) may take on this role in 
ALI/ARDS. 
 
The suppression of fibrinolysis occurs in part due to a disproportionate elevation in 
TFPI when compared with elevated TF, but also inactivation of TFPI (112).  Further 
fibrinolytic suppression occurs via the actions of PAI-1, α2-antiplasmin and PAI-2 
(103).  Insufficient AT activity is also implicated, alongside reduced APC (102).  APC 
exhibits anticoagulant effects by inactivation of FVa and FVIIIa, alongside anti-
inflammatory actions and stabilisation of endothelial barrier permeability via PAR-1 
and endothelial cell protein C receptor (113).  The PROWESS study has shown that 
intravenous APC in severe sepsis can reduce mortality (114) but this benefit has not 
been shown in ALI/ARDS (115). 
 
A variety of other therapeutic strategies have been investigated in ALI/ARDS 
including animal studies of intravenous (116) and nebulised (117) heparin which 
showed promise with nebulised therapy reducing lung oedema, cast formation and 
cellular infiltrates but no benefit when intravenous heparin was used.  Phase 1 
human studies of nebulised heparin have demonstrated practical application and a 
lack of serious adverse events but further study is required for this therapy (118).  
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β2 receptor agonists show potential benefit in this setting acting via 
bronchodilatation, increasing clearance of lung oedema and anti-inflammatory 
effects but randomised controlled studies investigating β2 agonists in this area are 
lacking (119).  The antioxidant N-acetylcysteine (NAC) does not confer benefit in 
established ALI/ARDS (120).  Attempts to increase fibrinolysis using uPA inhalation 
in animal studies demonstrated increased alveolar fibrinolysis (121) and phase 1 
human studies of plasminogen activator therapy in humans show a lack of 
significant side effects (122).  Finally, inhibition of TF-mediated coagulation has 
demonstrated mixed results.  Active site inactivated recombinant FVIIa showed 
increased mortality against placebo and a trend to increased risk of serious 
bleeding as doses increased (123).  Using anti-TF antibodies, phase I trials 
demonstrated safety using intravenous administration (124). 
 
1.6 Coagulation in asthma 
There has been increased focus on the role of coagulation in asthma in recent 
years.  Evidence from post mortem examination of the lungs of a patient who died 
of status asthmaticus shows fibrin deposition along the distal airways and alveoli 
(125).  Murine models of airway inflammation confirm this deposition of fibrin and 
demonstrate increased AHR with administration of nebulised fibrinogen and 
thrombin that is reduced with administration of the fibrinolytic initiator uPA (125).  
PAI-1 is a major suppressor of fibrinolysis and increased fibrinolysis by either 
increased uPA or decreased PAI-1 has been shown to reduce AHR in mouse models.  
Furthermore, the pro-fibrotic chemokine TGF-β1 increases bronchial expression of 
PAI-1 and the resulting airway remodelling may be reduced by uPA administration 
(126).  Plasminogen itself increases leukocyte recruitment into the airways in 
murine models (127).  A reduction in FVII levels in mice results in decreased AHR, 
airway remodelling and eosinophilic airway inflammation (128), and increased FXa 
expression is observed in airway inflammation and is again linked to airway 
remodelling (129). 
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Plasma exudation resulting from inflammation in asthma carries with it coagulation 
factors.  However, in cell culture models of normal human bronchial epithelium 
(NHBE) subjected to mechanical scrape damage, a TF-dependent repair response 
has been observed that occurs in the absence of plasma (92).  Conversely, NHBE cell 
cultures subjected to compressive stress such as that which occurs during 
bronchospasm, promotes a fibrinolytic response (130).  This increase in fibrinolysis 
could represent increased epithelial damage and defective repair, however, 
attenuated wound repair has been observed in NHBE cell cultures by blocking the 
uPA-uPA receptor (uPAR) interaction (131), demonstrating fibrinolysis as well as 
fibrinogenesis is necessary for efficient epithelial wound repair. 
 
Human studies in asthma reveal increased thrombin generation in the airways that 
may be linked to airway remodelling (132).  Bronchial allergen challenge activates 
airway coagulation independently of leukocyte infiltration (133).  BALF after 
allergen challenge demonstrates increased thrombin activity, and this BALF exhibits 
mitogenic activity when exposed to cultured human fibroblasts, which is 
suppressed by hirudin, a specific thrombin inhibitor (134).  Platelets are a source of 
numerous cytokines and coagulation factors, and are activated in the asthmatic 
airway after allergen challenge (135).  During asthma exacerbation, higher levels of 
platelet activation are observed when compared with healthy controls, an effect 
that increases with steroid treatment (136). 
 
When examining clinical asthma subgroups, in stable severe asthma, an exudative 
pro-fibrinogenic and anti-fibrinolytic environment occurs despite treatment.  
However, in moderate treated asthma, the balance slightly favours fibrinolysis akin 
to the normal airway, but if inhaled steroid treatment is weaned in this group, the 
balance increases in favour of fibrinolysis (137).  These observations suggest that; in 
milder forms of the disease inhaled steroids optimise epithelial repair; but in more 
severe disease excessive fibrinogenesis results in increased AHR and remodelling as 
seen in murine models (125).  The importance of the balance between 
fibrinogenesis and fibrinolysis is reflected in the observation that while uPA and 
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PAI-1 are both increased in asthmatic sputum compared with healthy controls, and 
both rise in response to allergen challenge, the ratio of uPA:PAI-1 falls (138).  This is 
further reflected when examining TAFI, a suppressor of fibrinolysis.  Murine models 
of airway inflammation demonstrate that the presence of TAFI reduces AHR and 
airway inflammation, an observation which contrasts the effect of PAI-1.  
Furthermore, a reduction in TAFI levels promotes airway remodelling, possibly due 
to compensatory increased PAI-1 (139), highlighting the complex interplay between 
the fibrinogenic and fibrinolytic pathways.    
 
Finally, when studying moderate stable asthma before and after weaning inhaled 
corticosteroids, Brims and colleagues (80) observed a marked shift towards a pro-
fibrinogenic environment within the airways of a patient 5 days prior to an 
exacerbation.  Of particular note, the inflammatory changes occurred without any 
detectable deterioration in conventional clinical parameters such as spirometry or 
FeNO, and before any symptoms of exacerbation were present. 
 
1.7 Hypothesis 
Given the potential importance of the coagulation cascade in acute respiratory 
disease states, the following hypothesis was tested: 
 
Markers of fibrin turnover are raised in plasma during exacerbations of asthma that 
improve with recovery; and their presence in urine predicts the onset of a new 
exacerbation in otherwise stable asthma.  
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2.0 METHODS 
 
2.1 Study design 
This is a cohort study in two parts comparing markers of fibrin turnover during 
asthma exacerbation, with the recovery state.  Part 1 recruited patients requiring 
treatment in hospital for acute exacerbation of asthma and comparison was made 
at recovery.  Part 2 prospectively recruited patients with moderate and severe 
asthma when well, and observed them until asthma exacerbation, and through to 
subsequent recovery.  A study period of two years was proposed with parts 1 and 2 
recruiting in parallel.  Target recruitment was 100 study subjects for Part 1, and 40 
subjects for Part 2, 20 with moderate and 20 with severe disease defined by 
baseline steroid dose and GINA criteria (appendix 2). 
 
The full study protocol is available in appendix 3, and details of study procedures 
will be outlined in relevant sections.  In brief, study activity included clinical and 
spirometric assessment at each study visit alongside measurement of FeNO, and 
urine and blood sampling.  Sputum induction and full pulmonary function tests 
(PFTs) were performed on selected participants.  Skin prick testing for sensitivity to 
common aeroallergens was performed at one study visit.  Participants were asked 
to record PEFR and symptom diaries between visits.  Part 2 participants were also 
asked to collect thrice weekly urine specimens. 
 
2.2 Approvals 
A favourable ethical opinion was granted by the Berkshire Research Ethics 
Committee (REC) on 12th August 2010 (REC reference 10/H0505/59 see appendix 4), 
and local research governance approval was granted for recruitment to commence 
on 23rd September 2010 by Portsmouth Hospitals NHS Trust (PHT) acting as study 
sponsor (appendix 5). 
 
During the course of the study period two substantial amendments to the study 
protocol and 1 minor amendment were submitted to the Berkshire REC and 
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received approval.  These amendments related to study recruitment activity and 
are detailed in the relevant sections below. 
 
2.3 Sample size/power 
Based on published studies (137), a 2 to 72-fold increase in pre-exacerbation levels 
of coagulation factors was observed in sputum compared to stable mild to 
moderate disease, and similar differences were expected in blood and urine.  
Simulations were performed after logarithmic transformation at 90% power (5% 
significance) to detect between 1 to 5 fold differences in coagulation factors.  Based 
on these calculations, 100 subjects for Part 1 would provide sufficient power to 
detect these differences.  Anticipating potential subgroup analyses, interim analysis 
was planned after recruiting 50 subjects to establish whether 100 recruits in total 
would be sufficient for comparison between subgroups.  The interim analysis would 
also provide useful preliminary data to guide any necessary sample size increase for 
Part 2.  In June 2011 after recruiting 50 subjects, statistical advice was sought 
regarding this interim analysis and although not formally recorded, it was estimated 
that nearly 300 participants, 100 per subgroup would be needed for subgroup 
comparisons.  The study team acknowledged this figure but with a maximum of one 
further year of study recruitment and 50 participants so far recruited in the 
preceding 10 months, this figure was most likely unattainable. 
 
The prospective Part 2 study is pilot work and the numbers based on experience of 
intensive prospective follow up of adults with asthma over about 4 months per 
subject.  Standard tests of significance (parametric and non-parametric) were used 
to compare between exacerbation and recovery time points.  Analysis of variance 
(ANOVA) was used to examine exacerbations preceded by a rise in coagulation 
factors compared to those that are not.  A minimum of 12 patients in each sub-
group (moderate and severe) were required for useful ANOVA analysis, and 
recruitment of 40 subjects (20 moderate and 20 severe) was chosen to allow for 
subject withdrawal and failure to exacerbate. 
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The details of statistical tests used to analyse specific data are presented alongside 
individual results in Chapter 3 and Chapter 4 of this thesis.  All statistical analyses of 
study results were performed using Stata version 12.1 (Statacorp LP, Texas, USA) by 
Paul Bassett of Statsconsultancy (Amersham, UK). 
 
2.4 Study subjects 
Written informed consent was obtained from all individuals recruited prior to 
commencement of any study activity (appendices 6, 7). 
 
2.4.1 Inclusion criteria 
Both Parts 1 and 2 of the study recruited “real life” patients with asthma without 
prior alteration of medications.  This strategy provides real strength to our results in 
terms of translating our findings to a patient population. 
For both study arms: 
 A diagnosis of asthma >1 year 
 Age 18-70 years 
Specific to Part 1: 
 An acute exacerbation of asthma requiring admission to hospital for 
treatment of that exacerbation 
Specific to Part 2: 
 Moderate asthma - chronic moderate persistent disease (appendix 2) 
requiring medium daily doses of inhaled corticosteroids (>500-1000mcg of 
BDP or equivalent (appendix 1)) 
 Severe asthma – severe persistent disease (appendix 2) requiring high dose 
inhaled corticosteroids (>1000-2000mcg BDP or equivalent(appendix 1)) 
and/or oral corticosteroid use 
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2.4.2 Exclusion criteria 
 Current or ex-smokers with >20 pack year history 
 Significant cardiopulmonary co-morbidities 
 Clinically significant neurological, renal, endocrine, gastrointestinal, hepatic 
or haematological abnormalities uncontrolled with standard treatment. 
 Regular use of an anticoagulant 
 Bleeding diathesis 
 Alcohol and recreational drug abuse 
 Treatment with other immunomodulators 
 Concurrent participation in another interventional study 
 Abnormal chest X-ray (CXR) 
 For Part 2: an asthma exacerbation in the 4 weeks prior to study recruitment 
(visit 1) 
 
For the purposes of an asthma diagnosis, prior physician diagnosis was accepted as 
sufficient evidence, and bronchial hyperreactivity testing was not undertaken in line 
with the majority of “real-life” practice.  In terms of other airway disease that may 
mimic asthma, the most likely condition would be chronic obstructive pulmonary 
disease (COPD).  In a UK population COPD is almost entirely due to smoking so an 
exclusion cut off was initially set at 10 pack years  (1 pack year = 20 cigarettes per 
day for 1 year or equivalent).  This was increased in a protocol amendment to a 
maximum of 20 pack years, as initial recruitment for Part 1 found a higher than 
anticipated pack year history amongst potential study recruits.  However, for those 
participants with between 10 and 20 pack years, full pulmonary function testing 
was performed to look for evidence of COPD other than airways obstruction such as 
a reduction in gas transfer. 
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For Part 1 study recruits, hospital admission for treatment included those admitted 
to a ward, those seen in the Emergency Department (ED) who sufficiently 
responded to treatment to be safely discharged, and patients treated on a similar 
basis at the Respiratory Centre at Queen Alexandra Hospital (QAH). 
 
In Part 2 subjects who did not require admission to hospital for their exacerbations, 
a chest X-ray was not performed to exclude other acute confounding co-morbidity 
(e.g. pneumonia) unless clinically suspected. 
 
The exclusion criterion of an abnormal CXR was designed to exclude acute 
inflammatory conditions such as pneumonia, or obvious diffuse parenchymal lung 
disease that may influence markers of fibrin turnover (98).  It is worthy of note that 
the term “abnormal CXR” did not clearly distinguish which factors were true 
exclusions, and the research team used clinical discretion in a few cases, for 
example, one case of minimal apical scarring due to tuberculosis (TB) as a child was 
not excluded as this was deemed not to be as significant confounding factor. 
Although not specifically stated, pregnancy was also an exclusion criteria as this is 
known to be a pro-thrombotic state as illustrated by high plasma D-dimer levels 
(140). 
 
2.4.3 Methods of recruitment 
In order to maximise the potential for achieving recruitment targets within the 
proposed timescale, two main study sites were identified, QAH/PHT and 
Basingstoke and North Hampshire NHS Foundation Trust (BNHFT). 
 
Part 1: 
For the acute admission arm, a daily search of PHT computer admission records was 
performed to identify patients admitted to QAH because of their asthma.  This was 
supported by posters (appendix 8) in the ED, Medical Assessment Unit (MAU) and 
respiratory wards at QAH inviting medical teams to contact the study team if they 
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identify patients admitted with acute asthma.  Respiratory Centre staff also visited 
the above clinical areas to liaise with clinicians and identify potential recruits.  
Patients identified as having an exacerbation during difficult asthma clinic visits at 
QAH, or patients attending The Respiratory Centre at QAH for treatment of an 
exacerbation were also invited to participate.  
 
At BNHFT, clinical teams highlighted potential recruits to Dr Sal Matti, site Principal 
Investigator (PI) who contacted Dr Owen who undertook study recruitment activity. 
 
Recruitment to Part 1 was relatively successful and 55% of those screened were 
recruited to the study.  This does not, however, account for a suspected significant 
number of potential recruits who were not screened.  Active recruitment was 
limited to 1 research fellow and 1 research nurse with the chief investigator 
covering for periods when the research fellow was unavailable.  Furthermore, study 
recruitment was essentially limited to the hours of 9am to 5pm Monday to Friday in 
line with the hours of work of the study team.  For those patients who attended ED 
but were discharged home without being referred to the admitting medical team it 
was hoped that the study team would be contacted but very few patients were 
identified and all of these patients declined to return to the hospital for screening 
when contacted.  Similar confounding factors were experienced on the MAU 
whereby the study team were very infrequently contacted regarding patients.  
Overall this was less of a problem as the study team were able to attend the MAU 
twice a day (to give potential patients an opportunity to participate in the 
research), and computerised admission records present in this area, allowed 
eligible recruits to be more readily identified.  Furthermore, the national pressures 
to admit or discharge patients within 4 hours that apply for the ED do not apply 
once a patient is admitted to MAU, allowing more time to address such patients. 
In terms of improving recruitment to Part 1, the key factors identified would be to 
have more staff cover after 5pm and also at weekends.  Within the ED, adhering to 
the time constraints upon clinical staff and maintaining patient throughput is 
paramount to ensure congestion and queuing of ambulances doesn’t occur.  While 
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not unique to QAH, this was a particular problem during the study period in part 
due to the physical layout and staffing levels in the ED.  In order to relieve some of 
these pressures, the ability for the research team to take patients to a separate 
area to complete study activity would enhance recruitment. 
Study recruitment did take place at BNHFT, however, this was dependent on 
patients being identified primarily by Dr Sal Matti, consultant respiratory physician 
who then contacted Dr Owen who travelled to BNHFT and performed screening and 
study activity.  This method of recruitment was entirely dependent on 1 individual 
to identify potential recruits and then on the availability of Dr Owen on a particular 
day.  Despite 100% of those screened at BNHFT being recruited, the total number 
was only 3 participants (4%) and the logistical constraints were considerable 
confounding factors.  A dedicated recruiting team at each site should be considered 
if the study were to be repeated. 
The initial target for recruitment to Part 1 was 100 study participants which was not 
reached during the research fellowship.  Dr Owen was granted a period of two and 
a half years out of his Wessex respiratory medicine training rotation for the 
purposes of undertaking a postgraduate research project.  This period finished in 
July 2012 so the decision was taken by the study team to cease recruitment activity 
by May 2012 to enable Dr Owen to complete the laboratory analyses prior to 
returning to full time clinical work.   
Part 2: 
Prospective study activity was limited to PHT for logistical reasons.  The difficult 
asthma clinic database was searched for potential recruits who were invited to 
participate by letter (appendix 9), or approached during routine clinic visits.  
Generic advertisements were placed in the local newspaper (The Portsmouth News) 
regarding respiratory research at QAH inviting interested people to make contact 
with the Respiratory Research Team.  Dr Owen was interviewed regarding 
respiratory research by local hospital radio and a further generic advert was placed 
on the PHT staff intranet inviting staff to contact the Respiratory Centre. 
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Local GP surgeries (Brook Lane Surgery in Locks Heath and Portsdown Group 
Practice in Cosham) were employed as Patient Identification Centres (PIC).  Surgery 
staff searched practice databases for potential recruits, then contacted patients 
seeking consent to send them a study Participant Information Sheet (PIS) with 
contact details of the Respiratory Centre if they wished to be seen for study 
recruitment (see appendix 10 for surgery invite letter). 
 
Initially it was expected that the majority of the recruits would be identified from 
the asthma database at QAH compiled in previous years from the local population 
attending the Respiratory Centre.  However, many of these patients were excluded 
in pre-screening from patient records due to factors such as cigarette consumption 
and immunomodulatory therapy.  Despite letters sent directly to patients (appendix 
9), response numbers were poor.  The design of the letters may have impacted on 
this and different approaches such as email or text message might be considered in 
the future in line with the cultural shift away from traditional written 
communication.  Although generic adverts for QAH research activity in local 
newspapers and on local radio were made, ethical approval for advertising specific 
to this study was not sought.  It is possible that a more specific advert for the study 
would have improved feedback.  It is also worth noting that those who did respond 
to the generic adverts had very mild asthma that was outwith the study inclusion 
criteria. 
There was particular difficulty in identifying patients with moderate asthma in 
terms of inhaled steroid dose.  When recruitment to Part 2 began, those patients 
contacting the research team through adverts were too mild and those identified 
from outpatient clinics and The Respiratory Centre database tended to be too 
severe.  It was anticipated that a significant proportion of patients with moderate 
asthma would be able to be recruited in line with previous work by our group (80, 
137), which was based on the GINA 2008 guidelines (7) which is unchanged in the 
latest iteration of GINA guidance published in 2014 (5).  In order to identify this 
population, a study amendment was submitted and approved to utilise local GP 
surgeries as PIC sites.  Although this strategy did identify 6 participants (10% of 
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those contacted), strict protocols were imposed by the approving body (Primary 
Care Research Network (PCRN)) detailing the methods to be employed for 
identifying patients.  Research staff were not allowed access to patient records 
within surgeries and surgeries were required to contact patients asking their 
permission to be sent the study invitation letter (appendix 9).  Research staff were 
only allowed to contact the patient after the patient had first contacted the 
research team.  Despite funds being provided by the PCRN to PIC sites, no staffing 
resources were provided to search databases and make contact with patients.   
The numerous steps involved in this strategy limited its success alongside 
resourcing limitations, particularly in terms of staff.  Future consideration should 
again be given towards email contact with patients and resourcing in terms of PCRN 
or community staff with more time and more access to the relevant details 
pertaining to the study who can research pseudo-anonymised patient records. 
In broad terms, it is difficult to explain why there were not more patients who fell 
into this group.  Knowing the inhaled steroids available for prescription, it is 
plausible that some patients will fall below the 500 mcg BDP threshold and some 
above the 1000 mcg.  There should, however, be a significant proportion receiving 
budesonide 800mcg or QVAR 400mcg (equivalent to 800 mcg BDP).  Local 
prescribing patterns may have an influence on the apparent paucity of these 
patients.  Equally this could be explained by this group being relatively well 
controlled and not requiring secondary care services, hence them being unknown 
to the hospital’s service.  Furthermore, if well controlled, such patients may be less 
inclined to take part in research. It is worth noting that of the 10 patients who did 
respond, 7 were too mild to be included which reflects inaccuracy in the records of 
the GP surgeries that were screened, or a failure by surgery staff to identify the 
correct target group.  Once the patient had received the invitation letter which 
clarifies the necessary steroid dose, they may have recognised themselves that they 
did not meet the inclusion criteria and hence did not respond. 
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Both study arms: 
Dr Owen and Prof Chauhan, as part of educational presentations regarding asthma 
within PHT, invited clinicians to identify potential research patients to the 
Respiratory Centre at QAH. 
 
Once patients had been highlighted to the study team, they were approached and 
given the relevant PIS for each study arm (appendices 11, 12). 
 
2.4.4 Screening 
Part 1: 
Once potential recruits were identified by staff, pre-screening of admission records 
was performed to identify any clear documented exclusion criteria such as past 
medical history (PMHx), anticoagulant medication, or concurrent admission 
diagnosis (e.g. pneumonia).  If none were identified, patients were approached by 
study personnel and given a PIS then left for at least half an hour to consider 
participation.  If patients wished to participate, written informed consent was 
obtained and screening was completed by checking all inclusion/exclusion criteria.  
Baseline assessment was performed at this initial screening visit and is detailed 
below. 
 
Part 2: 
After identification, potential participants were given a PIS if agreeable, and after at 
least a day to consider taking part, an appointment was made for screening and 
initial assessment which took place at the same visit. 
 
After successful recruitment in both study arms, a letter was sent to the 
participant’s GP informing them of their patient’s involvement in the study 
(appendix 13) along with the relevant PIS. 
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2.4.5 Study visit schedule 
Study visit schedules are outlined for Parts 1 and 2 in figures 4 & 5 respectively.  
Participants were offered a second follow up visit if not recovered at the first follow 
up.  Participation completed at the second follow up whether recovery was 
achieved or not. 
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Figure 4 – Part 1 study visit schedule
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Figure 5 – Part 2 study visit schedule
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2.4.6 Study follow up 
Overall, the rate of participants lost to follow up was small, 15 of 84 (18%) for Part 1 
and none in Part 2. 
In Part 1, a follow up appointment was planned for 4 weeks after admission to 
assess recovery, then a further follow up was offered at 8 weeks if recovery was not 
achieved at follow up 1.  Part 2 was designed to mirror this model after the 
exacerbation visit.  The follow up visit was scheduled at the time of exacerbation in 
both Parts 1 and 2 of the study.  The fact that patients were being given a date for 
follow up during an acute admission, may in part explain why failure to attend 
appointments occurred, for example, patients not having access to diaries or 
schedules. Several of the patients had follow up appointments made with clinical 
teams in line with national guidelines (4).  This may have added a degree of 
confusion in that some patients were unclear that they were due to attend both 
appointments and some may have been unwilling to attend more than one 
appointment due to other commitments.  The patients were not given a specific 
appointment card or sent a reminder letter for this research appointment which 
could also have impacted on their attendance.  Failure to attend follow up was not 
a problem in Part 2 of the study, but this is likely to reflect a selection bias as those 
patients who had committed to Part 2 were already regularly collecting samples 
and had attended an outpatient appointment at baseline.  Although the offer was 
made to reimburse travel costs for study participants, very few recruits made this 
request.  No other incentive was offered to patients when approached regarding 
study enrolment which could be a consideration to increase both initial recruitment 
and subsequent follow up attendance.  Whether or not financial incentives should 
be offered over and above reimbursing costs is reviewed by Draper and colleagues 
(141) and remains a matter of debate. 
It is worth noting that although follow up was planned to be for 4 and 8 weeks post-
exacerbation, in Part 1 first follow up occurred on average 35 days (5 weeks) with a 
range of 28-91 days, and second follow up 65 days (9 weeks 2 days) with a range of 
41-96 days.  In Part 2 exacerbation to first follow up average was 30 days (4 weeks 2 
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days) with a range of 28-37 days, and exacerbation to second follow up 61 days (8 
weeks 5 days) with a range of 56-70 days. 
The variation in duration between visits is due to factors discussed previously 
including, staffing levels, lack of appointment reminders, confusion between clinical 
and research follow up, but also due to flexibility on the part of the study team in 
order to work around patient’s availability.  Future studies should consider a more 
formal arrangement for scheduling appointments and a reminder service, possibly 
in writing but also considering text or email contact.  In terms of comparable 
results, a more rigid window in which to schedule appointments should be 
considered, for example follow up 1 should be arranged at 28 days +/- 4 days and 
follow up 2 56 days +/- 4 days. 
The time from asthma exacerbation to clinical recovery and resolution of acute 
inflammation will be discussed in more detail below. 
 
2.4.7 Study documents and data recording 
A number of documents were designed and approved for use in the study by the 
Berkshire REC, copies of which are contained in appendices 3-19.  Paper 
documentation was used primarily due to study budget but had the additional 
advantage of being transferable across study sites without the need for using 
different information technology (IT) systems and the potential data protection 
consideration involved.  In broad terms the study documentation was successful in 
recording a comprehensive set of study data. 
During the study, further improvements were made to the CRF to facilitate 
improved data recording that included changes in the layout, and addition of the 
GINA 2008 disease severity criteria. There were other areas where participants 
failed to record some data. For example, the admission study activity for Part 1 took 
place as close to the day of admission as possible, however, participants could 
remain an inpatient for several days then retrospective recording of medication 
changes and duration was required by reviewing casenotes which were not readily 
available or always clearly accurate.  This was also apparent when calculating 
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durations of drugs such as oral corticosteroids or antibiotics at follow up, which 
relied heavily on patient recollection.  Although the PEFR and symptom diary had 
areas for this to be recorded, some participants failed to record information or 
forgot to return their diary.   
 
2.5 Study visit activity 
2.5.1 Clinical parameters 
At each study visit a clinical history was taken and physical examination including 
blood pressure, pulse, oximetry and respiratory examination was performed.  CRFs 
were used to record study visits and are contained in appendices 14 and 15.  Key 
asthma symptoms (breathlessness, cough, wheeze, chest tightness, night wakening, 
chest pain and sputum production) were recorded alongside reliever use per 
twenty-four hour period, and a composite score of symptomatology was obtained 
at each time point. 
 
2.5.2 Spirometry 
Spirometry was measured at every visit.  Where possible, three consistent 
measurements were taken in line with ATS/ERS guidelines (142).  However, 
investigator discretion was allowed when symptoms such as cough occurred, 
especially at exacerbation visits. 
 
Two handheld spirometers were used throughout the study period, the first a 
Microlab 3500 (Carefusion, Hampshire, UK) and the second a Vitalograph Alpha 
Touch (Vitalograph, Buckinghamshire, UK).  Regular calibration of the machines was 
performed as per manufacturer’s instructions.  The European Community of Coal 
and Steel (ECCS)/ERS 1993 (143) reference values for normal range were used.  
Individual study participants used only one machine for all of their spirometric 
measurements allowing accurate intra-individual comparison between study visits. 
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2.5.3 Exhaled nitric oxide 
FeNO was measured at all study visits (except when too breathless at exacerbation) 
using a NIOX MINO machine (Aerocrine, Solna, Sweden).  Two machines were used 
for this test, the NIOX MINO 03-1000 and the NIOX MINO 09-1000 as per 
manufacturer’s instructions.  Both are self-calibrating and according to the 
manufacturer, results from each machine are interchangeable as both devices use 
the same internal sensor. 
 
2.5.4 Skin prick testing 
Skin prick testing (SPT) for sensitisation to common aeroallergens was performed 
on all study participants with the exception of those who were unable to stop 
antihistamines on clinical grounds,  in these circumstances consent was obtained to 
use any previous available results.  SPT was performed at follow up for Part 1 and at 
visit 1 for Part 2. 
 
The panel of allergens tested consisted of positive and negative controls, tree 
pollen, grass pollen, house dust mite, cat epithelia, dog  and Aspergillus fumigatus.  
Allergens were applied to the forearm and introduced into the skin using a lancet, 
and excess allergen was removed by blotting with a tissue, taking care not to cross-
contaminate allergens.  In line with existing PHT practice, results were read at 15 
minutes and measured in millimetres at the widest point of any weal.  A positive 
result was regarded as a weal 3mm greater than that of negative control.  Allergens 
were purchased from Diagenics Ltd (Milton Keynes, UK) and are detailed in table 1 
below. 
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Table 1 – Skin prick test reagents used 
Number Reagent name Constituents Concentration 
Allergopharma D-21462 
901 Negative control Glycero-saline n/a 
902 Positive control Histamine dihydrochloride 1.7mg/ml 
013 Tree mix, mid blossoming n/a 100000 BU/ml 
306 Dog n/a 10000 BU/ml 
401 Aspergillus fumigatus n/a 10000 BU/ml 
725 House dust mite Dermatophagoides pteronyssinus 50000 SBU/ml 
Merck skin testing solution 
006 Grass mix n/a 50000 SBU/ml 
309 Cat epithelia n/a 50000 SBU/ml 
n/a = not available, SBU = Standardised Biological Units, BU = Biological Units 
 
 
2.5.5 Pulmonary function testing 
In terms of this study, full PFTs refers to the combination of dynamic and static lung 
volumes and gas transfer.  Although spirometry is routinely measured as part of this 
test at PHT, the results reported for spirometry in this study were taken from the 
isolated spirometric analysis described above to enable comparison between study 
visits.  Both body plethysmography and helium dilution methods were employed 
for lung volume and gas transfer evaluation. 
 
Full PFTs were performed on all Part 2 recruits at visit 1.  For Part 1, PFTs were only 
performed at follow up if smoking history exceeded 10 pack years (1 year smoking 
20 cigarettes per day = 1 pack year).  This was to exclude confounding smoking-
related airways disease such as COPD.  Usual medications were not withheld prior 
to measuring PFTs.  PFTs were measured as per PHT protocols by the Respiratory 
Physiology Department using nSpire ZAN 310 FRC-He and ZAN 500 Body USB 
machines (nSpire Health Ltd, Hertfordshire, UK) in line with manufacturer’s 
instructions.  PHT employs the Association for Respiratory Technology and 
Physiology (ARTP)/BTS testing protocol for measurement of lung volumes and gas 
transfer (143).  Normal reference values used were ECCS (143). 
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2.5.6 Sputum induction 
Sputum induction and analysis was intended to allow inflammatory classification of 
study participants.  Furthermore, the examination of markers of fibrin turnover in 
sputum during asthma exacerbation was planned.  Although such markers have 
been investigated in stable asthma (137) and viral-induced models (144), only 
fibrinogen has previously been investigated during acute asthma exacerbation in 
sputum (145). 
Specific written informed consent was obtained from study participants after 
receiving written information regarding the procedure (appendices 16, 17).   
 
Sputum induction was performed in line with PHT protocols and documented on a 
protocol worksheet (appendix 18).  Standard protocol was employed for the 
majority of participants, and a second protocol used for those deemed at high risk 
of bronchoconstriction.  The factors used to determine those at risk of 
bronchoconstriction are as follows: 
 
 Known brittle asthma 
 Low baseline FEV1 (<1 litre) or FEV1 <50% predicted 
 Previous bronchoconstriction with nebulised saline 
 Development of significant symptoms during induction 
 Participant request 
 Investigator discretion 
 
2.5 mg nebulised salbutamol was given prior to commencing sputum induction and 
FEV1 was measured (see spirometry, section 2.5.2) at baseline for both protocols.  
FEV1 was measured at variable intervals throughout the procedure depending on 
the protocol employed.  Nebulised saline at differing concentrations (0.9 to 5%) was 
administered via a DeVILBISS Ultraneb (Sunrise Medical Ltd, West Midlands, UK) 
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according to manufacturer’s instructions for the purposes of sputum induction.  For 
FEV1 measurement intervals and saline concentration schedule please refer to 
appendix 18.  Prior to study commencement but after completion of study 
documents, trust clinical protocols for sputum induction were changed using 5% 
saline as the standard alternative to 4.5% saline and this was also adopted for study 
purposes. 
 
Acute bronchospasm is a recognised complication of sputum induction (146) and 
during study design, it was felt that attempted sputum induction during acute 
asthma exacerbation posed unacceptable risk to participants of worsening that 
exacerbation.  However, it was anticipated that a significant proportion of patients 
during exacerbation would expectorate sputum, enabling comparison with sputum 
induced at recovery for both study arms, and also at baseline in Part 2.  Where 
participants did not expectorate sputum during exacerbation, the lack of a paired 
comparative sample made sputum induction at recovery unnecessary, and equally 
when sputum induction in Part 2 was unsuccessful at baseline, further induction 
attempts in these participants was not attempted. 
 
The number of participants expectorating sputum was unexpectedly low, only 19 of 
82 (23%).  As far as we are aware, the incidence of spontaneous sputum 
expectoration at the time of asthma exacerbation has not previously been 
published.  Anecdotally, the clinicians involved in the study had anticipated nearer 
half of the subjects would expectorate sputum during exacerbation due to the 
acute inflammation that occurs.  For reasons that included baseline severity of 
asthma and spontaneous expectoration at follow up, only 8 sputum inductions 
were attempted in Part 1 and in Part 2, a further 14 were made.  Of the 22 sputum 
inductions attempted during the study, 13 (59%) were successful in producing a 
sputum sample.  Other studies report a success of 80-90% (6).  The protocol used in 
our study was in line with international guidelines (147), and the exact reasons for 
our lower success are unclear. 
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There is emerging evidence that sputum induction is safe even during acute severe 
exacerbation of asthma (145, 148, 149) and this should be taken into consideration 
for future study design.  Due to the overall paucity of samples, sputum was not 
examined as part of this study. 
 
2.5.7 Peak flow and symptom diary 
PEFR was recorded at each study visit.  Participants were also asked to complete a 
symptom and PEFR diary between study visits (see appendix 19 for copy of diary 
sheet).  PEFR was recorded on a scale from 0-700 l/min and patients were 
instructed to take the best value of 3 blows taken sitting down prior to taking their 
regular morning and evening preventer inhaler.  Extra pre-and post-nebuliser 
measurements taken by clinical teams during hospital admission were not recorded 
for study purposes.  PEFR measurement was taken by participants using a Mini-
Wright standard range EU-scale peak flow meter (Clement Clarke International Ltd, 
Essex, UK). 
 
The presence or absence of a symptom in a 24 hr period was indicated by a yes or 
no answer.  Reliever use was recorded as number of puffs of inhaler in 24 hrs or 
number of reliever nebulisers.  The dose of any oral steroids taken on a given day 
was also recorded, as were days when menstruating where applicable.  For Part 2, a 
day when a urine sample was given was also recorded. 
 
The PEFR and symptom diaries used were prospective paper records, and while the 
use of prospective diary data is more accurate than retrospective recall (150), it has 
been observed that up to a third of patients do not measure their PEFR when asked 
to do so, and there is a significant drop off in recording data as time passes after 
contact with a clinician (151).  In Part 1, 52 of 64 participants (81%) who completed 
the study returned their PEFR diary and 14 of 15 participants (93%) who completed 
Part 2 did the same.  It is worth noting that many diaries were incomplete.  The use 
of electronic devices has been shown to improve data recording and accuracy (152) 
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and should be considered for future studies as recommended by the ATS/ERS joint 
statement on asthma research (6). 
 
2.5.8 Exacerbation 
For both Parts 1 and 2 of the study, acute asthma exacerbation was defined as 
deterioration in symptoms severe enough to warrant treatment with oral 
corticosteroids, or a significant increase in dose for those already on maintenance 
oral steroids, either prescribed by treating clinicians, or as part of an individual 
patient self-management plan.  Treatment dose steroids must be given for at least 
3 days, consistent with the ATS/ERS definition of a severe exacerbation (6).  Any 
treatment given by the asthma team for exacerbation was in line with pre-existing 
patient management plans and/or BTS guidelines. 
 
2.5.9 Recovery 
Clinical recovery was determined as patient-reported return to their pre-
exacerbation state, not necessarily a return to ideal asthma control. 
 
2.5.10 Blood and urine samples 
Blood and urine samples were taken at each study visit, details of which are 
outlined below. 
 
2.6 Sample collection and storage 
It was planned to test blood, urine and sputum using a variety of techniques.  While 
patient visits for both study arms would take place at hospital, Part 2 required 
prospective urine collection before symptoms had even developed.  Initial sample 
collection and handling was designed to balance participants’ time, volume of 
samples being processed, specimen degradation and detection limits of planned 
tests.  Furthermore, samples were processed at both QAH and The University of 
Portsmouth (UoP).  This section outlines the initial sample collection and handling. 
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2.6.1 Blood  
Blood was taken from participants at every study visit into Vacutainer (BD UK Ltd, 
Oxford, UK) tubes.  Samples were drawn into 1 citrate, 1 
ethylenediaminetetraacetic acid (EDTA) and 1 serum separating (clot-activator) 
tube and sent to the PHT laboratory for full blood count (FBC), urea and electrolyte 
(U+E), liver function (LFT), glucose, C-reactive protein (CRP), calcium, D-dimer, 
fibrinogen, international normalised ratio (INR) and activated partial 
thromboplastin ratio (APTR).  These tests were performed by the pathology services 
at PHT and BHNFT using commercial analysers and standard protocols.  Details of 
the analysers in use during the study period are outlined in appendices 20 (PHT) 
and 21 (BNHFT).  The methods employed at the two laboratories were deemed 
comparable prior to study commencement with the exception of IgE measurement.  
All IgE testing was performed at PHT for this reason. 
 
In usual clinical practice at QAH, the D-dimer test requires a special request to limit 
unnecessary testing and costs.  Despite samples being labelled as research 
specimens and prior arrangement with the laboratory being made, several samples 
were not processed and therefore data was missing.  A more failsafe system should 
be considered for future projects. 
 
Further blood was collected in EDTA tubes for plasma and processed at QAH as 
follows.  Samples were centrifuged at 1559 g for 10 minutes in line with QAH 
laboratory practice.  Plasma was then aspirated from the samples leaving cell layers 
undisturbed.  If more than 1 tube was collected, plasma was mixed before aliquots 
were frozen and stored at -80o C.  It is worthy of note that although our method of 
plasma processing should result in plasma with a low platelet count, it was not 
“platelet poor plasma” recommended by the manufacturer of the Enzyme-Linked 
Immunosorbent Assay (ELISA) kits used.  This would require a further centrifugation 
step, and platelet free plasma a further high speed centrifugation (153).  When 
comparing the method used to prepare plasma with other published work that 
have used the same ELISA kits (154) the levels of PF4 in the present study are of a 
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magnitude 10x greater.  The normal values reported by Peterson and colleagues 
(154) refer to platelet poor plasma.  The different plasma preparation used in the 
present study would be expected to give higher platelet counts and hence would 
explain the higher values.  The use of EDTA compared to citrate should result in less 
overall platelet activation (155) and hence α granule release, including PF4. 
Tutluoglu and colleagues (136) observed higher PF4 levels in plasma in subjects 
with asthma compared with healthy controls, a factor that could account for 
increased PF4 levels in the present study population, however, it is likely that the 
increased platelet count overall is responsible for this observed difference in PF4. 
 
Plasma was subsequently analysed for PAI-1, TGF-β1, VEGF, TAFI, TF and PF4 using 
enzyme-linked immunosorbent assays (ELISA), and IL-5, IL-6, IL-8, IL-12P40, IL-13, 
IL17A, eotaxin, RANTES, interferon (IFN)-γ and TNF-α using immunofluorescence.  
Each assay is described below. 
 
2.6.2 Urine 
The specific requirements for each test are outlined below but in brief, a mixture of 
immediately frozen and “fresh” (refrigerated up to 1 week but not frozen) urine 
was required.  The workflow for urine processed at study visits is outlined in figure 
6. 
 
Creatinine was tested on all urine samples to enable standardisation of urine 
sample concentrations at PHT and BNHFT laboratories.  The commercial analysers 
used are detailed in appendices 20 and 21. 
 
The FDP analysis required “fresh” urine that had not been frozen and defrosted.  
The manufacturer of this test advised that it could be performed on urine for up to 
a week that had been refrigerated at 4oC, but degradation of the FDPs occurred 
with freezing, if not refrigerated, or if analysed beyond 1 week.  A further planned 
mass spectrometry analysis required immediate processing and snap-freezing to 
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prevent protein degradation.  Furthermore, sample analysis took place both at QAH 
and UoP laboratories. 
 
For prospective urine samples collected in Part 2, participants were asked to give 
samples at home into universal specimen pots provided.  Instructions were given to 
provide 3 samples a week.  Samples should ideally be the first sample after waking 
up, and subsequent urination from that day or following days, should not be added 
to increase volume.  Once given, samples should be stored at 4oC in participants’ 
refrigerators.  Two samples should be given per week on alternate days.  A weekly 
collection or drop off of samples was arranged, the third sample of the week was 
on the day of collection/drop off to maintain the “freshest” possible specimens. 
 
Once non-visit specimens arrived at QAH, they were divided into 2x 1000 μl aliquots 
and 1x 15 ml bulk specimen for retention at QAH, and then the remainder was used 
at UoP.  The processing at UoP required a minimum of 3 mls, so QAH bulk specimen 
volumes were adjusted to meet this requirement.  Both aliquots and bulk 
specimens retained at QAH were frozen and stored at -80oC.  Remaining specimens 
for UoP were refrigerated at 4oC and subsequently transferred to the University 
where they were again refrigerated until processing took place.  Processing at UoP 
occurred within 1 week of each sample being given.  After UoP processing, any 
remaining samples were frozen in bulk and stored at -20oC at UoP. 
 
The need to process fresh urine required staff to be available at both PHT and UoP 
on most days.  During the period from November 2011 to January 2012, one 
member of the research team at UoP who was performing the majority of the urine 
testing for FDPs, MMPs and GAGs, took a period of leave.  After discussion within 
the research team and an unplanned statistical analysis of FDP results until that 
time, the decision was taken to suspend analysis of fresh urine during this period, 
hence missing data for these tests during this period. 
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Figure 6 – Urine sample handling
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2.6.3 Sputum 
After sputum induction or expectoration, sputum was kept on ice and processed in 
the research laboratory at PHT immediately.  The mucoid portion of sample was 
selected to avoid salivary contamination and then diluted 1:9 with 10% sputolysin 
(Calbiochem, UK), vortexed for 10 seconds, and placed on a roller for 30 minutes.  
After mixing, the sample was filtered through a 100 µm cell strainer, then 
centrifuged at 790 g at 4oC for 10 minutes.  Supernatant was then removed and 
frozen at -80oC for subsequent analysis. 
 
The cell pellet was then re-suspended in 1 ml of PBS.  20 µl of suspension was 
added to 20 µl of trypan blue.  Using a Cellometer vision fluorescent cell counter 
and Peqlab software (Peqlab Ltd, Sarisbury Green, UK), the volume required to 
adjust the concentration of cell suspension to 0.5x106/ml was calculated.  The 
volume was adjusted as calculated and a cytospin was performed at 450 g for 6 
minutes to produce slides.  Once dry, slides were stained with eosin and methylene 
blue, differential cell counts were then performed manually. 
 
Whether spontaneously expectorated or induced, sputum samples were processed 
in line with established protocols using the approach of selecting viscid portions of 
sputum (156).  Expectorated and induced sputum samples have been shown to be 
comparable in terms of differential cell counts (147).  Although supernatant from 
samples was frozen and stored, no further analysis was performed due to the 
overall paucity of samples. 
 
2.7 Blood and urine analyses 
 
2.7.1 Plasminogen activator inhibitor-1 (PAI-1) plasma ELISA 
PAI-1 in plasma was analysed using a human PAI-1 ELISA Duoset® ELISA 
development system (R&D Systems, USA).  A Nunc-ImmunoTM 96 well MaxiSorpTM 
high protein-binding affinity plate (Thermo-Fisher Scientific, USA) was coated with 
100 µl per well of capture antibody (mouse anti-human PAI-1 antibody) at a 
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working concentration of 4 µg/ml in 1x phosphate buffered saline (PBS) without 
Ca2+ or Mg2+.  Following incubation overnight at room temperature, the plate was 
washed with 200 µl per well of wash buffer (0.05% Tween 20 (Fisher Scientific, UK) 
in 1x PBS without Ca2+ or Mg2+) repeated 3 times to complete the wash step.  The 
plate was then blocked with 200 µl per well of block buffer (1% bovine serum 
albumin (BSA) in PBS without Ca2+ or Mg2+) and incubated for a minimum of 1 hour 
at room temperature. 
 
Samples were defrosted on ice and then diluted 1:10 with reagent diluent (1% BSA 
in PBS without Ca2+ or Mg2+), and recombinant human PAI-1 was serially diluted in 
reagent diluent to provide a 7 point standard curve (20,000 pg/ml, 10,000 pg/ml, 
5000 pg/ml, 2500 pg/ml, 1250 pg/ml, 625 pg/ml, 312.5 pg/ml) and reagent diluent 
as zero.  After incubation with block buffer, the wash step was repeated and 100 µl 
of standards or samples were added to each well, in duplicate, and incubated for 2 
hours at room temperature.  After 2 hours incubation, the wash step was repeated 
and 100 µl of detection antibody (biotinylated goat anti-human PAI-1 antibody) at a 
working concentration of 400 ng/ml in reagent diluent with 2% normal goat serum 
was added to each well. 
 
After a further 2 hours incubation at room temperature, the plate was again 
washed as described above and to each well was added 100 µl of streptavidin 
horseradish peroxidase (HRP) at a dilution of 1:200 in reagent diluent.  The plate 
was incubated for 20 minutes at room temperature obscured from direct light.  A 
final wash step was then performed, after which 100 µl of substrate buffer solution 
(tetramethylbenzidine (TMB) see appendix 22) was added to each well for a final 20 
minute incubation obscured from light before 50 µl of stop solution (2 M H2SO4) 
was added per well. 
 
The optical densities of the plate were immediately read at 450 nm with a 570 nm 
wavelength correction using a Dynex MRXe plate reader and Revelation version 
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4.25 software (Dynex technologies, USA).  See appendix 23 for sample standard 
curve. 
 
2.7.2 Transforming growth factor-β1 (TGF-β1) plasma ELISA 
TGF-β1 in plasma was analysed using a human TGF-β1 ELISA Duoset® ELISA 
development system (R&D Systems, USA).  A Nunc-ImmunoTM 96 well MaxiSorpTM 
high protein-binding affinity plate (Thermo-Fisher Scientific, USA) was coated with 
100 µl per well of capture antibody (mouse anti-human TGF-β1) at a working 
concentration of 2 µg/ml in 1x PBS without Ca2+ or Mg2+.  Following incubation 
overnight at room temperature, the plate was washed with 200 µl per well of wash 
buffer (0.05% Tween 20 (Fisher Scientific, UK) in 1x PBS without Ca2+ or Mg2+) 
repeated 3 times to complete the wash step.  The plate was then blocked with 200 
µl per well of block buffer (5% Tween 20 (Fisher Scientific, UK) in PBS without Ca2+ 
or Mg2+) and incubated for a minimum of 1 hour at room temperature. 
 
This ELISA kit measures only active TGF-β1 therefore latent TGF-β1 must be 
activated by the addition of 1 M HCl.  An initial test plate was run with samples that 
did not go undergo the activation step at a 1:2 dilution compared with the same 
samples after activation at a 1:6 dilution.  This confirmed a significant difference 
following activation (<20 pg/ml vs >300 pg/ml) and all subsequent analyses 
included this activation step. 
 
Plasma samples were defrosted on ice.  To 40 µl of sample was added 20 µl of 1 M 
HCl to activate the latent TGF-β1 present.  After 10 minutes incubation at room 
temperature, the reaction was stopped by adding 20 µl of 1.2 M NaOH/0.5 M 
HEPES.  This activated sample was further diluted by adding 160 µl of reagent 
diluent (1% BSA in 0.05% Tween 20 (Fisher Scientific, UK) in 1x PBS without Ca2+ or 
Mg2+), giving a final 1:6 dilution.  Recombinant human TGF-β1 was serially diluted in 
reagent diluent to give a 7 point standard curve (2000 pg/ml, 1000 pg/ml, 500 
pg/ml, 250 pg/ml, 125 pg/ml, 62.5 pg/ml, 31.25 pg/ml) and neat reagent diluent 
was used as a control. 
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After incubation with block buffer, the plate was washed as described above and to 
each well was added 100 µl of sample or standard in duplicate.  After 2 hours 
incubation the plate was again washed and to each well was added 100 µl of 
detection antibody (biotinylated chicken anti-human TGF-β1) at a working 
concentration of 300 ng/ml diluted in reagent diluent.  The plate was incubated for 
a further 2 hours at room temperature and then washed again, then 100 µl of 
streptavidin-HRP diluted 1:200 in reagent diluent was added to each well and 
incubated for 20 minutes at room temperature obscured from light.  A final wash 
step was then performed and 100 µl of TMB substrate was added to each well and 
incubated obscured from light for 20 minutes before the reaction was stopped by 
adding 50 µl of 2 M H2SO4. 
 
The plate was read immediately at 450 nm wavelength with a 570 nm wavelength 
correction using the same Dynex plate reader.  See appendix 23 for sample 
standard curve. 
 
2.7.3 Vascular endothelial growth factor (VEGF) plasma ELISA 
VEGF in plasma was analysed using a human VEGF ELISA Duoset® ELISA 
development system (R&D Systems, USA).  A Nunc-ImmunoTM 96 well MaxiSorpTM 
high protein-binding affinity plate (Thermo-Fisher Scientific, USA) was coated with 
100 µl per well of capture antibody (mouse anti-human VEGF) at a working 
concentration of 1 µg/ml in 1x PBS without Ca2+ or Mg2+.  Following incubation 
overnight at room temperature, the plate was washed with 200 µl per well of wash 
buffer (0.05% Tween 20 (Fisher Scientific, UK) in 1x PBS without Ca2+ or Mg2+) 
repeated 3 times to complete the wash step.  The plate was then blocked with 200 
µl per well of block buffer (10% fetal calf serum (FCS) in 1x PBS without Ca2+ or Mg2+ 
and incubated at room temperature for a minimum of 1 hour. 
 
Plasma samples were defrosted on ice and analysed undiluted.  Recombinant 
human VEGF was serially diluted in 10% FCS in 1x PBS without Ca2+ or Mg2+ to give a 
7 point standard curve (2000 pg/ml, 1000 pg/ml, 500 pg/ml, 250 pg/ml, 125 pg/ml, 
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62.5 pg/ml, 31.25 pg/ml) and neat 10% FCS in 1x PBS without Ca2+ or Mg2+ was used 
as control.  Once the blocking step was complete the plate was washed as 
described and 100 µl of sample or standard was added to each well in duplicate and 
incubated for 2 hours at room temperature. 
 
Once sample incubation was complete, a further wash step was performed then 
100 µl of detection antibody (biotinylated goat anti-human VEGF) at a working 
concentration of 100 ng/ml in reagent diluent (1% BSA in 1x PBS without Ca2+ or 
Mg2+) was added to each well and incubated for 2 hours at room temperature.  The 
plate was then washed and to each well was added 100 µl of streptavidin-HRP 
diluted 1:200 with reagent diluent, and incubated for 20 minutes obscured from 
light.  A final wash step was then performed before adding 100 µl of TMB substrate 
to each well for a final 20 minute incubation at room temperature obscured from 
light.  The reaction was stopped after 20 minutes by adding 50 µl of 2 M H2SO4. 
 
The plate was read immediately at 450 nm wavelength with 570 nm wavelength 
correction using the Dynex plate reader described above. 
 
It was anticipated, based on the findings of Lee and colleagues (74) that plasma 
VEGF levels would be in excess of 200 pg/ml for stable asthmatics.  The initial test 
ELISA run showed levels at a maximum of 87 pg/ml, including samples from 
patients during exacerbation.  To evaluate whether VEGF was being bound in the 
plasma, a spiking experiment was performed by adding VEGF standard to a 
concentration of 10,000 pg/ml.  The returned concentrations were between 1400 
pg/ml and 2000 pg/ml, therefore 80-86% of the added VEGF was no longer 
detectable, presumably due to binding within plasma. 
 
The ELISA instructions advise reagent diluents should be developed for samples 
other than cell culture.  A further test plate with 3 standard curves of different 
reagent diluents (10% fetal calf serum, 50% fetal calf serum and 1% bovine serum 
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albumin) was run to evaluate whether this would affect non-specific binding, with 
no remarkable difference.  See appendix 23 for sample standard curves. 
 
2.7.4 Thrombin-activatable fibrinolysis inhibitor (TAFI) plasma ELISA 
Two different ELISA methods were used to analyse plasma for TAFI due to 
quantities of antibodies available. 
 
The first employed a matched pair antibodies set, TAFI-EIA (Affinity Biologicals, 
Ontario, Canada).  The capture antibody was diluted 1:100 in carbonate-
bicarbonate buffer, pH 9.6 (Sigma capsules).  100 µl per well was added to a Nunc-
ImmunoTM 96 well MaxiSorpTM high protein-binding affinity plate (Thermo-Fisher 
Scientific, USA) which was incubated overnight at 4oC.  After incubation, the wells 
were emptied and 100 µl of block buffer (1% BSA in 1x PBS without Ca2+ or Mg2+) 
was added to each well, then incubated for 1 hour at room temperature.  The plate 
was then washed 3 times with 200 µl of wash buffer (0.1% Tween 20 in 1 x PBS 
without Ca2+ or Mg2+).  A 7 point standard curve was generated using standard 
reference plasma (Affinity Biologicals) (2.18 ng/ml, 4.36 ng/ml, 8.73 ng/ml, 17.45 
ng/ml, 34.9 ng/ml, 69.8 ng/ml and 139.6 ng/ml), diluted in sample diluent (0.1% 
Tween 20 in 1x PBS without Ca2+ or Mg2+). 
 
100 µl of sample or standard was added to each well then incubated for 2 hours at 
room temperature.  Samples were diluted 1:500 with reagent diluent.  After 2 hours 
incubation, the wash step was repeated and 100 µl per well of detection antibody 
was applied for a further 1 hour incubation at room temperature.  After incubation, 
100 µl of TMB substrate solution was added to each well, then the reaction was 
stopped after 20 minutes with 50 µl of 2 M H2SO4 and the plate read immediately at 
490 nm using the Dynex plate reader.  See appendix 23 for sample standard curve. 
 
The second TAFI ELISA employed was a VisuLize TAFI antigen kit (Affinity Biologicals, 
Ontario, Canada) which was used according to manufacturers’ instructions.  A six 
point standard curve was generated using reference plasma (69.8 ng/ml, 34.9 
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ng/ml, 17.45 ng/ml, 8.73 ng/ml, 4.36 ng/ml, 2.18 ng/ml).  Samples were diluted 
1:500 with sample diluent.  A pre-coated plate was washed 3 times with 200 µl per 
well of wash buffer, then coated with 100 µl of sample or standard and incubated 
for 1 hour at room temperature.  The wash step was repeated then to each well 
was added 100 µl of detecting antibody.  After a further 30 minute incubation at 
room temperature, the wash step was repeated and to each well was added 100 µl 
of TMB substrate.  After 10 minutes, the reaction was stopped by adding 100 µl per 
well of stop solution.  The plate was then read immediately at 450 nm wavelength 
using the Dynex plate reader.  See appendix 23 for sample standard curve. 
 
2.7.5 Tissue Factor (TF) plasma ELISA 
TF in plasma was analysed using a human TF ELISA Duoset® ELISA development 
system (R&D Systems, USA).  A Nunc-ImmunoTM 96 well MaxiSorpTM high protein-
binding affinity plate (Thermo-Fisher Scientific, USA) was coated with 100 µl per 
well of capture antibody (mouse anti-human TF) at a working concentration of 4 
µg/ml diluted in 1x PBS without Ca2+ or Mg2+.  Following incubation overnight at 
room temperature, the plate was washed with 200 µl per well of wash buffer 
(0.05% Tween 20 (Fisher Scientific, UK) in 1x PBS without Ca2+ or Mg2+) repeated 3 
times to complete the wash step.   
 
The plate was then blocked by adding 200 µl per well of reagent diluent (1% BSA in 
1x PBS without Ca2+ or Mg2+) and incubated for 1 hour at room temperature.  
Samples were defrosted on ice and were analysed undiluted.  Recombinant human 
TF was serially diluted in 1% BSA in 1x PBS without Ca2+ or Mg2+ to give a 7 point 
standard curve (500 pg/ml, 250 pg/ml, 125 pg/ml, 62.5 pg/ml, 31.25 pg/ml, 15.63 
pg/ml, 7.81 pg/ml).  100 µl of sample or standard was added to each well and 
incubated at room temperature for 2 hours.  A further wash step was then 
performed and 100 µl of detection antibody (biotinylated goat anti-human TF) 
diluted to a working concentration of 200 ng/ml in reagent diluent was added to 
each well and incubated for 2 hours at room temperature. 
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The plate was then washed and to each well was added 100 µl of streptavidin-HRP 
diluted 1:200 with reagent diluent, and incubated for 20 minutes obscured from 
light.  A final wash step was then performed before adding 100 µl of TMB substrate 
to each well for a final 20 minute incubation at room temperature obscured from 
light.  The reaction was stopped after 20 minutes by adding 50 µl of 2 M H2SO4.  See 
appendix 23 for sample standard curve. 
 
A test TF plate was run with 1:10 and 1:50 sample dilutions, both returned 
undetectable levels of TF.  A spike experiment was therefore performed where a 
plasma sample was spiked with TF standard to a concentration of 125 pg/ml.  This 
spiked control sample was then diluted 1:10 and 1:50.  The undiluted, un-spiked  
plasma returned a concentration of 5 pg/ml, the 125 pg/ml undiluted sample 
returned a concentration of 18.5 pg/ml, after a 1:10 dilution, 53.8 pg/ml and after 
1:50 85 pg/ml.  This experiment confirmed there was 86% TF binding in plasma 
rendering it undetectable by this ELISA.  This was unexpected as manufacturer’s 
instructions for the TF ELISA explained all TF both bound and unbound should be 
measured by this test.  Despite attempts to contact the manufacturer, no 
explanation was forthcoming for this finding and further TF analyses were 
abandoned. 
 
2.7.6 Platelet factor 4 (PF4) plasma ELISA 
PF4 in plasma was analysed using a human PF4 ELISA Duoset® ELISA development 
system (R&D Systems, USA).  A Nunc-ImmunoTM 96 well MaxiSorpTM high protein-
binding affinity plate (Thermo-Fisher Scientific, USA) was coated with 100 µl per 
well of capture antibody (mouse anti-human PF4) at a working concentration of 2 
µg/ml diluted in 1x PBS without Ca2+ or Mg2+.  Following incubation overnight at 
room temperature, the plate was washed with 200 µl per well of wash buffer 
(0.05% Tween 20 (Fisher Scientific, UK) in 1x PBS without Ca2+ or Mg2+) repeated 3 
times to complete the wash step.  The plate was then blocked with 200 µl per well 
of block buffer (10% fetal calf serum (FCS) in 1x PBS without Ca2+ or Mg2+ and 
incubated at room temperature for a minimum of 1 hour. 
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Plasma samples were defrosted on ice and analysed diluted with reagent diluent as 
described below. 
 
Recombinant human PF4 was serially diluted in sample diluent, 10% FCS in 1x PBS 
without Ca2+ or Mg2+ to give a 7 point standard curve (1000 pg/ml, 500 pg/ml, 250 
pg/ml, 125 pg/ml, 62.5 pg/ml, 31.25 pg/ml, 15.63 pg/ml) and neat 10% FCS in 1x 
PBS without Ca2+ or Mg2+ was used as control.  Once the blocking step was 
complete the plate was washed as described and 100 µl of sample or standard was 
added to each well in duplicate and incubated for 2 hours at room temperature.   
 
Once sample incubation was complete, a further wash step was performed then 
100 µl of detection antibody (biotinylated goat anti-human PF4) at a working 
concentration of 200 ng/ml in reagent diluent (1% BSA in 1x PBS without Ca2+ or 
Mg2+) was added to each well and incubated for 2 hours at room temperature.  The 
plate was then washed and to each well was added 100 µl of streptavidin-HRP 
diluted 1:200 with reagent diluent, and incubated for 20 minutes obscured from 
light.  A final wash step was then performed before adding 100 µl of TMB substrate 
to each well for a final 20 minute incubation at room temperature obscured from 
light.  The reaction was stopped after 20 minutes by adding 50 µl of 2 M H2SO4. 
 
The plate was read immediately at 450 nm wavelength with 570 nm wavelength 
correction using the Dynex plate reader described above. 
 
A test plate was run initially with serial dilutions of 1:2500, 1:5000, 1:10,000, 
1:20,000, 1:60,000, 1:120,000 and 1:240,000 and 1:480,000.  This determined that 
1:5000 was an appropriate dilution to bring both exacerbation and recovery 
samples within the detection range of the ELISA.  See appendix 23 for sample 
standard curve. 
 
For the subsequent sample analyses, samples were diluted 1:5000 with reagent 
diluent. 
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2.7.7 Plasma multiplex cytokine analysis 
Plasma multiplex analysis was performed for IL-5, IL-6, IL-8, IL12P40, IL-13, IL-17A, 
IFN-γ, TNF-α, eotaxin and RANTES using the Millipore™ Milliplex© Map Mouse 
cytokine/chemokine kit (Millipore corp, Missouri, USA) according to manufacturer’s 
instructions.  Mouse cytokine standard was reconstituted with 250 µl deionised 
water to a concentration of 10,000 pg/ml and serially diluted to 2000 pg/ml, 400 
pg/ml, 80 pg/ml, 16 pg/ml and 3.2 pg/ml standards with assay buffer as control.  
The 96 well microtitre plate was pre-wetted by adding 200 µl wash buffer per well 
for 10 minutes then removed. 
 
25 µl of sample buffer and 25 µl serum matrix was added to each well, then 25 µl or 
sample was added according to a plate map.  To each well was then added 25 µl of 
premixed beads and the plate was covered and incubated for 2 hrs at room 
temperature.  After incubation, fluid was removed from wells and 2x 200 µl washes 
with wash buffer were performed. 
 
25 µl of detection antibody was then added to each well and incubated at room 
temperature for 1 hr.  After incubation 25 µl of streptavidin-phycoerythrin was 
added to each well and the plate was incubated for a further 30 minutes at room 
temperature.  All fluid was then removed and a further wash cycle was performed.  
150 µl of sheath fluid was then added to each well and the plate was agitated for 5 
minutes on a plate shaker to re-suspend beads. 
 
The plate was then read immediately using a Luminex 200™ analyser (Luminex 
corporation, Austin, Texas, USA) according to manufacturer’s instructions and 
recommended settings.  See appendix 23 for sample standard curve. 
 
2.7.8 Urine fibrin(ogen) degradation product (FDP) analysis 
The Remel Thrombo-Wellcotest (Thermo Fisher Scientific, Oxoid, Basingstoke, UK), 
a commercially available latex agglutination test was used according to 
manufacturers’ instructions to analyse FDPs in urine.  The minimum detectable 
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concentration of FDPs by this test is 2 µg/ml.  It detects human fibrinogen 
fragments D and E which are both fibrin and fibrinogen breakdown products. 
 
Urine stored for up to 1 week at 4oC was centrifuged at 1100 g for 10 minutes at 
4oC in a 15 ml Falcon tube.  1 ml of supernatant was then filtered in a 5 ml syringe 
using a GELMAN 30 mm diameter 0.45 µm polytetrafluoroethylene (PTFE) 
membrane filter (PALL Life Sciences, Southampton, UK) into a 1.5 ml eppendorf 
tube.  40 µl of sample and 40 µl of antibody-coated latex was mixed on a black-
coloured glass plate using a plate shaker at 75 rpm.  A positive result is indicated by 
agglutination and samples were examined at 2, 10 and 30 minute time points.  If 
sample was positive by 10 minutes, a 1:2 serial dilution was performed and samples 
were re-tested as above until a negative reaction occurred.  A semi-quantitative 
value for FDP was then reported (e.g. a 1:4 dilution indicates a minimum of 8 µg/ml 
FDP). 
 
2.7.9 Urine Glycosaminoglycan (GAG) analysis 
The assay will detect sulphated GAGs, but not hyaluronic acid, in both free and 
bound form (157). 
 
Refrigerated samples were centrifuged for 10 minutes at 4oC and 1100 g.  GAGs 
were precipitated by adding 1 ml of supernatant to 4 mls of 100% ethanol and 
refrigerating at 4oC overnight.  After precipitation, the sample was centrifuged at 
4oC and 1100 g for 20 minutes. 
 
The pellet was then re-dissolved in 0.125 ml of PBS/0.5 M NaCl (10 ml 1x PBS 
without Ca2+ or Mg2+ + 2.92 g NaCl)  by warming at 56oC in an incubator on shaking, 
and vortex mixing at 30 minute intervals for at least 2 hours.  Samples were then 
centrifuged for a further 10 minutes at 4oC at 1100 g.  The sample was then diluted 
1:10 in PBS/0.5 M NaCl (10 µl sample + 90 µl PBS/0.5 M NaCl). 
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7.5 µl of both the dilute and neat sample is added to each well of a microtitre plate 
in duplicate.  250 µl of 1,9-dimethyl-methylene blue colour reagent was then added 
and mixed in the wells with the samples.  The colour reagent consists of 500 mls 
H2O + 8 mg 1,9-dimethyl-methylene blue + 1.52 g glycine + 1.19 g NaCl, adjusted to 
pH 3.0 with HCl. 
 
After mixing the samples and colour reagent with a pipette 7 times, the absorbance 
was read at 620 nm exactly 4 ½ minutes from adding the last of the colour reagent.  
The standard curve was constructed using reagent blanks and heparin in a 
concentration range of 0-2 µg/50 µl (0 µg/50 µl, 0.25 µg/50 µl, 0.5 µg/50 µl, 1 µg/50 
µl, 1.5 µg/50 µl, 2 µg/50 µl). 
 
2.7.10 Urine matrix metalloproteinase (MMP) analysis 
The EnzChek Gelatinase/Collagenase Assay Kit (Invitrogen, Life Technologies, 
Paisley, UK) was used to quantitatively ascertain the levels of gelatinases present in 
urine, according to manufacturers’ instructions. 
 
Urine was refrigerated at 4oC prior to processing then centrifuged at 4oC for 10 
minutes at 1100 g as universal preparation for all analyses outlined above.  A 
further centrifugation step was performed again at 4oC for 10 minutes but for 1910 
g.  A 96-well fluoronunc microplate (Thermo-Fisher Scientific, USA) was used.  To 
each well in duplicate was added 100 µl of standard, sample or control and 80 µl of 
1x reaction buffer.  Next to these wells in duplicate was added 100 µl of standard, 
sample or control with 60 µl of 1x reaction buffer and 20 µl of 10 mM 1,10-
phenanthroline.  Control was 1x reaction buffer and standards 0.001, 0.01 and 
0.1U/ml of collagenase (from Clostridium histolyticum).  Samples were undiluted 
and taken from supernatant after centrifugation taking care not to disturb any 
pellet formed. 
 
Plates were kept on ice and to each well was added 20 µl of 100 µg/ml DQ gelatin 
giving a total volume of 200 µl per well.  Plates were read immediately using a 
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fluorescence microplate reader at 495 nm and fluorescence emission at 515 nm.  
Each plate run was for 2 hours and sequential readings were taken at time 0 and 
every 10 minutes for the duration of the run.
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3.0 PART 1 RESULTS 
 
3.1 Part 1 screening, recruitment, withdrawal and completion 
We successfully recruited 82 patients with acute exacerbation of asthma, 64 of 
whom completed the study.  This is the largest study to date investigating 
coagulation and fibrinolysis in acute exacerbation of asthma. 
A total of 147 patients were screened for Part 1 and 82 participants were recruited 
to this arm of the study.  The reasons for study exclusion at screening are outlined 
below in figure 7.  Of these 82, 16 were not seen at follow up, 15 of which did not 
attend and hence withdrew, and 1 was diagnosed with pneumonia the day after 
study recruitment and hence withdrawn.  The remaining 66 were seen at follow up 
visit 1 and 2 were withdrawn at this time, one because they experienced a second 
exacerbation and the other required omalizumab treatment at review necessitating 
withdrawal.   
 
Of the remaining 64 participants, 41 recovered at follow up 1 and the remaining 23 
were offered a second follow up appointment.  All 23 attended their second follow 
up and 14 had recovered at this visit, leaving 9 study participants who did not 
recover during the study period.  See figure 7 below for summary of Part 1 
recruitment. 
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Figure 7 – Part 1 screening
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3.1.1 Adverse events – Part 1 
There were 7 adverse events during the study period (table 4), all classified as 
serious adverse events (SAE), 6 due to participants being admitted to hospital, and 
1 because the participant had a prolonged hospital stay. 
 
Table 2 – Adverse events – Part 1 
Study 
number* 
Adverse event Related to study 
activity? 
J1013XX Re-admission to hospital with asthma No 
J1015XX Re-admission to hospital with asthma No 
J1027XX Pneumonia after initial admission No 
J1030XX Re-admission to hospital with asthma No 
J1042XX Re-admission to hospital with asthma No 
J1052XX Re-admission to hospital with asthma No 
J1069XX Admitted for observation after induced sputum Yes 
* Participant initials removed to preserve anonymity 
Only 1 SAE was deemed to be related to study activity, but was subsequently 
deemed by the study sponsor a recognised complication of the procedure (sputum 
induction) that was addressed in the study protocol and design. 
 
3.2 Participant characteristics – Part 1 
Patient characteristics were summarised for all patients in Part 1 of the study. 
Continuous variables were summarised by either the mean and standard deviation, 
if found to be normally distributed, or median and inter-quartile range if not 
normally distributed. Categorical variables were summarised by the number and 
percentage of patients in each category. 
 
Comparisons were made between patients who did and did not complete the 
study. The analysis of continuous variables found to be normally distributed was 
performed using the unpaired t-test, whilst continuous variables not found to be 
normally distributed were analysed using the Mann-Whitney test. Binary 
categorical variables, and those with no ordering of the categories were analysed 
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using Fisher's exact test. Ordinal categorical variables were analysed using the 
Mann-Whitney test (in order to take account of the order of the categories, which is 
not utilised using Fisher's exact test). 
 
Results 
A summary of the patient characteristics is given in the two subsequent tables 
(table 3 continuous variables and table 4 categorical). The figures reported are the 
results for all patients, and then split by those who withdrew from the study and 
those who did not. P-values indicating the significance of the difference between 
those who did and did not withdraw are also presented. 
 
Table 3 – Participant characteristics Part 1 continuous variables 
Variable All patients 
(n=82) 
Completed  
(n=64) 
Withdrawn 
(n=16) 
P-value  
     
Age (years) (*) 40.1 (13.4) 42.1 (13.5) 32.8 (10.2)   0.008 
Hospital admissions 
(**) 
0 (0, 2) 0 (0, 1) 1 (0, 2) 0.02 
Steroid courses (**) 3 (1, 6) 2 (1, 6) 4 (2, 9) 0.13 
Body mass index 
(BMI) (kg/m2)  (**) 
28.9 (25.0, 
34.8) 
30.5 (25.4, 
35.6) 
27.7 (24.7, 
31.2) 
0.14 
     
(*)   Mean (standard deviation) reported 
(**) Median (inter-quartile range) reported 
 
The results suggested a significant difference in age and number of hospital 
admissions due to asthma between those who withdrew and those who completed 
the study. Those who withdrew tended to be younger, with a mean age of 32, 
compared to 42. 
 
No significant differences were observed for the number of steroid courses over 2 
years or for BMI comparing study subjects who withdrew and those who completed 
the study. 
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Table 4 – Participant characteristics Part 1 categorical variables 
Variable Category All patients 
(n=82) Completed 
(n=64) 
Withdrawn 
(n=18) 
P-value  
      
Sex Male 26 (32%) 22 (34%) 4 (22%) 0.40 
 Female 56 (68%) 42 (66%) 14 (78%)  
      
GINA 2008 Intermittent 8 (10%) 7 (11%) 1 (6%) 0.07 
 Mild Persist. 20 (24%) 17 (27%) 3 (17%)  
 Mod. Persist 25 (30%) 21 (33%) 4 (22%)  
 Severe Persist 29 (35%) 19 (30%) 10 (56%)  
      
Asthma Mild 27 (33%) 22 (34%) 5 (28%) 0.55 
Severity Moderate 23 (28%) 18 (28%) 5 (28%)  
 Severe 32 (39%) 24 (38%) 8 (44%)  
      
Eosinophilic No 33 (40%) 27 (42%) 6 (33%) 0.59 
 Yes 49 (60%) 37 (58%) 12 (67%)  
      
Smoking Current 14 (17%) 10 (16%) 4 (22%) 0.14 
status Ex 24 (29%) 16 (25%) 8 (44%)  
 Never 44 (54%) 38 (59%) 6 (33%)  
      
Obese No 40 (50%) 28 (44%) 12 (71%) 0.10 
 Yes 40 (50%) 35 (56%) 5 (29%)  
      
Atopy  No 13 (22%) 13 (22%) 0 (0%) 1.00 
(SPT positive) Yes 47 (78%) 46 (78%) 1 (100%)  
      
Atopy No 30 (38%) 25 (40%) 5 (31%) 0.58 
(raised IgE) Yes 49 (62%) 38 (60%) 11 (69%)  
      
 
Comparing categorical patient characteristics, there was no significant difference 
between those who completed and those who withdrew from the study.  
Participants who withdrew tended towards more severe asthma as defined by GINA 
2008 criteria, although this result was only of borderline statistical significance.  
 
Discussion 
Study recruitment into Part 1 of the study took place in 2 centres, BNHFT 
Basingstoke and QAH Portsmouth, both of which are located in Hampshire, UK.  The 
population served by both centres is predominantly white Caucasian, and although 
not formally recorded in the CRF data, this was reflected in the study population 
recruited.  The majority of the study recruits were female (68%), consistent with the 
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known trends in asthma prevalence among adults (158).  In terms of asthma 
inflammatory phenotype, our study population was predominantly eosinophilic 
(60%) and/or atopic (78% by skin prick test positivity, 62% by elevated IgE levels).  
This is consistent with the observation that eosinophilia is most commonly seen in 
classic atopic asthma (159), however, the definition of eosinophilic asthma and 
variability in the presence of eosinophilia must be considered and is discussed 
below alongside the definitions used in this study. 
Comparing participants who completed the study compared with those who 
withdrew, those who withdrew were on average 10 years younger (p=0.008) and 
were more likely to have had an exacerbation requiring hospital admission within 
the 2 years preceding study enrolment (p=0.02).  There were no other significant 
differences in terms of patient demographics between those who withdrew and 
those who completed the study.  Admission to hospital within the previous year is 
recognised as a risk factor for death from asthma (4, 158).  Furthermore, failure to 
attend appointments is also recognised as a risk for asthma death (4).  It is worth 
noting that the reason for withdrawal from Part 1 of the study in 15 of 18 patients 
(83%) was failure to attend follow up.  Other risks for asthma death such as adverse 
psychosocial factors (4, 158) were not recorded as part of the data collected for this 
study but should be considered in the design of future projects.  Our study recorded 
hospital admission for asthma in the preceding 2 years, whereas 1 year would be 
consistent with evidence of risk for asthma death and of greater relevance.  The 
significance of the younger age of those who withdrew is not clear from the data 
collected and potential factors such as employment, family or financial 
commitments could just as easily explain a younger or older age bias so do not 
narrow speculation on this matter. 
Overall it is worth taking the above factors into consideration if extrapolating the 
findings of this study when looking at different populations. 
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3.3 Plasma and urine analyses – Part 1 
Plasma and urine markers of fibrin turnover and cytokines were measured at 
admission, and then at two subsequent follow-up timepoints. The admission visit in 
Part 1 corresponds with asthma exacerbation and subsequent follow up visits are 
after treatment with oral corticosteroids and a period of recovery from 
exacerbation.  To simplify the analyses comparisons were performed between 
values at admission (exacerbation) and values at each of two follow-up timepoints 
separately. 
 
The majority of variables were measured on a continuous scale. The statistical 
methods used were dependent on the distribution of the values. Where the values 
were normally distributed, the paired t-test was used to compare between 
timepoints. For a large number of the variables the values were not normally 
distributed, and the Wilcoxon matched-pairs test was preferred. 
 
One variable was measured on a binary scale. The paired exact test was used to 
compare this variable between timepoints. 
 
Results 
The first set of analyses examined the change in values from admission to the first 
follow-up timepoint, and a summary of the results is given in the table 5 below. The 
first figures reported are the number of patients with measurements at both 
timepoints. For those variables where the values were not normally distributed, the 
median and inter-quartile range at each timepoint is reported, along with the 
median difference and corresponding confidence interval.  For those variables 
where the values were normally distributed, the mean and standard deviation at 
each timepoint is reported, along with the mean difference and corresponding 
confidence interval. P-values indicating the significance of the results are also given. 
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Table 5 – Part 1 plasma and urine results admission vs follow up 1 
Variable N Admission 
median (IQR) or 
mean (SD)
(*)
 or 
number (%)
(**) 
Follow-up 1  
median (IQR) or 
mean (SD)
(*)
 or 
number (%)
(**)
 
Change 
exacerbation -
follow up 1 
median (95% CI) 
P-value  
Plasma Fibrin 
markers 
     
TAFI (ng/ml)
(*) (†)
 59 6360 (2573) 7306 (2739) 945 (13, 1878) 0.05 
PAI-1 (pg/ml) 59 15400  
(10400, 29300) 
16500 
(9273, 34900) 
1700  
(-1704, 3868) 
0.55 
D-dimer (µgFEU/ml) 59 0.19 (0.13, 0.37) 0.21 (0.15, 0.28) 0.0 (-0.07, 0.04) 0.40 
Fibrinogen (g/l) 
(*)
 59 3.00 (0.85) 2.92 (0.61) -0.08 (-0.30, 0.13) 0.45 
Plats (10
*
9/l) 
(*)
 32 276 (88) 278 (77) 2 (-18, 22) 0.82 
PF4 (µg/ml)
(*)
 56 1.8 (1.6) 2.3 (1.9) 0.6 (0.1, 1.1) 0.03 
TGFβ1 (pg/ml) 59 1637  
(759, 3138) 
1619  
(1020, 2534) 
63 (-192, 344) 0.78 
VEGF (pg/ml) 59 2.6 (0.0, 28.2) 5.3 (0.0, 37.0) 0.0 (0.0, 0.0) 0.92 
Eosinophils (10
*
9/l) 32 0.10 (0.00, 0.48) 0.30 (0.20, 0.48) 0.13 (0.10, 0.20)   0.003 
Plasma Cytokines      
IL-6 (pg/ml) 57 1.4 (0.0, 5.1) 0.9 (0.0, 2.3) 0.0 (-1.4, 0.0) 0.02 
IFN (pg/ml) 57 24 (8, 49) 19 (8, 32) -3 (-10, 0)   0.003 
IL-13 (pg/ml) 57 0.0 (0.0, 4.5) 0.0 (0.0, 2.0) 0.0 (-0.2, 0.0) <0.001 
RANTES (pg/ml)
(*)
 57 2736 (1193) 2134 (873) -601 (-938, -266) <0.001 
IL-12 P40 (pg/ml) 57 16 (0, 49) 7 (0, 39) 0 (-30, 2) 0.01 
IL-17A (pg/ml) 57 3.4 (0.0, 13.1) 1.9 (0.0, 6.4) -0.3 (-3.2, 0.0)   0.002 
IL-8 (pg/ml) 57 2.6 (1.2, 5.9) 2.5 (1.7, 4.4) 0.2 (-0.7, 0.7) 0.56 
TNF-α (pg/ml) 57 7.2 (4.5, 11.0) 6.6 (4.6, 10.0) -0.9 (-1.6, 0.6) 0.11 
Eotaxin (pg/ml) 57 53 (42, 69) 63 (49, 80) 9 (2, 17)   0.002 
IL-5 (pg/ml) 57 3.0 (1.1, 7.0) 1.9 (1.2, 4.6) -0.4 (-1.5, 0.0)   0.007 
Urine tests      
FDP  (+/-)
(**)
 47 10 (21%) 8 (17%) -4% (-23%, 15%) 0.80 
MMP activity (FU) 5 0.0014 
(0.0009,0.0026) 
0.0008 
(0.003, 0.0023) 
-0.0006 
(-0.008, 0.0005) 
0.14 
GAG:Creatinine 
(µg/mmol) 
27 0.44 (0.29, 0.62) 0.29 (0.19, 0.40) -0.21 (-0.27, 0.03) 0.04 
(*)   Mean (standard deviation) reported, along with mean change (95% CI) 
(**) Number (%) with positive responses reported, along with percentage change (95% CI) 
(†) Omitting one patient with extremely high value at follow-up 
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The results suggested a number of significant changes between admission and 
follow-up 1.  
 
There were significantly higher values in plasma samples taken at follow up 1 
compared with admission for PF4, eosinophils and eotaxin. For example, there was 
a median increase in eosinophils of 0.13 x10*9/l. There was also slight evidence of 
an increase in TAFI, but the result for this variable was only of borderline statistical 
significance. 
 
Conversely there was a significant decrease from admission to follow up 1 for GAGs, 
IL-6, IFN, IL-13, RANTES, IL-12, IL-17A and IL-5. For example, the mean decrease in 
RANTES was 601 pg/ml between the two study visits. There was a median reduction 
of 0.21 µg/mmol over time for GAGs. 
 
A similar set of analyses were performed to examine the change in the various 
parameters from admission to the second follow-up visit. The results are 
summarised in the table 6 below. 
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Table 6 – Part 1 plasma and urine admission vs follow up 2 
Variable N Admission 
median (IQR) or 
mean (SD)
(*)
 or 
number (%)
(**)
 
Follow-up 2  
median (IQR) or 
mean (SD)
(*)
 or 
number (%)
(**)
 
Change admission – 
follow up 2 
median (95% CI) 
P-
value  
Plasma Fibrin markers      
TAFI (ng/ml)
(*)
 21 5956 (1776) 7242 (2915) 1285 (-151, 2722) 0.08 
PAI-1 (pg/ml) 21 14200  
(6811, 23300) 
17400 
(7301, 28650) 
6200  
(-2191, 10240) 
0.04 
D-dimer (µgFEU/ml) 22 0.19 (0.10, 0.34) 0.26 (0.14, 0.33) 0.03 (-0.06, 0.10) 0.53 
Fibrinogen (g/l)
(*)
 22 2.97 (0.99) 3.12 (0.70) 0.15 (-0.22, 0.51) 0.41 
Plats (10
*
9/l)
(*)
 9 241 (71) 270 (82) 30 (1, 58) 0.05 
PF4 (µg/ml)
(*)
 21 1.8 (1.4) 1.9 (1.5) 0.1 (-0.7, 1.0) 0.80 
TGFβ1 (pg/ml) 21 1793  
(874, 3652) 
1332  
(648, 2334) 
-351 (-1625, 114) 0.10 
VEGF (pg/ml) 21 0.3 (0.0, 31.6) 7.2 (0.0, 35.0) 0.0 (0.0, 3.8) 0.68 
Eosinophils (10
*
9/l) 9 0.00 (0.00, 0.13) 0.20 (0.10, 0.70) 0.10 (0.00, 0.80) 0.04 
Plasma Cytokines      
IL-6 (pg/ml) 20 0.8 (0.2, 5.1) 1.9 (0.0, 4.7) 0.1 (-0.3, 1.9) 0.60 
IFN (pg/ml) 20 18 (8, 39) 19 (10, 39) 1 (-21, 20) 0.82 
IL-13 (pg/ml) 20 0.0 (0.0, 6.9) 0.0 (0.0, 12.4) 0.0 (0.0, 1.0) 0.83 
RANTES (pg/ml)
(*)
 20 2568 (1128) 2374 (1257) -193 (-785, 398) 0.50 
IL-12 P40 (pg/ml) 20 18 (0, 46) 3 (0, 52) 0 (-4, 26) 0.68 
IL-17A (pg/ml) 20 1.4 (0.0, 11.7) 2.5 (0.0, 15.3) 0.1 (-0.2, 5.4) 0.41 
IL-8 (pg/ml) 20 2.6 (1.2, 7.8) 3.3 (2.2, 6.2) 0.4 (-2.3, 1.3) 0.85 
TNF-α (pg/ml) 20 7.3 (4.5, 11.5) 8.1 (5.8, 13.2) 1.5 (0.0, 4.9) 0.35 
Eotaxin (pg/ml) 20 57 (43, 71) 63 (51, 90) 12 (-5, 23) 0.07 
IL-5 (pg/ml) 20 2.9 (1.0, 5.9) 2.4 (1.3, 7.9) 0.0 (-1.1, 2.4) 0.99 
Urine tests      
FDP (+/-)
(**)
 17 5 (29%) 2 (12%) -18%  
(-48%, 13%) 
0.38 
MMP activity (FU) 3 0.0015  
(0.0009, 0.0018) 
0.0005 
(0.0002, 0.0014) 
-0.0004 
(-0.0016, 0.0000) 
0.11 
GAG:creatinine 
(µg/mmol) 
4 0.37 (0.16, 0.51) 0.47 (0.13, 1.24) 0.26 (-0.49, 1.46) 0.47 
(*)   Mean (standard deviation) reported, along with mean change (95% CI) 
(**) Number (%) with positive responses reported, along with percentage change (95% CI) 
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The results suggested few significant differences between admission and follow-up 
2.  
 
There was a significant increase in PAI-1 from admission to follow up 2, with a 
median increase of 6200 pg/ml. There was also a significant increase in eosinophils, 
with a median increase of 0.10 x10*9/l. 
Additionally there was some evidence of an increase in TAFI, platelets and eotaxin 
at follow up 2 compared with admission, but these results were not quite 
statistically significant.  
 
It should be noted that although there were fewer differences from admission to 
the second follow-up timepoint, this may be partly attributable to smaller numbers 
of patients with measurements at this latter follow-up point. Some of the lack of 
significance may be due to smaller differences, but some may be due to lower 
power with smaller numbers. For example, the change in eotaxin from admission to 
follow-up 2 was greater than from admission to follow-up 1, but the result was less 
statistically significant due to the smaller numbers. 
 
3.3.1 Exacerbation vs clinical recovery – Part 1 
Although the study incorporated 2 follow up timepoints, those participants who 
recovered at their first follow up visit did not require a second follow up, and 
conversely, only those who had not clinically recovered at follow up 1 were offered 
a second follow up visit.  Furthermore, some participants did not clinically recover 
at second follow up.   
 
From a clinical perspective, the comparison between exacerbation and clinical 
recovery is perhaps more pertinent than a 35 day or 65 day temporal interval.   
 
Data from participants who clinically recovered at the first follow up at 35 days 
(rapid recovery), were grouped with data from the second follow-up timepoint at 
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65 days (delayed recovery), and compared with admission visit data.  Patients who 
did not recover were omitted from the analyses. 
 
The majority of variables were measured on a continuous scale. The statistical 
methods used were dependent on the distribution of the values. Where the values 
were normally distributed, the paired t-test was used to compare between 
timepoints. For a large number of the variables the values were not normally 
distributed, and the Wilcoxon matched-pairs test was preferred. 
 
One variable was measured on a binary scale. The paired exact test was used to 
compare this variable between timepoints. 
 
Results – exacerbation vs clinical recovery Part 1 
The analyses examined the change in values from exacerbation to recovery and a 
summary of the results is given in table 7 below. The first figures reported are the 
number of patients with measurements at both timepoints. For those variables 
where the values were not normally distributed, the median and inter-quartile 
range at each timepoint is reported, along with the median difference and 
corresponding confidence interval.  For those variables where values were normally 
distributed, the mean and standard deviation at each timepoint is reported, along 
with the mean difference and corresponding confidence interval. P-values 
indicating the significance of the results are also given. 
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Table 7 – Part 1 plasma and urine exacerbation vs clinical recovery 
Variable N Exacerbation 
median (IQR) or 
mean (SD)
(*)
 or 
number (%)
(**)
 
Clinical recovery 
median (IQR) or 
mean (SD)
(*)
 or 
number (%)
(**)
 
Change 
exacerbation – 
clinical recovery 
median (95% CI) 
P-
value  
Plasma fibrin markers      
TAFI (ng/ml) 
(*) (†)
 50 6283 (2504) 7205 (2406) 921 (-39, 1882) 0.06 
PAI-1 (pg/ml) 50 15900  
(10550, 29325) 
16550 
(8089, 33175) 
1219  
(-1963, 4518) 
0.53 
D-dimer (µgFEU/ml) 48 0.21 (0.13, 0.36) 0.21 (0.14, 0.31) 0.00 (-0.07, 0.03) 0.47 
Fibrinogen (g/l)
(*)
 48 2.89 (0.66) 2.87 (0.61) -0.02 (-0.25, 0.22) 0.87 
Plats (10
*
9/l)
(*)
 20 282 (89) 274 (75) -8 (-38, 22) 0.59 
PF4 (µg/ml)
(*)
 47 1.9 (1.7) 2.2 (1.8) 0.3 (-0.4, 0.9) 0.41 
TGFβ1 (pg/ml) 50 
1702 (805, 2832) 
1609 (921, 2411) -63 (-331, 354) 0.92 
VEGF (pg/ml) 50 6.1 (0.0, 30.9) 10.4 (0.0, 37.1) 0.0 (0.0, 0.0) 0.76 
Eosinophils (10
*
9/l) 20 0.00 (0.00, 0.33) 0.30 (0.20, 0.40) 0.15 (0.10, 0.29) 0.02 
Plasma Cytokines      
IL-6 (pg/ml) 48 1.4 (0.0, 3.4) 1.0 (0.0, 4.1) 0.0 (-0.7, 0.3) 0.56 
IFN (pg/ml) 48 24 (6, 50) 21 (10, 33) -1 (-7, 2) 0.12 
IL-13 (pg/ml) 48 0.0 (0.0, 4.3) 0.0 (0.0, 2.1) 0.0 (0.0, 0.0) 0.07 
RANTES(pg/ml) 
(*)
 48 2813 (1264) 2410 (1075) -403 (-800, -6) 0.05 
IL-12 P40 (pg/ml) 48 9 (0, 40) 7 (0, 50) 0 (-1, 2) 0.66 
IL-17A (pg/ml) 57 3.3 (0.0, 10.5) 2.5 (0.2, 8.7) 0.0 (-1.4, 0.7) 0.42 
IL-8 (pg/ml) 57 2.3 (1.2, 5.4) 2.6 (1.7, 4.5) 0.4 (-2.0, 1.2) 0.61 
TNF-α (pg/ml) 57 6.3 (4.2, 10.1) 8.2 (5.6, 11.8) 0.8 (-0.8, 1.8) 0.31 
Eotaxin (pg/ml) 57 51 (39, 66) 59 (49, 84) 12 (3, 22) <0.001 
IL-5 (pg/ml) 57 2.8 (1.1, 5.9) 2.4 (1.3, 5.5) -0.1 (-0.9, 0.2) 0.20 
Urine tests      
FDP (+/-)
(**)
 43 9 (21%) 9 (21%) 0% (-19%, 19%) 1.00 
MMP activity (FU) 7 0.0015  
(0.0009, 0.0018) 
0.0008  
(0.0002, 0.0020) 
-0.0006  
(-0.0013, 0.0003) 
0.06 
GAG:creatinine 
(µg/mmol) 
17 0.44 (0.24, 0.62) 0.32 (0.16, 0.63) -0.11 (-0.39, 0.19) 0.59 
(*)   Mean (standard deviation) reported, along with mean change (95% CI) 
(**) Number (%) with positive responses reported, along with percentage change (95% CI) 
(†) Omitting one patient with extremely high value at follow-up 
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The results suggested strong evidence of a change from exacerbation to recovery 
for only two of the parameters, eosinophils and eotaxin. Both of these parameters 
increased from exacerbation to recovery, the median increase in eosinophils being 
0.15 x10*9/l, whilst the median increase in eotaxin was 12 pg/ml. 
 
There was also some evidence of increase from exacerbation to recovery for TAFI, 
and a decrease for IL-13, RANTES and MMPs between the same visits, but these 
results were not quite statistically significant. 
 
3.3.2 Rapid and delayed recovery – Part 1 
As outlined above study participants in Part 1 either recovered by their first follow 
up visit at 35 days, by their second follow up at 65 days, or did not clinically recover 
during the study period.  From a clinical perspective it is useful to be able to 
distinguish between those who rapidly recover and those who have a delayed 
recovery as this may impact on management of such groups.  Those participants 
who had recovered by 35 days were classified as rapid recovery and those by 65 
days a delayed recovery.  The numbers of recruits who did not recover during the 
study period was too small to make any viable comparison. 
 
Results – exacerbation vs rapid recovery Part 1 
Analyses were performed to examine the change in values from exacerbation to 
first follow-up in patients who recovered rapidly.  A summary of the results is given 
in table 8 below. The first figures reported are the number of patients with 
measurements at both timepoints. For those variables where the values were not 
normally distributed, the median and inter-quartile range at each timepoint is 
reported, along with the median difference and corresponding confidence interval.  
For those variables where the values were normally distributed, the mean and 
standard deviation at each timepoint is reported, along with the mean difference 
and corresponding confidence interval. P-values indicating the significance of the 
results are also given. 
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Table 8 – Part 1 plasma and urine exacerbation vs rapid recovery 
Variable N Exacerbation 
median (IQR) or 
mean (SD)
(*)
 or 
number (%)
(**)
 
Rapid recovery 
median (IQR) or 
mean (SD)
(*)
 or 
number (%)
(**)
 
Change 
exacerbation - 
rapid recovery  
median (95% CI) 
P-value  
Plasma Fibrin markers      
TAFI (ng/ml)
(*) (†)
 36 6395 (2860) 7262 (2397) 867 (-300, 2034) 0.14 
PAI-1 (pg/ml) 36 16950  
(10825, 29375) 
16050 
(8251, 34325) 
238  
(-2992, 3409) 
0.83 
D-dimer (µgFEU/ml) 35 0.20 (0.15, 0.38) 0.20 (0.17, 0.27) 0.00 (-0.07, 0.05) 0.37 
Fibrinogen (g/l)
(*)
 35 2.94 (0.66) 2.82 (0.63) -0.11 (-0.37, 0.14) 0.38 
Plats (10
*
9/l)
(*)
 19 286 (89) 279 (73) -7 (-39, 25) 0.64 
PF4 (µg/ml)
(*)
 33 1.8 (1.8) 2.2 (1.9) 0.4 (-0.4, 1.2) 0.30 
TGFβ1 (pg/ml) 36 1421 (752, 2532) 1593 (938, 2196) 112 (-187, 503) 0.36 
VEGF (pg/ml) 36 5.0 (0.0, 25.9) 6.2 (0.0, 28.9) 0.0 (-1.0, 0.0) 0.94 
Eosinophils (10
*
9/l) 19 0.00 (0.00, 0.40) 0.30 (0.20, 0.40) 0.10 (0.07, 0.23) 0.04 
Plasma Cytokines      
IL-6 (pg/ml) 35 1.4 (0.0, 3.4) 0.4 (0.0, 3.3) 0.0 (-1.4, 0.0) 0.17 
IFN (pg/ml) 35 24 (7, 52) 20 (10, 31) -3 (-16, 0) 0.01 
IL-13 (pg/ml) 35 0.0 (0.0, 2.9) 0.0 (0.0, 0.3) 0.0 (-0.3, 0.0) 0.01 
RANTES (pg/ml)
 (*)
 35 2866 (1287) 2342 (966) -524 (-1003, -45) 0.03 
IL-12 P40 (pg/ml) 35 8 (0, 46) 7 (0, 42) 0 (-11, 1) 0.20 
IL-17A (pg/ml) 35 3.4 (0.0, 12.0) 2.4 (0.6, 7.6) 0.0 (-4.1, 0.4) 0.08 
IL-8 (pg/ml) 35 2.4 (1.1, 5.1) 2.2 (1.5, 3.8) 0.2 (-0.8, 0.7) 0.45 
TNF-α (pg/ml) 35 6.2 (4.2, 9.9) 7.6 (5.6, 11.6) 0.1 (-1.2, 1.3) 0.86 
Eotaxin (pg/ml) 35 51 (38, 65) 58 (48, 81) 12 (3, 22)   0.002 
IL-5 (pg/ml) 35 2.9 (1.1, 7.9) 2.2 (1.3, 5.0) -0.4 (-2.0, 0.0) 0.03 
Urine tests      
FDP (+/-)
(**)
 30 5 (17%) 7 (23%) 7% (-17%, 31%) 0.75 
MMP activity (FU) 4 0.0015  
(0.0010, 0.0030) 
0.0014  
(0.0003, 0.0025) 
-0.0007  
(-0.0008, 0.0004) 
0.14 
GAG:creatinine 
(µg/mmol) 
15 0.44 (0.27, 0.62) 0.32 (0.17, 0.70) -0.11 (-0.39, 0.19) 0.53 
(*)   Mean (standard deviation) reported, along with mean change (95% CI) 
(**) Number (%) with positive responses reported, along with percentage change (95% CI) 
(†) Omitting one patient with extremely high value at follow-up 
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The results suggested evidence of a statistically significant change from 
exacerbation to rapid recovery for eosinophils, IFN, IL-13, RANTES, eotaxin and IL-5. 
Of these variables, there was a significant increase in eosinophils and eotaxin, 
whilst there was a significant decrease in IFN, IL-13, RANTES and IL-5. 
 
Results – exacerbation vs delayed recovery Part 1 
The next set of analyses examined the change in values from exacerbation to 2nd 
follow up in patients with a delayed recovery.  A summary of the results is given in 
table 9 below.  
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Table 9 – Part 1 plasma and urine exacerbation vs delayed recovery 
Variable N Exacerbation 
median (IQR) or 
mean (SD)
(*)
 or 
number (%)
(**)
 
Delayed 
recovery 
median (IQR) or 
mean (SD)
(*)
 or 
number (%)
(**)
 
Change 
exacerbation – 
delayed recovery 
median (95% CI) 
P-value  
Plasma Fibrin 
markers 
     
TAFI (ng/ml) 
(*) 
 14 5995 (1215) 7057 (2514) 1062 (-849, 2974) 0.25 
PAI-1 (pg/ml) 14 15900  
(9674, 27200) 
17350 
(7725, 32200) 
6530  
(-3152, 13988) 
0.16 
D-dimer (µgFEU/ml) 13 0.22 (0.09, 0.30) 0.25 (0.12, 0.32) 0.03 (-0.11, 0.10) 0.92 
Fibrinogen (g/l)
(*)
 13 2.75 (0.67) 2.99 (0.56) 0.23 (-0.33, 0.80) 0.38 
Plats (10
*
9/l) 
(*)
 1 insufficient data   
PF4 (µg/ml) 
(*)
 14 2.4 (1.3) 2.3 (1.5) -0.1 (-1.3, 1.2) 0.91 
TGFβ1 (pg/ml) 14 2564 (1226, 4019) 2057 (840, 3976) -718 (-1958, 845) 0.30 
VEGF (pg/ml) 14 16 (0, 52) 26 (0, 48) 0 (0, 9) 0.44 
Eosinophils (10
*
9/l) 1 insufficient data   
Plasma Cytokines      
IL-6 (pg/ml) 13 0.8 (0.1, 5.4) 2.5 (0.0, 6.2) 0.7 (-0.6, 2.7) 0.36 
IFN (pg/ml) 13 20 (3, 36) 22 (10, 42) 2 (-15, 20) 0.38 
IL-13 (pg/ml) 13 0.0 (0.0, 11.4) 1.1 (0.0, 17.8) 0.0 (-3.9, 2.4) 0.72 
RANTES (pg/ml)
 (*)
 13 2671 (1237) 2593 (1354) -78 (-854, 698) 0.83 
IL-12 P40 (pg/ml) 13 14 (0, 36) 1 (0, 59) 0 (-3, 30) 0.24 
IL-17A (pg/ml) 13 0.2 (0.0, 10.3) 5.6 (0.0, 16.2) 0.0 (-0.9, 8.7) 0.27 
IL-8 (pg/ml) 13 2.3 (1.2, 8.8) 3.7 (2.6, 6.6) 0.6 (-3.1, 1.5) 0.92 
TNF-α (pg/ml) 13 6.4 (4.3, 11.0) 9.3 (5.6, 15.2) 2.4 (-1.2, 6.0) 0.22 
Eotaxin (pg/ml) 13 51 (44, 69) 63 (52, 108) 17 (-10, 56) 0.11 
IL-5 (pg/ml) 13 2.6 (0.5, 4.8) 2.5 (0.9, 8.6) 0.3 (-1.4, 4.2) 0.33 
Urine tests      
FDP(+/-) 
(**)
 13 4 (31%) 2 (15%) -15%  
(-52%, 21%) 
0.63 
MMP activity (FU) 3 0.0015  
(0.0009, 0.0018) 
0.0005  
(0.0002, 0.0014) 
-0.0004  
(-0.0016, 0.0000) 
0.10 
GAG:creatinine 
(µg/mmol) 
2 insufficient data   
(*)   Mean (standard deviation) reported, along with mean change (95% CI) 
(**) Number (%) with positive responses reported, along with percentage change (95% CI) 
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The results suggested no changes from exacerbation to recovery in those study 
subjects with a delayed recovery. However, it is noted that the numbers of patients 
in the analyses are relatively small. 
 
3.3.3 Eosinophils, platelets, PF4 and Eotaxin 
There is clinical significance in the relationship between eosinophils and eotaxin, 
platelets and PF4, and eosinophils and platelets.  The following analyses examined 
the strength of the association between these variables. All variables were 
measured on a continuous scale, and several of the variables had skewed 
distributions. As a result, Spearman's rank correlation was used for all analyses.  
 
Results 
The correlation between platelets and eosinophils, platelets and PF4 and eotaxin 
and eosinophils were examined at each study visit. Examination of an association 
between variables was only possible where data was present for both comparators 
at the same study visit.  The data is summarised in table 10 below, where N denotes 
the number of participants who had paired data at each study visit alongside their 
correlation coefficient and significance is denoted by p-value. 
 
Table 10 – Part 1 admission and follow up visits, correlation for platelets, 
eosinophils, eotaxin and PF4 
Timepoint Variable 1 Variable 2 N Correlation Coefficient P-value  
Admission Platelets Eosinophils 82 0.28 0.01 
 Platelets PF4 57 0.30 0.02 
 Eosinophils Eotaxin 60 0.51 <0.001 
Follow-up 1 Platelets Eosinophils 32 -0.07 0.69 
 Platelets PF4 27 0.28 0.15 
 Eosinophils Eotaxin 27 -0.01 0.95 
Follow-up 2 Platelets Eosinophils 9 0.48 0.19 
 Platelets PF4 7 -0.23 0.61 
 Eosinophils Eotaxin 7 0.76 0.05 
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There were significant positive correlations at admission between eosinophils and 
eotaxin, platelets and eosinophils, and platelets and PF4.  Although statistically 
significant the observed correlations were relatively weak with the exception of 
eosinophils and eotaxin. 
 
No significant correlations were observed at either follow up timepoint, however, 
less paired data were available for comparison at these follow up visits due to 
reduced blood sampling from study participants as discussed in Chapter 2. 
 
3.3.4 Urine dilution and FDP result 
The dilution of urine samples collected during the study may have an effect on 
urine analyte results.  Urinary creatinine was measured in order to normalise urine 
concentration during subsequent analyses.  MMP activity was measured rather 
than absolute values.  GAG analyses above utilised GAG:creatinine ratio for this 
purpose.  FDP results were binary so further analyses were performed comparing 
the urine creatinine in patients with and without an FDP at each timepoint. The 
urine creatinine values were found to have a positively skewed distribution, and 
thus the Mann-Whitney test was used for the analyses. 
 
Results – urine dilution and FDP Part 1 
A comparison of the urine creatinine values was made between patients who were 
FDP negative and positive, and the results are summarised in table 11 below. The 
figures presented are the number of patients in each group, along with the median 
and inter-quartile range urine creatinine values.  P values are presented to denote 
significance. 
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Table 11 – Part 1 urine FDP results and urine dilution 
Timepoint FDP negative FDP positive P-value  
 N median (IQR) N median (IQR)  
Admission 57 9.0 (4.8, 13.0) 13 7.0 (5.0, 19.0) 0.90 
Follow-up 1 43 12.8 (4.0, 6.5) 8 6.0 (4.0, 6.5) 0.10 
Follow-up 2 18 10.4 (5.0, 14.4) 2 10.7 (2.0, 19.3) 0.90 
Recovery 37 10.5 (5.1, 17.0) 9 6.0 (4.0, 7.0) 0.24 
      
 
The results suggested no evidence of a difference in the urine creatinine values in 
patients with FDP negative and positive results.   
 
There was a trend towards urine creatinine values being lower and hence urine 
being more dilute in FDP positive patients at first follow-up, but the result was not 
statistically significant. 
 
These results suggest the dilution of urine does not have a significant impact on 
whether FDP is detectable when present in urine.  This is an important observation 
for the development of a future clinical test, particularly if used in point-of-care 
testing. 
 
3.4 Inflammatory phenotype comparison 
Alongside their categorisation by asthma severity, study participants can also be 
categorised by inflammatory phenotype into eosinophilic or non-eosinophilic 
subgroups. 
 
Eosinophilia and rate of recovery 
A comparison was made to examine whether a relationship exists between 
eosinophilic status and rate of recovery from asthma exacerbation.   Rate of 
recovery was defined in terms of rapid and delayed as described as above.  
Eosinophilic phenotype was determined as described by Schleich and colleagues 
(160) and is discussed in Chapter 5.  Due to the categorical nature of both variables, 
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the analysis was performed using Fisher's exact test, and the results are presented 
in table 12 below. 
 
Table 12 – Part 1 eosinophilia and rate of recovery 
Recovery Non-Eosinophilic 
N (%) 
Eosinophilic 
N (%) 
P-value  
Rapid 16 (59%) 25 (68%) 0.12 
Delayed 9 (33%) 5 (14%)  
Never 2 (7%) 7 (19%)  
    
 
No significant difference in rate of recovery was observed between the two groups. 
 
Blood and urine markers in eosinophilic and non-eosinophilic subgroups 
Further sub-group analysis was performed repeating examinations of the analysed 
study parameters but comparing eosinophilic with non-eosinophilic participants.  
Only those patients who recovered were included.  The majority of variables were 
measured on a continuous scale. The statistical methods used were dependent on 
the distribution of the variables. Where the values were normally distributed, the 
paired t-test was used to compare exacerbation and recovery.  A large number of 
the variables were not normally distributed, and the Wilcoxon matched-pairs test 
was preferred. One variable was measured on a binary scale and the paired exact 
test was used in this case to compare exacerbation and recovery.   
 
Changes from exacerbation to recovery – non-eosinophilic patients 
Table 13 summarises the results when comparing exacerbation and recovery in 
non-eosinophilic patients. 
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Table 13 – Part 1 exacerbation vs recovery in non-eosinophilic patients 
Variable N Exacerbation 
median (IQR) or 
mean (SD)
(*)
 or 
number (%)
(**)
 
Recovery 
median (IQR) or 
mean (SD)
(*)
 or 
number (%)
(**)
 
Change 
exacerbation - 
recovery 
median (95% CI) 
P-
value  
Plasma Fibrin 
markers 
     
TAFI (ng/ml) 
(*) 
 23 6569 (2301) 7468 (2501) 899 (-706, 2503) 0.26 
PAI-1 (pg/ml) 23 19500  
(13800, 43700) 
19800 
(10800, 43600) 
3700  
(-3896, 7790) 
0.38 
D-dimer (µgFEU/ml)  22 0.18 (0.11, 0.33) 0.22 (0.12, 0.33) 0.01 (-0.07, 0.05) 0.81 
Fibrinogen (g/l) 
(*)
 22 2.75 (0.69) 3.05 (0.69) 0.29 (-0.07, 0.65) 0.10 
Plats (10*9/l) 
(*)
 6 299 (59) 341 (63) 42 (-12, 95) 0.10 
PF4 (µg/ml) 
(*)
 21 1.8 (1.4) 2.5 (2.0) 0.6 (-0.5, 1.7) 0.24 
TGF (pg/ml) 23 1378  
(753, 2538) 
1599  
(965, 2198) 
-3 (-546, 823) 0.69 
VEGF (pg/ml) 23 7.4 (0.0, 32.8) 0.6 (0.0, 38.0) -8.4 (-48.9, 0.0) 0.13 
Eosinophils (10*9/l) 6 0.00 (0.00, 0.10) 0.20 (0.10, 0.23) 0.20 (0.01, 0.20) 0.03 
Plasma Cytokines      
IL-6 (pg/ml) 23 1.3 (0.0, 3.4) 2.1 (0.0, 4.5) 0.0 (-0.1, 1.2) 0.51 
IFN (pg/ml) 23 25 (4, 50) 25 (11, 33) 0 (-14, 4) 0.63 
IL-13 (pg/ml) 23 0.0 (0.0, 10.6) 0.0 (0.0, 2.1) 0.0 (-0.8, 0.0) 0.39 
RANTES (pg/ml) 
(*) 
 23 2837 (1266) 2415 (1050) -422 (-1047, 203) 0.18 
IL-12 P40 (pg/ml) 23 14 (0, 39) 5 (0, 52) 0 (-9, 5) 0.93 
IL-17A (pg/ml) 23 0.2 (0.0, 8.8) 2.4 (0.0, 11.3) 0.0 (-2.3, 2.0) 0.82 
IL-8 (pg/ml) 23 2.1 (0.9, 4.5) 2.8 (1.5, 4.1) 0.6 (-0.5, 1.2) 0.52 
TNF-α (pg/ml) 23 6.2 (4.1, 9.1) 9.3 (5.6, 11.6) 1.7 (0.1, 4.3) 0.04 
Eotaxin (pg/ml) 23 47 (41, 68) 63 (48, 86) 17 (1, 27) 0.01 
IL-5 (pg/ml) 23 2.6 (0.9, 4.3) 2.6 (0.8, 6.1) 0.0 (-0.6, 0.5) 0.94 
Urine tests      
FDP (+/-) 
(**)
 21 5 (24%) 3 (14%) -10%  
(-37%, 18%) 
0.69 
MMP activity (FU) 3 0.0018  
(0.0009, 0.0035) 
0.0005  
(0.0002, 0.0027) 
-0.0008  
(-0.0016, -0.0004) 
0.11 
GAG:creatinine 
(µg/mmol) 
7 0.29 (0.21, 0.54) 0.17 (0.12, 0.71) -0.09 (-0.46, 0.50) 0.87 
(*)   Mean (standard deviation) reported, along with mean change (95% CI) 
(**) Number (%) with positive responses reported, along with percentage change (95% CI) 
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The results suggested strong evidence of a change from exacerbation to recovery in 
only eosinophils, TNF- and eotaxin, all increasing in value from exacerbation to 
recovery.  
 
Changes from exacerbation to recovery  -  Eosinophilic patients 
A similar set of analyses was examined to compare exacerbation and recovery for 
eosinophilic patients, with the results summarised in table 14 below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
94 
 
Table 14 – Part 1 exacerbation vs recovery in eosinophilic patients 
Variable N Exacerbation 
median (IQR) or 
mean (SD)
(*)
 or 
number (%)
(**) 
Recovery 
median (IQR) or 
mean (SD)
(*)
 or 
number (%)
(**) 
Change 
exacerbation - 
recovery 
median (95% CI) 
P-
value  
Plasma Fibrin markers      
TAFI (ng/ml) 
(*) (†)
 27 6040 (2683) 6981 (2346) 941 (-302, 2184) 0.13 
PAI-1 (pg/ml) 27 13000  
(6694, 21700) 
12000 
(5610, 23000) 
-1506  
(-2824, 3260) 
0.79 
D-dimer (µgFEU/ml) 26 0.22 (0.16, 0.38) 0.20 (0.15, 0.28) 0.00 (-0.11, 0.04) 0.44 
Fibrinogen (g/l) 
(*)
 26 3.00 (0.64) 2.72 (0.51) -0.28 (-0.59, 0.02) 0.06 
Plats (10*9/l) 
(*)
 20 275 (100) 245 (6+1) -29 (-63, 5) 0.09 
PF4 (µg/ml) 
(*)
 26 2.1 (1.9) 2.0 (1.6) 0.0 (-0.8, 0.7) 0.91 
TGF (pg/ml) 27 1767  
(811, 3244) 
1798  
(898, 25244) 
-112 (-696, 317) 0.67 
VEGF (pg/ml) 27 1.4 (0.0, 28.2) 10.9 (0.0, 37.0) 0.0 (0.0, 11.1) 0.08 
Eosinophils (10*9/l) 14 0.05 (0.00, 0.53) 0.35 (0.20, 0.53) 0.10 (-0.03, 0.30) 0.12 
Plasma Cytokines      
IL-6 (pg/ml) 25 1.4 (0.0, 4.1) 0.3 (0.0, 2.8) 0.0 (-1.6, 0.0) 0.17 
IFN (pg/ml) 25 24 (6, 54) 19 (9, 24) -3 (-16, 2) 0.10 
IL-13 (pg/ml) 25 0.0 (0.0, 2.9) 0.0 (0.0, 1.6) 0.0 (-0.2, 0.0) 0.08 
RANTES (pg/ml) 
(*)
 25 2791 (1287) 2405 (1119) -386 (-931, 159) 0.16 
IL-12 P40 (pg/ml) 25 8 (0, 45) 7 (0, 40) 0 (-19, 5) 0.59 
IL-17A (pg/ml) 25 4.4 (0.2, 14.4) 2.7 (0.3, 8.2) 0.0 (-3.7, 1.0) 0.37 
IL-8 (pg/ml) 25 2.5 (1.3, 6.9) 2.5 (1.8, 5.1) -0.4 (-2.5, 1.0) 0.25 
TNF-α 25 6.4 (4.3, 12.6) 7.0 (4.6, 13.1) -0.8 (-1.8, 1.0) 0.49 
Eotaxin (pg/ml) 25 53 (38, 64) 57 (49, 86) 6 (2, 24) 0.02 
IL-5 (pg/ml) 25 3.0 (1.2, 8.4) 1.9 (1.3, 4.6) -0.4 (-3.1, 0.2) 0.12 
Urine tests      
FDP (+/-) 
(**)
 22 4 (18%) 6 (27%) 9% (-20%, 36%) 0.73 
MMP activity (FU) 4 0.0015  
(0.0010, 0.0016) 
0.0011  
(0.0003, 0.0018) 
-0.0003 
(-0.0008, 0.0005) 
0.27 
GAG:creatinine(µg/mmol) 10 0.47 (0.31, 0.66) 0.35 (0.22, 0.51) -0.18 (-0.47, 0.26) 0.44 
Additional tests      
FeNO (ppb) 30 57 (24, 94) 40 (28, 74) -3 (-34, 17) 0.33 
      
(*)   Mean (standard deviation) reported, along with mean change (95% CI) 
(**) Number (%) with positive responses reported, along with percentage change (95% CI) 
(†)   Omitting one patient with extremely high value at follow-up 
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Only eotaxin changed significantly from exacerbation to recovery in eosinophilic 
patients, demonstrating an increase at recovery. 
 
3.5 Clinical parameters – Part 1 
In order to provide objective measures of clinical recovery and to investigate 
whether clinical measurements used in practice were statistically justified markers 
of asthma exacerbation, FeNO, FEV1 and PEFR was compared between 
exacerbation and recovery.  Those participants who did not recover during the 
study period were excluded. 
 
Where the values were normally distributed, the paired t-test was used to compare 
between timepoints, and the mean and standard deviation at each visit is reported 
alongside the mean difference and corresponding confidence interval.  Where 
variables are not normally distributed, the Wilcoxon matched-pairs test was used 
and the median and inter-quartile range at each timepoint is reported, along with 
the median difference and corresponding confidence interval.  P-values indicating 
the significance of the results are also given. The results are summarised in table 15 
below. 
  
Table 15 – Part 1 clinical markers at exacerbation and clinical recovery 
Variable N Exacerbation 
median (IQR) or 
mean (SD)
(*)
 
Recovery 
median (IQR) or 
mean (SD)
(*)
 
Change 
exacerbation - 
recovery 
median (95% CI) 
P-value  
FeNO (ppb) 54 25 (13, 62) 24 (16, 47) -1 (-5, 6) 0.65 
FEV1 (l) 
(*)
 50 1.96 (0.77) 2.54 (0.72) 0.58 (0.43, 0.72) <0.001 
PEFR (l/min) 
(*)
 55 269 (112) 389 (111) 120 (87, 153) <0.001 
(*)  Mean (standard deviation) reported, along with mean change (95% CI) 
 
There was no significant change in FeNO, but FEV1 and PEFR significantly increased 
from exacerbation to recovery. There was a mean increase of 0.6 litres in FEV1 and 
120 l/min in PEFR between the two timepoints. 
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FeNO in eosinophilic and non-eosinophilic subgroups 
FeNO is a surrogate marker of airway eosinophilic inflammation and therefore 
specific subgroup examination was made of this marker comparing eosinophilic 
(table 16) and non-eosinophilic (table 17) subjects at exacerbation and at clinical 
recovery. 
 
Table 16 – Part 1 FeNO exacerbation vs recovery in eosinophilic asthma 
Variable N Exacerbation 
median (IQR) 
Recovery 
median (IQR) 
Change 
exacerbation - 
recovery 
median (95% CI) 
P-value  
FeNO (ppb) 30 57 (24, 94) 40 (28, 74) -3 (-34, 17) 0.33 
 
Table 17 – Part 1 FeNO exacerbation vs recovery in non-eosinophilic asthma 
Variable N Exacerbation 
median (IQR) 
Recovery 
median (IQR) 
Change 
exacerbation - 
recovery 
median (95% CI) 
P-value  
FeNO (ppb) 24 14 (10, 22) 17 (13, 22) 3 (-4, 8) 0.37 
 
When comparing FeNO at exacerbation with recovery, there was no significant 
difference observed in eosinophilic or non-eosinophilic inflammatory phenotypes. 
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4.0 PART 2 RESULTS 
 
4.1 Part 2 screening, recruitment, withdrawal and completion 
Part 2 successfully recruited 24 patients with stable asthma, 15 of whom were 
followed up until acute exacerbation and through to subsequent recovery.  This is 
the largest prospective study to date examining coagulation and fibrinolysis in 
asthma both in stable and exacerbation states. 
 
Screening and recruitment to Part 2 is summarised in figure 8 below.  25 patients 
were eventually screened and 24 recruited, of which 6 had moderate and 18 severe 
asthma by study criteria.  Only 1 participant withdrew after several months of study 
involvement and prior to an asthma exacerbation, this participant had severe 
asthma.  Of the remaining 23, 6 had not exacerbated by the time of study closure in 
June 2012 and were withdrawn, 4 were moderate and 2 severe.   
 
Of the 17 remaining participants, 1 severe asthmatic experienced pneumonia at the 
time of exacerbation and was hence withdrawn and 1 had a second exacerbation at 
the time of the second recovery visit and was then withdrawn. 
 
15 participants completed the study, 9 of who recovered at recovery visit 1, 5 
recovered at recovery visit 2 and 1 did not recover during the study period.  See 
Figure 8 below for a summary of Part 2 study recruitment and screening. 
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Figure 8 – Part 2 screening
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4.1.1 Part 2 adverse events 
There was 1 adverse event from the Part 2 population during the study period, 
which was a SAE due to the participant being admitted to hospital. 
 
Table 18 – Part 2 adverse events 
Study 
number 
Adverse event Related to study 
activity? 
J2004XX
* 
Re-admission to hospital with asthma No 
*initials removed to preserve anonymity 
 
4.2 Part 2 participant characteristics 
Patient characteristics were summarised for all patients in Part 2 of the study. 
Continuous variables were summarised by both the mean and standard deviation, if 
found to be normally distributed, or median and inter-quartile range if not normally 
distributed. Categorical variables were summarised by the number and percentage 
of patients in each category. 
 
Comparisons were made between patients who did and did not complete the 
study. The analysis of continuous variables found to be normally distributed was 
performed using the unpaired t-test, whilst continuous variables not found to be 
normally distributed were analysed using the Mann-Whitney test. Binary 
categorical variables and those with no ordering of the categories were analysed 
using Fisher's exact test. Ordinal categorical variables were analysed using the 
Mann-Whitney test (in order to take account of the order of the categories, which is 
not utilised using Fisher's exact test). 
 
Results 
A summary of the patient characteristics is given in the two subsequent tables (19 
and 20). The figures reported are the results for all patients, and then split by those 
who withdrew from the study and those who did not. P-values indicating the 
significance of the difference between those who did and did not withdraw are also 
presented. 
100 
 
Table 19 – Participant characteristics Part 2 continuous variables 
Variable All patients 
(n=24) 
Not withdrawn 
(n=15) 
Withdrawn (n=9) P-value  
     
Age (years) 
(*)
 47.1 (12.6) 48.8 (13.9) 44.3 (10.1) 0.41 
Hospital admissions 
(**)
 0 (0, 1) 0 (0, 2) 1 (0, 1) 0.86 
BMI (kg/m
2
) 
(**)
 28 (25, 33) 29 (24, 32) 27 (26, 33) 0.68 
     
(*)   Mean (standard deviation) reported 
(**) Median (inter-quartile range) reported 
 
The results suggested no significant differences been those who did and didn't 
withdraw for the three continuous variables examined. 
 
Table 20 – Participant characteristics Part 2 categorical variables 
Variable Category All patients 
(n=24) 
Not withdrawn 
(n=15) 
Withdrawn 
(n=9) 
P-value  
      
Sex Female 20 (83%) 12 (80%) 8 (89%) 1.00 
 Male 4 (17%) 3 20%) 1 (11%)  
      
GINA 2008 Intermittent 4 (17%) 2 (13%) 2 (22%) 0.04 
 Mild Persist. 6 (25%) 2 (13%) 4 (44%)  
 Mod. Persist 4 (17%) 2 (13%) 2 (22%)  
 Severe Persist 10 (42%) 9 (60%) 1 (11%)  
      
Asthma Moderate 6 (25%) 2 (13%) 4 (44%) 0.15 
Severity Severe 18 (75%) 13 (87%) 5 (56%)  
      
Eosinophilic No 9 (37%) 3 (20%) 6 (67%) 0.04 
 Yes 15 (63%) 12 (80%) 3 (33%)  
      
Smoking Current 0 (0%) 0 (0%) 0 (0%) 0.15 
status Ex 10 (83%) 7 (100%) 3 (60%)  
 Never 2 (17%) 0 (0%) 2 (40%)  
      
Obese No 13 (54%) 8 (53%) 5 (56%) 1.00 
 Yes 11 (46%) 7 (47%) 4 (44%)  
      
Atopy No 5 (24%) 5 (33%) 0 (0%) 0.26 
(SPT positive) Yes 16 (76%) 10 (67%) 6 (100%)  
      
Atopy No 8 (38%) 5 (33%) 3 (50%) 0.63 
(raised IgE) Yes 13 (62%) 10 (67%) 3 (50%)  
      
Recovery Rapid - 9 (60%) - - 
 Delayed - 5 (33%) -  
 Never - 1 (7%) -  
 DNA - - 4 (44%)  
 Withdrawn - - 5 (56%)  
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There were significant differences between participants who completed the study 
and those who withdrew when looking at asthma severity and eosinophilic 
inflammatory status.  Those participants who withdrew had less severe asthma and 
those who completed the study had more eosinophilic inflammation. 
 
Table 21 – Part 2 time from recruitment to exacerbation 
Study number Days 
2001XX 67 
2002XX 13 
2003XX 83 
2006XX 74 
2009XX 270 
2010XX 31 
2011XX 8 
2012XX 54 
2013XX 28 
2014XX 15 
2015XX 53 
2016XX 98 
2017XX 52 
2018XX 28 
2023XX 42 
XX Initials removed to preserve anonymity 
 
The number of days from study recruitment to asthma exacerbation in Part 2 is 
listed in table 21 above.  The time from recruitment to exacerbation is 61 days or 46 
days if the outlier 2009XX is excluded. 
 
Discussion 
Recruitment to Part 2 of the study was only from the QAH catchment population.  
By definition, the population was narrowed by the inclusion criteria requiring 
subjects to have either moderate or severe asthma defined by inhaled steroid doses 
(158).  As with Part 1 the majority of the study population was female (83%), 
eosinophilic (63%) and atopic (76% by skin prick test, 62% by elevated IgE).  Again it 
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was not formally recorded on the CRF but ethnicity of the study recruits was 
predominantly white Caucasian due to the local population.  As discussed in 
chapter 2, recruitment of subjects with moderate asthma was more difficult than 
those with severe resulting in 75% of Part 2 subjects having severe asthma.  This 
will be discussed in more detail below. 
In contrast to Part 1 of the study, those who were withdrawn or withdrew from 
Part 2 were in the main (78%) those who did not exacerbate and hence more 
stable.  This is consistent with our finding that the group who withdrew had less 
severe asthma and hence were less likely to exacerbate.  Furthermore, those who 
did complete the study (and hence exacerbated) were more likely to be eosinophilic 
and therefore more prone to exacerbate (32).  
It is worth noting that overall, the population who completed Part 2 was very small 
(15 subjects).  Clearly this will have an impact on the statistical strength of the 
results from this population.  Again, the factors discussed here should be taken into 
consideration when extrapolating findings onto other populations. 
 
4.3 Part 2 plasma analyses 
Patients in part 2 of the study were seen on a first visit, at exacerbation, and then 
potentially at two subsequent follow-up timepoints. Attention was focussed on a 
comparison between two pre-determined sets of values at visits with clinical 
relevance. 
 
The first set of analyses compared the differences in values between the first visit 
(baseline) and values at exacerbation.  
 
A second set of analyses examined the changes from the baseline first visit to the 
patient recovery. Data from the first follow-up timepoint (30 days from 
exacerbation) was used for those who rapidly recovered, whilst data from the 
second follow-up timepoint (61 days from exacerbation) was used for those with 
delayed recovery. Patients who did not recover were omitted from the analyses. 
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All outcome variables were measured on a continuous scale. The statistical 
methods used were dependent on the distribution of the variables. Where the 
values were normally distributed, the paired t-test was used to compare between 
timepoints. For a large number of the variables the values were not normally 
distributed, and the Wilcoxon matched-pairs test was preferred. 
 
4.3.1 Part 2 clinical comparison results 
The first set of analyses examined the change in values from the first visit to 
exacerbation, and a summary of the results is given in the subsequent table (table 
22). The first figures reported are the number of patients with measurements at 
both timepoints. For those variables where the values were not normally 
distributed, the median and inter-quartile range at each timepoint is reported, 
along with the median difference and corresponding confidence interval.  For those 
variables where the values were normally distributed, the mean and standard 
deviation at each timepoint is reported, along with the mean difference and 
corresponding confidence interval. P-values indicating the significance of the results 
are also given. 
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Table 22 – Part 2 plasma baseline vs exacerbation 
Variable N Baseline 
median (IQR) or 
mean (SD)
(*)
  
Exacerbation 
median (IQR) or 
mean (SD)
(*)
  
Change baseline - 
exacerbation 
median (95% CI) 
P-value  
Plasma Fibrin 
markers 
     
TAFI (ng/ml)
(*) 
 17 5406 (2591) 4764 (2030) -641 (-1967, 683) 0.32 
PAI-1 (pg/ml) 17 15000  
(10336, 30100) 
16200 
(11400, 37850) 
2000  
(-3634, 9390) 
0.33 
D-dimer 
(µgFEU/ml) 
14 0.21 (0.12, 0.29) 0.25 (0.20, 0.42) 0.07 (-0.01, 0.15) 0.02 
Fibrinogen (g/l)
(*)
 13 3.08 (0.57) 3.21 (0.50) 0.12 (-0.19, 0.43) 0.40 
Plats (10
*
9/l)
(*)
 13 305 (61) 318 (64) 13 (-12, 38) 0.28 
PF4 (µg/ml) 
(*)
 17 3.9 (2.9) 2.6 (1.6) -1.4 (-3.1, 0.4) 0.12 
TGFβ1 (pg/ml) 17 1801  
(721, 2570) 
966  
(682, 2376) 
-666 (-1289, -2) 0.02 
VEGF (pg/ml) 17 23 (3, 94) 20 (0, 37) -1 (-17, 3) 0.22 
Eosinophils 
(10
*
9/l) 
13 0.30 (0.15, 0.50) 0.30 (0.20, 0.85) 0.00 (-0.10, 0.38) 0.28 
Plasma Cytokines      
IL-6 (pg/ml) 15 0.0 (0.0, 1.4) 1.2 (0.0, 3.2) 0.6 (0.0, 2.3) 0.19 
IFN (pg/ml) 15 22 (8, 43) 16 (8, 51) 3 (-18, 22) 0.61 
IL-13 (pg/ml) 15 0.0 (0.0, 14.6) 0.0 (0.0, 3.8) 0.0 (-4.3, 0.0) 0.43 
RANTES (pg/ml)
 (*)
 15 2803 (1148) 2433 (944) -371  
(-1059, -318) 
0.27 
IL-12 P40 (pg/ml) 15 14 (0, 49) 7 (0, 38) 0 (-13, 5) 0.45 
IL-17A (pg/ml) 15 1.9 (0.0, 4.5) 0.4 (0.0, 8.5) 0.0 (-1.8, 5.2) 0.75 
IL-8 (pg/ml) 15 3.5 (1.0, 6.8) 2.6 (0.6, 4.8) 0.0 (-4.0, 1.5) 0.53 
TNF-α (pg/ml) 15 9.1 (3.9, 10.3) 5.7 (3.5, 12.9) -1.1 (-4.2, 2.7) 0.69 
Eotaxin (pg/ml) 15 65 (47, 96) 61 (41, 74) -15 (-38, 6) 0.10 
IL-5 (pg/ml) 15 1.6 (0.0, 4.9) 2.2 (0.0, 6.0) 0.6 (-1.8, 3.8) 0.39 
      
(*) Mean (standard deviation) reported, along with mean change (95% CI) 
 
Only D-dimer and TGFβ1 significantly changed from baseline to exacerbation.  
There was a significant increase in D-dimer at exacerbation with a median increase 
105 
 
of 0.07 µgFEU/ml. Conversely there was a significant decrease in TGFβ1 at 
exacerbation, with a median decrease of over 650 pg/ml. 
 
Additionally, there was very weak evidence of a decrease in eotaxin from baseline 
to exacerbation, but this result was not quite statistically significant. 
 
A similar set of analyses were performed to examine the change in the various 
parameters from baseline to recovery and a summary of the results is given in the 
subsequent table (table 23). 
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Table 23 – Part 2 plasma baseline vs recovery 
Variable N Baseline 
median (IQR) or 
mean (SD)
(*)
  
Recovery 
median (IQR) or 
mean (SD)
(*)
  
Change baseline - 
recovery 
median (95% CI) 
P-value  
Plasma Fibrin 
markers 
     
TAFI (ng/ml)
(*)
 14 5596 (2799) 5994 (1921) 398 (-1467, 2263) 0.65 
PAI-1 (pg/ml) 14 16200  
(12000, 33425) 
16350 
(13750, 22325) 
1211  
(-6562, 3291) 
0.64 
D-dimer 
(µgFEU/ml) 
14 0.18 (0.09, 0.27) 0.21 (0.11, 0.36) 0.03 (0.00, 0.08) 0.08 
Fibrinogen (g/l)
(*)
 12 2.91 (0.48) 3.04 (0.54) 0.13 (-0.29, 0.56) 0.50 
Plats (10
*
9/l)
(*)
 14 293 (63) 318 (110) 24 (-13, 61) 0.18 
PF4 (µg/ml)
 (*)
 14 3.9 (3.0) 2.2 (0.8) -1.7 (-3.4, -0.1) 0.04 
TGFβ1 (pg/ml) 14 1425  
(779, 2111) 
1193  
(565, 2310) 
-132 (-936, 236) 0.27 
VEGF (pg/ml) 14 21 (1, 101) 9 (0, 46) -3 (-5, 1) 0.13 
Eosinophils 
(10
*
9/l) 
14 0.30 (0.10, 0.43) 0.20 (0.10, 0.50) 0.00 (-0.20, 0.10) 0.61 
Plasma Cytokines      
IL-6 (pg/ml) 13 0.0 (0.0, 1.9) 0.0 (0.0, 1.5) 0.0 (0.0, 0.2) 0.37 
IFN (pg/ml) 13 22 (7, 45) 21 (2, 37) -5 (-14, 4) 0.16 
IL-13 (pg/ml) 13 0.0 (0.0, 10.3) 0.0 (0.0, 1.9) 0.0 (-1.5, 0.0) 0.16 
RANTES (pg/ml)
 (*)
 13 2861 (1215) 2265 (850) -596 (-1356, 163) 0.11 
IL-12 P40 (pg/ml) 13 14 (0, 45) 0 (0, 32) -7 (-14, 0) 0.05 
IL-17A (pg/ml) 13 2.5 (0.0, 5.4) 2.5 (0.0, 5.3) 0.0 (-1.2, 0.0) 0.28 
IL-8 (pg/ml) 13 3.4 (0.5, 6.0) 2.2 (0.0, 4.5) 0.0 (-2.3, 0.5) 0.31 
TNF-α (pg/ml) 13 6.4 (3.9, 10.1) 5.0 (3.7, 8.7) -0.9 (-3.7, 1.6) 0.31 
Eotaxin (pg/ml) 13 65 (43, 105) 60 (50, 88) 5 (-43, 14) 0.97 
IL-5 (pg/ml) 13 1.4 (0.0, 5.6) 0.9 (0.0, 3.9) -0.2 (-1.8, 0.6) 0.38 
      
(*)   Mean (standard deviation) reported, along with mean change (95% CI) 
 
PF4 significantly decreased from baseline to recovery, with a mean decrease of 1.7 
µg/ml between the two timepoints. 
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There was some evidence of a reduction in IL-12 values over the same time period, 
with a median decrease of 7 pg/ml. This reduction was only of borderline statistical 
significance.  There was also weak evidence that the D-dimer values were higher at 
recovery than at visit 1, but again the result did not reach statistical significance. 
 
Changes from baseline to recovery were not found to be significant in the other 
parameters examined. 
 
4.3.2 Part 2 plasma baseline through exacerbation to recovery 
Patients in part 2 of the study were measured on a first visit (baseline), at 
exacerbation, and then potentially at two subsequent follow-up timepoints. Data 
from the last timepoints was combined to give recovery data.  The first follow-up 
timepoint (30 days) was used for those who recovered rapidly, whilst data from the 
second follow-up timepoint (61 days) was used for those with delayed recovery, 
giving a linear comparison from baseline through exacerbation to subsequent 
clinical recovery.  Patients who did not recover were omitted from these analyses. 
 
Data from all three timepoints were included in the analysis. For variables that were 
normally distributed, the analysis was performed using two way ANOVA, with the 
two factors being patient and time. The patient differences were not of interest, 
but were included to allow for repeat measurements from the same patient. For a 
large number of the variables the values were not normally distributed, and the 
Friedman test was preferred for these measures. 
 
Results 
The analyses examined the change in values over the three timepoints, and a 
summary of the results is given in table 24. For the non-normally distributed, the 
median and inter-quartile range at each timepoint are reported, whilst for normally 
distributed variables the mean and standard deviation at each timepoint are 
reported. P-values indicating the significance of the overall difference between 
timepoints are also reported. 
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Table 24 – Part 2 plasma linear progression from baseline through exacerbation to 
recovery 
Variable N Baseline 
median (IQR) or 
mean (SD)
(*)
  
Exacerbation 
median (IQR) or 
mean (SD)
(*)
  
Recovery 
median (IQR) or 
mean (SD)
(*)
  
P-value  
Plasma Fibrin 
markers 
     
TAFI (ng/ml)
(*) 
 14 5596 (2799) 4966 (2095) 5994 (1921) 0.42 
PAI-1 (pg/ml) 14 16200  
(12300, 31800) 
19500 
(11000, 38200) 
16350  
(14400, 21000) 
0.69 
D-dimer 
(µgFEU/ml) 
11 0.19 (0.10, 0.29) 0.23 (0.18, 0.34) 0.19 (0.13, 0.38) 0.07 
Fibrinogen (g/l)
(*)
 12 2.91 (0.48) 3.22 (0.53) 3.03 (0.52) 0.65 
Plats (10
*
9/l) 
(*)
 14 293 (63) 311 (61) 318 (110) 0.39 
PF4 (µg/ml)
 (*)
 14 3.9 (3.0) 2.6 (1.7) 2.2 (0.8) 0.08 
TGFβ1 (pg/ml) 14 1425  
(780, 2111) 
894  
(638, 1939) 
1193  
(565, 2310) 
0.12 
VEGF (pg/ml) 14 21 (1, 101) 14 (0, 32) 9 (0, 46) 0.50 
Eosinophils 
(10
*
9/l) 
12 0.30 (0.13, 0.48) 0.30 (0.15, 0.63) 0.20 (0.10, 0.48) 0.89 
Plasma Cytokines      
IL-6 (pg/ml) 12 0.0 (0.0, 1.1) 1.6 (0.0, 3.0) 0.0 (0.0, 0.4) 0.11 
IFN (pg/ml) 12 18 (7, 43) 14 (8, 48) 13 (1, 33) 0.28 
IL-13 (pg/ml) 12 0.0 (0.0, 12.4) 0.0 (0.0, 4.5) 0.0 (0.0, 2.9) 0.48 
RANTES (pg/ml)
 (*)
 12 2810 (1183) 2479 (1019) 2265 (850) 0.16 
IL-12 P40 (pg/ml) 12 14 (0, 47) 6 (0, 56) 0 (0, 32) 0.05 
IL-17A (pg/ml) 12 1.3 (0.0, 4.4) 0.2 (0.0, 8.4) 1.3 (0.0, 4.1) 0.96 
IL-8 (pg/ml) 12 3.5 (0.2, 6.3) 2.3 (0.3, 7.2) 1.9 (0.0, 4.7) 0.74 
TNF-α (pg/ml) 12 6.2 (3.8, 10.2) 4.5 (3.3, 10.5) 4.8 (3.3, 8.6) 0.65 
Eotaxin (pg/ml) 12 65 (44, 110) 53 (40, 71) 62 (50, 94) 0.50 
IL-5 (pg/ml) 12 1.4 (0.0, 3.9) 1.3 (0.0, 3.7) 0.5 (0.0, 2.2) 0.65 
      
(*) Mean (standard deviation) reported 
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The results suggested no strong evidence of a change in values between the three 
timepoints. However, there was some evidence of a difference between timepoints 
for D-dimer, PF4 and IL-12, although these results were only of borderline statistical 
significance. 
 
D-dimer values increased from baseline to exacerbation, and then decreased again 
at recovery, to similar levels observed at visit 1. Both PF4 and IL-12 showed a steady 
decrease over the three timepoints from baseline, through exacerbation to 
recovery. 
 
4.4 Part 2 urine analyses 
In Part 2 of the study, alongside the study visits, participants prospectively collected 
urine samples allowing linear comparison of urine results in relation to clinical 
exacerbation. 
 
4.4.1 Part 2 FDP in relation to exacerbation 
The association between FDP and exacerbation was examined by splitting the 
observation time for each patient into time intervals. Various lengths of time 
interval were used from 4 to 15 days. The intervals were so created so that a 
positive FDP result occurred at the start of each interval, and so the interval lengths 
considered ranged from FDP+3 days up to FDP+14 days. The occurrence of an 
exacerbation in intervals starting with a positive FDP were compared to the 
occurrence of exacerbation in other time intervals with no positive FDP. Data after 
exacerbation was omitted from the analysis, and only whole intervals were 
included in the analysis. Days that only formed part of an interval were omitted. 
 
A feature of this data is that each patient contributed several time intervals. 
Therefore to allow for the repeat measurements from each patient the analysis was 
performed using multilevel statistical methods. Two-level models were used with 
individual time intervals contained within patients. Due to the binary nature of the 
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outcome (i.e. exacerbation, yes/no), the analysis was performed using multilevel 
logistic regression. 
 
Results of the analyses using different time window widths are summarised in table 
25 below. The first column represents the number days that comprise each time 
window.  The second and third columns outline the occurrence of the pre-
determined time window beginning with either a negative or positive urine FDP, 
and the number and percentage of each occurrence. The size of difference between 
groups was summarised as an odds ratio, giving the odds of exacerbation with a 
positive FDP result relative to the odds of no exacerbation with a negative FDP 
result. P-values indicating the significance of the results are also reported. 
 
Table 25 – Part 2 urine FDP related to exacerbation 
Time Window Positive or negative 
FDP 
Number of time 
windows (%) 
Odds Ratio 
(95% CI) 
P-value  
     
4 days No FDP 15/231 (6%)   1 0.21 
(FDP+3days) FDP 2/12 (17%) 2.86 (0.56, 14.6)  
     
8 days No FDP 13/112 (12%)   1 0.03 
(FDP+7days) FDP 4/11 (36%) 4.35 (1.12, 16.9)  
     
11 days No FDP 12/78 (15%)   1 0.02 
(FDP+10days) FDP 5/10 (50%) 5.50 (1.38, 21.9)  
     
15 days No FDP 11/56 (20%)   1 0.02 
(FDP+14days) FDP 6/10 (60%) 6.07 (1.43, 25.8)  
     
 
There was a significantly increased occurrence of exacerbation after a positive FDP 
result using window widths of 8, 11 and 15 days.  
 
For example using an interval length of 11 days, 15% of all intervals with no positive 
FDP contained exacerbation, compared to 50% of all intervals starting with a 
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positive FDP result. The odds of exacerbation in the 10 days after a positive FDP 
result exacerbation were 5.5 times greater than at other times. 
 
4.4.2 Part 2 FDP and urine dilution 
Analyses comparing the urine creatinine in samples with positive and negative FDP 
results were performed to examine whether urine dilution affects FDP result. The 
urine creatinine values were found to have a positively skewed distribution, and 
thus the Mann-Whitney test was used for the analyses. 
 
A comparison of the urine creatinine values was made between measurements that 
were FDP negative and positive, and the results are summarised in table 26 below. 
The figures presented are the number of patients in each group, along with the 
median and inter-quartile range creatinine values. 
 
Table 26 – urine creatinine and FDP 
FDP Number of 
patients 
Creatinine (nmol/ml) 
Median (IQR) 
P-value 
    
Negative 412 10.1 (6.1, 15.4) 0.39 
Positive 22 11.1 (8.1, 15.5)  
    
 
The results suggested no evidence of a difference in the urine creatinine values in 
samples that were FDP negative and positive results.  Hence urine dilution had no 
effect on the likelihood of a positive or negative FDP result. 
 
4.4.3 Urine GAG analysis 
Analyses examined if the GAG:creatinine ratio was higher or lower in the period 
immediately preceding an exacerbation, relative to the previous time period. The 
first interval considered was the day of exacerbation plus the one day before 
exacerbation. The mean GAG:creatinine ratio in this period was calculated for each 
patient and compared to the mean value in the days preceding this period. The 
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analysis was repeated this time considering exacerbation plus the preceding five 
days, and also exacerbation plus the preceding seven days. The paired t-test was 
used to compare the GAG:creatinine ratio in the period before exacerbation to 
previous values 
 
The paired t-test was used to compare the GAG:creatinine ratio at and immediately 
before exacerbation to the values on earlier days. A summary of the results is given 
in table 27 below. The figures reported are the mean and standard deviation values 
for each interval. P-values indicating the significance of the results are also 
presented. 
 
Table 27 – GAG:creatinine ratio (µg/mmol) related to exacerbation 
Recent Time period N Exacerbation + preceding 
days 
mean (SD) 
Previous days 
mean (SD) 
P-value  
     
Exacerbation + 1 day
 
 12 0.74 (0.58) 0.49 (0.14) 0.15 
Exacerbation + 5 days 14 0.62 (0.27) 0.45 (0.20) 0.06 
Exacerbation + 7 days 14 0.61 (0.25) 0.45 (0.18) 0.03 
     
 
The results suggested some evidence that GAG:creatinine ratio was higher on the 
day of exacerbation and earlier days when the 5 and 7 day windows were used, 
however, the result was only of borderline significance for the 5 day period. Using 
the 7 day window, there was a significant increase in GAG:creatinine ratio before 
exacerbation.  The mean GAG:creatinine ratio was 0.61 µg/mmol before 
exacerbation, increased from 0.45 µg/mmol in the preceding period. 
 
4.5 PEFR analyses 
PEFR was measured and recorded by Part 2 study subjects prospectively during the 
study period.  Greater diurnal variation on PEFR is considered clinically significant in 
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terms of asthma instability or exacerbation, as are overall lower values in relation 
to predicted or best measured. 
 
4.5.1 PEFR related to exacerbation – Part 2 
The first set of analyses examined whether PEFR demonstrated significant 
variability just before exacerbation, compared with the preceding measurements 
throughout the study.  Average daily PEFR values were used for this analysis. 
 
The variation in the peak flow values over a time interval was quantified by 
calculating the standard deviation of the measurements. The higher the standard 
deviation the greater the variation in values. The first interval considered was the 
day of exacerbation plus the one day before exacerbation. The variation in peak 
flow in this period was calculated for each patient along with the variation in the 
days preceding this period. The analysis was repeated this time considering peak 
flow at exacerbation plus the preceding five days, and then days before this time 
period. The paired t-test was used to compare variation in peak flow before 
exacerbation to previous variation. 
 
Initially the peak flow values over time for each patient were examined, and a plot 
of the change in values over time for each patient is given in figure 9. 
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Figure 9 – PEFR (l/min) over time 
 
 
The paired t-test was used to compare the variation in peak flow values at and 
immediately before exacerbation to the variation on earlier days. A summary of the 
results is given in table 28 below. The figures reported are the mean and standard 
deviation variation (as measured by the standard deviation over the time period) in 
each interval. P-values indicating the significance of the results are also presented.  
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Table 28 - PEFR variability (l/min) immediately before exacerbation relative to 
preceding days 
Recent Time period N Exacerbation + preceding 
days 
mean (SD) 
Previous days 
mean (SD) 
P-value  
     
Exacerbation + 1 day
 
 12 19.2 (14.7) 22.3 (17.8) 0.65 
Exacerbation + 5 days 14 20.5 (13.8) 21.0 (16.5) 0.93 
     
 
There was no significant difference observed between PEFR in the 5 days 
immediately prior to exacerbation, compared with the preceding days.   
 
4.5.2 PEFR at exacerbation relative to baseline 
Further analyses were performed to examine if the peak flow in the days 
immediately preceding exacerbation differed compared to peak flow values at 
baseline. The baseline period was considered to be the first two weeks of 
measurement. Two different time periods before exacerbation were considered, 7 
days or 14 days. The mean peak flow value in each period was calculated, and the 
paired t-test was used to compare between time periods. One patient had only 15 
days of measurements and was excluded from this analysis. 
 
The paired t-test was used for the analysis, and a summary of the results is given in 
table 29 below. The figures reported are the mean and standard deviation of peak 
flow in each interval. P-values indicating the significance of the results are also 
presented. 
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Table 29 – PEFR (l/min) at baseline relative to PEFR (l/min) before exacerbation 
Pre-exacerbation time 
window 
N Baseline  
mean (SD) 
Pre-exacerbation 
mean (SD) 
P-value  
     
Exacerbation – 7 days 14 304 (106) 281 (105) 0.01 
Exacerbation – 14 days 14 304 (106) 284 (99) 0.01 
     
 
When comparing baseline PEFR measured for 2 weeks at the beginning of study 
enrolment with the pre-exacerbation period, PEFR was significantly lower during 
the 7 or 14 days pre-exacerbation than at baseline. 
 
While this is useful to demonstrate objective evidence of exacerbation, it is worthy 
of note that in clinical terms, a mean fall of 20 l/min in PEFR could be due to inter-
test variability. 
 
4.6 Symptoms and reliever use – Part 2 
Alongside PEFR data clinical symptoms were recorded prospectively by Part 2 study 
participants.  The presence or absence of asthma symptoms during a 24 hour 
period was recorded alongside the number of times asthma reliever medication 
was used. Table 30 below outlines the symptoms recorded and the score given for 
each parameter. 
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Table 30 – Part 2 symptoms, reliever use and assigned score 
Parameter Score 
Wheeze 1 
Night waking 1 
Chest tightness 1 
Breathlessness 1 
Reliever use  
≤ 2 0 
3 – 9 1 
≥ 10 2 
 
When analysing these data, a symptom score from 0-4, the reliever use 
independent of symptoms and a composite score of symptoms and reliever use 
together (scored from 0-7) were used. 
 
Data was collected from around 9 months before exacerbation to 2 months post 
exacerbation in some patients, although the range was less in most patients. One 
option would be to try and model scores throughout this time period. However, by 
doing this, the wide range might imply that the important time period around 
exacerbation was not given sufficient attention. Instead it was decided to focus only 
on values in the period from 30 days before to 30 days post exacerbation. 
 
All of the three outcome variables of interest (symptom score, composite score, 
and reliever use) were measured on continuous scales. Reliever use was found to 
have a positively skewed distribution, and was thus analysed on the log scale. 
 
The change in outcomes over time were modelled. As there were repeat 
measurements from the same patients during this time period, it was necessary to 
account for this in the analysis. As a result, all analysis was performed using 
multilevel linear regression. Two-level models were used with individual scores 
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nested within patients. To allow a flexible relationship between time and the 
outcomes, both linear and squared terms for time were included in the analysis 
(and also a cubic term if this was statistically significant). 
 
Results 
Multilevel regression models were used to model the outcomes over time. A 
summary of the regression coefficients from these models are summarised in table 
31 below. These are given as the change in outcome for a one-week increase in 
time. P-values indicating the overall significance of the change in scores over time 
are also presented. 
 
Table 31 – Summary of regression coefficients 
Outcome Term Coefficient (95% CI) P-value  
    
Symptom score Linear 0.035 (0.001, 0.070) <0.001 
 Squared -0.036 (-0.051, -0.021)  
    
Composite score Linear 0.022 (-0.018, 0.063) <0.001 
 Squared -0.045 (-0.064, -0.027)  
    
Reliever use 
(*)
 Linear -0.036 (-0.074, 0.001)   0.002 
 Squared -0.012 (-0.019, -0.005)  
 Cubic 0.003 (0.000, 0.006)  
    
(*) Variable analysed on the log scale 
 
The results suggested that there were significant changes in all three outcomes 
over time. Due the inclusion of squared and cubic terms for time, it is difficult to 
interpret the nature of the scores over time from these coefficients alone. 
Therefore, the fitted relationship between time and the scores from the regression 
models were determined, and the results are shown graphically in the next charts. 
Additional charts were produced using the mean values of the raw data values at 
each day. 
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Figure 10 below, is for symptom score using the fitted regression lines. 
 
Figure 10 – Symptom score using fitted regression lines 
 
 
The graph suggests that the peak symptom score was at exacerbation, or just after. 
Scores increased in the run-up to exacerbation, with a decrease in scores post-
exacerbation. 
 
A similar representation of the data using the mean value at each day is shown in 
the next graph (figure 11). 
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Figure 11 – Symptom score using mean daily value 
 
 
The next graph (figure 12) shows the changes over time for the composite score, 
based on the fitted regression model. This graph shows a similar picture to that for 
the symptom scores. That is an increase in score preceding exacerbation, with peak 
values at exacerbation or just after. Again, there was a decrease in scores after 
exacerbation.  Figure 13 demonstrates the changes over time for composite score 
using raw data. 
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Figure 12 – Composite score using fitted regression model 
 
 
Figure 13 – Composite score using raw data 
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The final graphs are for reliever use, figure 14 is the graph from the fitted 
regression model and figure 15 uses the raw data for reliever use. 
 
Figure 14 – Reliever use using regression model 
 
 
The graph indicates that, as with the other outcomes, there is an increase in 
reliever use prior to exacerbation. However, for this outcome, the peak values are 
observed around a week before exacerbation. After this peak there is a decrease in 
scores up to exacerbation, and a further decrease post-exacerbation. 
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Figure 15 – Reliever use using raw data 
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5.0 DISCUSSION 
 
5.0.1 Summary of key results 
This study observed people with asthma and compared baseline, acute 
exacerbation and recovery states, examining biochemical signals to identify 
potential markers of asthma exacerbation.   
Part 1 
Part 1 of the study observed people with asthma who required hospital admission 
for acute asthma exacerbation.  Admission (exacerbation) and the first follow up 
visit after 35 days in all participants, including fully recovered and recovering 
patients were compared.  Statistically significant increases from admission to first 
follow up were observed in plasma PF4 (median 9 µg/ml (95 % CI 2, 17), p=0.002), 
eosinophils (median 0.13 x10*9/l (95% CI 0.10, 0.20), p=0.003) and eotaxin (median 
9 pg/ml (95% CI 2, 17), p=0.002). Conversely, there was a statistically significant 
decrease from admission to follow up 1 in plasma IL-6 (median 0.0 pg/ml (95% CI -
1.4, 0.0) p=0.02), IFN-γ (median -3 pg/ml (95% CI -10, 0) p=0.003), IL-13 (median 0.0 
pg/ml (95% CI -0.2, 0.0) p<0.001), RANTES (median -601 pg/ml (95% CI -938, -266) 
p<0.001), IL-12 P40 (median 0 pg/ml (95% CI -30, 2) p=0.01), IL-17A (median -0.3 
pg/ml (95% CI -3.2, 0.0) p=0.002), IL-5 (median -0.4 pg/ml (95% CI -1.5, 0.0) 
p=0.007) and urine GAG:creatinine (median -0.21 µg/mmol (95% CI -0.27, 0.03) 
p=0.04).  Comparing admission to follow up 2 (mean 65 days) including those who 
had a delayed recovery and those who never recovered during the study, a 
statistically significant increase in plasma PAI-1 (median 6200 pg/ml (95% CI -1291, 
10240) p=0.04) and eosinophils (median 0.10 x10*9/l (95% CI 0.00, 0.80) p=0.04) 
was observed. 
There was no significant difference observed between asthma exacerbation and 
any follow up timepoint in Part 1 for plasma TAFI, D-dimer, fibrinogen, platelets, 
TGFβ1, VEGF, urine FDP or urine MMP activity. 
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Comparing exacerbation with recovery in all study subjects, a more clinically 
relevant comparison, there was a statistically significant increase in eosinophils 
(median 10*9/l (95% CI 0.10, 0.29) p=0.02) and eotaxin (median 12 pg/ml (95% CI 3, 
22) p<0.001).  Examining those who recovered rapidly at 35 days and comparing 
exacerbation with recovery, there was a statistically significant increase in 
eosinophils (median 0.10 10*9/l (95% CI 0.07, 0.23) p=0.04) and eotaxin (median 12 
pg/ml (95% CI 3, 22) p=0.002), and statistically significant decreases in IFN (median -
3 pg/ml (95% CI -16, 0) p=0.01), IL-13 (median 0.0 pg/ml  (95% CI -0.3, 0.0) p=0.01), 
RANTES (median -524 pg/ml (95% CI -1003, -45) p=0.03) and IL-5 (median -0.4 
pg/ml (95% CI -2.0, 0.0) p=0.03).  Examining eosinophilic and non-eosinophilic 
asthma subjects comparing exacerbation and recovery, there was a statistically 
significant increase in the eosinophilic group for eotaxin (median 6 pg/ml (95% CI 2, 
24) p=0.02), and a statistically significant increase in the non-eosinophilic group for 
eosinophils (median 0.20 10*9/l (95% CI 0.01, 0.20) p=0.03), TNFα (median 1.7 
pg/ml (95% CI 0.1, 4.3) p=0.04) and eotaxin (median 17 pg/ml (95% CI 1, 27) 
p=0.01). 
There were significant positive correlations at admission (exacerbation) between 
eosinophils and eotaxin (p<0.001), platelets and PF4 (p=0.02) and platelets and 
eosinophils (p=0.01). 
Observing clinical parameters of exacerbation and recovery both PEFR (median 120 
l/min (95% CI 87, 153) p<0.001) and FEV1 (median 0.58 l (95% CI 0.43, 0.72) 
p<0.001) significantly increased at recovery compared with exacerbation.  There 
was no statistically significant difference between exacerbation and recovery for 
FeNO. 
Part 2 
Part 2 prospectively observed participants at baseline, through exacerbation and to 
recovery.  Looking prospectively at the relationship between a positive urine FDP 
result and asthma exacerbation, there was a statistically significant relationship.  
Examining the 8, 11 and 15 days prior to an exacerbation of asthma, the presence 
of a positive FDP result when compared with a negative FDP result was associated 
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with an odds ratio of 4.35 (95% CI 1.12, 16.9) (p=0.03), 5.50 (95% CI 1.38, 21.9) 
(p=0.02) and 6.07 (95% CI 1.43, 25.8) (p=0.02) respectively of a subsequent asthma 
exacerbation.  This supports the initial hypothesis that markers of fibrin turnover 
are increased in blood and urine before and during exacerbation of asthma.   
 
When comparing baseline state with asthma exacerbation, a statistically significant 
increase in plasma D-dimer (median 0.07 µgFEU/ml (95% CI -0.01, 0.15) p=0.02) and 
a significant decrease in plasma TGFβ1 (median -666 pg/ml (95% CI -1289, -2) 
p=0.02) was observed.  Comparing baseline and recovery there was a statistically 
significant decrease in plasma PF4 (-1.7 µg/ml (95% CI -3.4, -0.1) p=0.04).  There 
was no significant difference observed when comparing baseline to exacerbation or 
recovery in any of the other plasma markers examined.  There was also a 
statistically significant increase in GAG:creatinine ratio in the 7 days preceding 
exacerbation (mean 0.45 µg/mmol (SD 0.18) p=0.03). 
 
Clinically in Part 2, there were statistically significant increases in symptom score 
(p<0.001), reliever use (p=0.002) and composite score of symptom and reliever use 
(p<0.001) in the days preceding asthma exacerbation that fell during recovery.  
PEFR variability increased in the 7days (p=0.01) and 14 days (p=0.01) prior to 
exacerbation when compared with baseline state. 
 
5.1 Plasma and urine parameters 
5.1.1 FDP – urine 
The primary objective of this study was to test the hypothesis that markers of fibrin 
turnover were detectable before and during asthma exacerbation in blood or urine.  
When looking prospectively, a significant increase in the incidence of asthma 
exacerbation following the detection of FDP in urine was observed.  This was 
limited to the Part 2 population, and in part this is likely due to the more severe 
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asthma population when compared with the heterogeneity of Part 1, and possibly 
due to systemic treatment with corticosteroids.  As discussed below, coagulation 
factors are consumed during fibrinogenesis and fibrinolysis results in the generation 
of FDPs (161).  Although the test employed was a generic agglutination test for 
FDPs and could not specify which FDP was detected, a positive test correlated with 
an increased incidence of asthma exacerbation in the following 2 weeks of up to 6x 
that of a negative FDP result.   
 
The strength of this study is not in the number of positive results but in the large 
number of negative results that were not followed by an exacerbation of asthma.  
Positive results were seen after exacerbation in the period of clinical recovery and 
before exacerbation without subsequent recovery.  A return to a negative test after 
exacerbation is less useful in clinical terms as signs and symptoms are now present 
and their resolution can be utilised to monitor recovery.  Whether subsequent 
exacerbation was more likely if further positive FDP results occurred was beyond 
the scope of this trial and in the one case where a second exacerbation occurred, 
the study participant was withdrawn from further study activity and results 
withdrawn from analysis.   
The number of participants experiencing asthma exacerbation in this study makes 
sample size too small to calculate positive and negative predictive values of this 
test.  Furthermore the test in its current form is neither sensitive nor specific 
enough to be used in clinical practice.  However, with the supporting evidence of an 
increased plasma D-dimer in this cohort at the time of exacerbation, FDPs are a 
viable target for future study as a biomarker of asthma exacerbation.  They have 
the potential to predict exacerbation prior to onset of clinical parameters enabling 
intervention and fulfil the required characteristics of a good biomarker, if a test can 
be developed prospectively that is sufficiently sensitive, specific and has accurate 
positive and negative prediction.  Furthermore, the detection of signal in plasma 
and urine makes the possibility of translating such a marker into a point-of-care test 
more feasible. 
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In terms of the clinical potential to intervene a window of 7-14 days should be 
significant time to enable intervention.  The FACET trial examined combined 
ICS/LABA inhaler use in asthma (162).  This study identified an increase in 
symptoms 10 days before an asthma exacerbation that accelerated 5 days before 
(75).  It is this window that has been successfully utilised in Symbicort Maintenance 
and Reliever Therapy (SMART) reducing time to severe exacerbation and number of 
those exacerbations (76).  The optimal prophylactic or ameliorating regime would 
need to be established as would the optimal treatment window in prospective 
interventional studies. 
 
5.1.2 Fibrinogenesis and fibrinolysis – plasma markers 
This study measured markers of fibrin turnover in plasma of patients before, during 
and at recovery from acute exacerbation of asthma.  Past studies have 
demonstrated that the balance of fibrin turnover is tipped in favour of fibrinolysis in 
the healthy lung, a state matched in moderate asthma treated with inhaled steroids 
(137).  In severe asthma, the balance favours fibrinogenesis regardless of treatment 
with steroids, and withdrawal of ICS in moderate asthma alters the airway milieu to 
a pro-coagulant environment (80, 137).  It is likely that an excess of PAI-1 is 
responsible for the shift towards fibrinogenesis observed (138, 163).  PAI-1 reduces 
fibrinolysis by inhibiting plasminogen activation, an effect which promotes airway 
remodelling via TGF-β that is counteracted by uPA administration in murine studies 
(126).  TAFI is also an inhibitor of fibrinolysis, however, in murine models of asthma, 
the presence of TAFI reduces AHR and airway inflammation, and reduced TAFI 
levels promote airway remodelling (139).  This implies a mechanism of action for 
PAI-1 on airway remodelling and AHR beyond its direct effect on plasminogen 
activation.  In light of these findings, it was expected that during acute asthma 
exacerbation there would be an increase in PAI-1 and a decrease in TAFI.  In Part 1 
of this study there was a significant increase in PAI-1 from exacerbation to follow up 
2 (65 days) when looking both at those who recovered at follow up 2 and those 
who did not recover during the study period.  When comparing exacerbation and all 
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subjects at first follow up (35 days), exacerbation and clinical recovery for all 
subjects, and exacerbation and delayed recovery there was also an increase at 
follow up visit but these results were not statistically significant.  This trend might 
be explained by the proposed increased PAI-1 expression being localised to the 
airway rather than systemically in this setting.   The trend for TAFI in all groups was 
for lower levels at exacerbation than recovery but again these results did not meet 
statistical significance.  If significant this would be in line with expected trends.  
Prospectively, PAI-1 increased from baseline to exacerbation and fell again at 
recovery, and TAFI mirrored this effect falling during exacerbation and rising upon 
recovery but again, these trends did not meet statistical significance.  It is likely that 
the Part 1 population was too heterogeneous to provide conclusive results whereas 
Part 2 was too small despite the more severe nature of these patients. 
 
Fibrinogen is cleaved to fibrin during fibrinogenesis and therefore consumed, and 
one might expect reduced fibrinogen detected during asthma exacerbation.  In both 
study arms no discernible difference was observed between any timepoints.  This 
would be in keeping with the observation by Perrio and colleagues that TF-
dependent coagulation of damaged airway epithelium occurs independently of 
plasma (92).  If the components of the coagulation cascade are produced and 
stored locally in airway epithelium, then a difference systemically may not be 
perceptible in coagulation factors between exacerbation and stable states.  
Furthermore, coagulation factors are consumed during fibrinogenesis and with the 
exception of FDPs, nothing remains after fibrinolysis.   
 
A difference was observed between baseline and exacerbation of D-dimer, but only 
in the Part 2 population.  D-dimer is a breakdown product of successful coagulation 
and indicates that both fibrinogenesis and fibrinolysis has occurred.  D-dimer is 
detectable systemically in a wide range of conditions, most widely recognised and 
utilised in the setting of venous thromboembolism (VTE) (161).  The observed 
difference in Part 2 and not Part 1 is again a likely reflection of the asthma severity 
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in the Part 2 population compared with the heterogeneity of Part 1 subjects (137).  
This also reflects the pro-coagulant state observed by Majoor and colleagues who 
observed increased VTE in severe asthma and those requiring oral corticosteroids 
(164).  The fact that only D-dimer was detectably increased at exacerbation of all 
the markers of fibrin turnover examined could be explained by the consumption of 
other coagulation factors during fibrinogenesis and subsequent fibrinolysis. 
 
5.1.3 Platelets and PF4 
In Part 1, PF4 was observed to be lower at exacerbation than first follow up at 35 
days, with no change in platelet counts between timepoints.  As discussed in 
chapter 2, laboratory analysis was not performed at follow up in a large number of 
study subjects reducing the power of looking at platelet numbers directly.  
Furthermore, the method used to prepare plasma in this study did not remove 
platelets completely from plasma samples.  However, standardised methods of 
platelet preparation were used, which should result in similar platelet 
concentrations in each sample.  Any excess platelet contents released by cell lysis 
during freeze-thaw cycles should be uniform.  PF4 is contained in platelet alpha 
granules and is released on platelet activation (81), so any detectable difference 
between PF4 levels should represent peripheral platelet activation, or a surrogate 
marker of peripheral blood platelet count. Indeed a positive correlation was 
observed between platelets and PF4 at admission.  This was not observed at 
subsequent timepoints most likely due to the reduced specimen numbers.  
Although differences between samples is likely to reflect differences in platelet 
activation and platelet count, the absolute values of factors contained in platelets 
are likely to be higher with these plasma samples than studies using platelet-poor 
or platelet-deplete plasma.  This should be noted if comparing this study with other 
published work.  Tutluoglu and colleagues observed higher peripheral blood PF4 
levels in asthma exacerbation compared with healthy controls (136), and PF4 
increased after treatment of exacerbation with oral steroids.  In a murine model of 
asthma, allergen challenge induced platelet migration into lung tissue (165), 
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furthermore platelets expressing P-selectin may be required for successful 
translocation of eosinophils into the lung (166).  In the present study, both platelets 
and eosinophils have been observed at lower levels in peripheral blood during 
exacerbation than at recovery, a finding that is consistent with such interdependent 
sequestration into the lung.  Furthermore, platelet and eosinophil counts 
demonstrated a significant correlation at admission supporting this hypothesis.  
Again, no correlation was seen at follow up visits likely due to specimen numbers as 
highlighted above.   
 
The treatment of this population with oral steroids and subsequent increase in PF4 
during recovery would be consistent with Tutluoglu’s observations (136) which 
could be explained by platelets that acutely migrated to the lungs during 
exacerbation being returned to the systemic circulation on recovery, perhaps 
because of the treatment with steroids.  In the prospective study arm, there was no 
significant change between baseline and exacerbation or between exacerbation 
and recovery, however a significant fall in PF4 was observed when comparing 
baseline and recovery.  It is likely that this is due to the effect of steroids described 
above and the lack of signal between other timepoints is probably explained by 
overall small sample size. 
 
5.1.4 Eosinophils 
In Part 1 of this study, lower levels of peripheral eosinophils were observed at 
exacerbation compared with recovery.  Airway eosinophilia is associated with 
exacerbation of asthma (167) and reduction of sputum eosinophils reduces asthma 
exacerbation (32).  The observed reduction in peripheral eosinophils during 
exacerbation could be explained in two ways.  Firstly, eosinophils migrate into the 
airway lumen in response to acute inflammatory insult (168) such as that seen 
during acute exacerbation of asthma.  A reduction in peripheral eosinophil counts 
may be due to eosinophil migration into the airways in response to inflammation 
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and chemotaxis.  Secondly, many of the study subjects received oral steroids prior 
to plasma samples being collected.  Although attempts were made to record the 
interval from first steroid dose to sample collection accurately, this was not 
consistently achieved for methodological reasons discussed in Chapter 2.  Although 
not accurate enough for formal statistical comparison, it is clear that considerable 
variation in this interval occurred, some subjects receiving oral steroids several days 
prior to admission, and in others this interval was only minutes.  The effects of 
treatment with oral steroids are rapid, with peak plasma levels being achieved in 
under an hour (169), and clinical effects being seen within 3 hours (4).  Although 
efforts were taken to assess patients for study participation as soon as possible 
after admission, delaying treatment for study participation was outwith the study 
protocol and was not practiced, therefore treatment effects may have influenced 
the observed peripheral eosinophil counts.  It is worth noting that although 
statistically significant, the fall in peripheral eosinophils would not normally be 
classed as significant in terms of clinical practice, in fact median peripheral 
eosinophil counts at exacerbation and recovery were within the normal range for 
adult subjects (see appendix 20).  A significant correlation between eosinophil 
count and eotaxin was observed at admission which is expected as eotaxin is an 
eosinophil chemokine.  This correlation was not observed at subsequent timepoints 
but as discussed in chapter 2, blood samples for FBC were not routinely taken at 
follow up visits reducing the power of these data for analysis at follow up visits. 
 
5.1.5 VEGF 
VEGF is a potent angiogenic factor that is present at higher levels in the sputum of 
asthmatic individuals when compared with healthy controls (170).  The effects of 
VEGF in asthma include increased angiogenesis and vascular leakage, but also 
increased eosinophilic inflammation, AHR and airway remodelling demonstrated by 
subepithelial collagen deposition and smooth muscle hyperplasia in murine models 
(171).  When comparing asthmatic subjects with healthy controls, Lee and 
colleagues found increased levels of VEGF in plasma in asthmatic subjects that 
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increased during exacerbation and subsequently fell with treatment over a 28 day 
period (74).  This could not be replicated in either study arm despite a variety of 
methodological considerations discussed in chapter 2.  Inhaled corticosteroids in 
different formulations and models have been shown to affect VEGF and its effects 
in asthma.  Inhaled budesonide in a murine model inhibited lung VEGF levels and 
angiogenesis (172).  Higher sputum VEGF has been observed in steroid-naïve 
asthmatic subjects compared with healthy controls, with VEGF levels negatively 
correlating with FEV1, and a subsequent reduction in sputum VEGF after inhaled 
BDP (173).  Similar observations have been made with inhaled fluticasone 
propionate in terms of reduced VEGF angiogenesis (174), and with BDP reducing 
VEGF and exercise-induced bronchospasm (175).  Combined therapy with 
budesonide/formoterol over 6 months reduces epithelial VEGF and VEGF receptor 
levels (176).  The failure to replicate the findings of Lee and colleagues in this study, 
is likely due to the population being “real life” asthmatics already receiving 
treatment with inhaled therapies, whereas Lee’s study population had not received 
inhaled or oral steroids for at least 6 months prior to study recruitment (74). 
 
In terms of the wider interactions of VEGF, it is important to note that TGFβ1 
stimulates VEGF expression in vitro (177).  Furthermore, in vitro stimulation of 
human lung epithelial cells by VEGF increases TGFβ1 and inhibition of VEGF reduces 
TGFβ1, an observation repeated in a murine model (178).  Examining the 
relationship between VEGF and MMP, in a murine model of asthma MMP-9 and 
VEGF levels are increased, correlate with each other, and the inhibition of VEGF 
reduces MMP-9 levels (73). 
 
5.1.6 TGFβ1 
TGFβ1 has both pro- and anti-inflammatory properties.  It inhibits Th1 and Th2 
responses reducing the inflammatory response, yet it is a potent chemotactic factor 
and activator that is released from inflammatory cells such as eosinophils and 
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macrophages, alongside structural cells including fibroblasts, epithelial cells and 
smooth muscle cells (179).  In asthma, eosinophils are the main source of TGFβ1 
and it is postulated that an initial lack of TGFβ1 leads to a lack of T regulatory cells 
allowing Th2 airway inflammation, eosinophilic inflammation and a resultant 
increase in TGFβ1 and subsequent airway remodelling (179).  TGFβ1 has potent 
effects on airway remodelling via epithelial mesenchymal transition (EMT) both in 
vitro (180) and in vivo (69).  This EMT effect is greater in asthmatic epithelium than 
in healthy controls (69) and in vitro, there is a synergistic effect on EMT between 
TGFβ1, IL-4 and IL-17 (Th2 and Th17 cytokines respectively) (181).  This is supported 
by the observation that TGFβ1 alone requires prolonged exposure to airway 
smooth muscle cells to induce proliferation (182).  The administration of anti-IL-5 
reduces airway eosinophils and also airway remodelling by removing the main 
source of airway TGFβ1 (183).  However, the dual role of TGFβ1 is illustrated by the 
fact that in a murine model of asthma, suppression of TGFβ1 reduced airway 
fibrosis at the expense of increased AHR (184). 
 
In Part 1 of the study no difference was observed in plasma TGFβ1 between acute 
exacerbation and any follow up time point.  Plasma TGFβ1 is higher in stable non-
atopic asthmatics compared with atopic asthmatics or healthy controls (185).  
Serum TGFβ1 has also been observed at higher levels in patients with asthma than 
healthy controls but higher still in steroid naïve asthma compared with moderate 
treated or remission asthma populations (186).  This is supported by an observed 
correlation between asthma control measured using the asthma control test (ACT), 
where uncontrolled asthma was associated with higher plasma TGFβ1 (70).  Higher 
BALF levels of TGFβ1 are seen in asthma than in healthy controls and these levels 
rise with allergen challenge (187).  This would be more analogous to acute 
exacerbation than steroid naivety or poor asthma control, however, it may be that 
such acute reactions are confined to the lungs hence why they could not be 
measured in plasma in the present study.  Indeed, in Part 2 a significant fall from 
baseline to exacerbation in plasma TGFβ1 was observed, which may represent a 
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translocation of TGFβ1 into the lungs possibly via inflammatory cell migration, 
although a significant fall in eosinophil numbers from baseline to exacerbation was 
not seen.  The population for Part 2 were all in the moderate to severe asthma 
groups whereas Part 1 included milder severities of asthma which may have 
influenced these results.  Finally, inhaled therapy with budesonide/formoterol has 
been shown to reduce TGFβ1 expression and spirometric and computed 
tomographic markers of airway remodelling (188).  The study populations were all 
taking inhaled therapy prior to study recruitment which may have suppressed any 
detectable difference in TGFβ1. 
 
5.1.7 MMP 
The matrix metalloproteinases (MMPs) are key enzymes involved in ECM 
breakdown and airway remodelling (189).  MMP-9 is particularly relevant and the 
balance between MMP-9 and tissue inhibitor of metalloproteinase-1 (TIMP-1) is 
increasingly recognised as important in airway remodelling in asthma (190).  We 
could not detect a significant difference in urinary MMP activity between 
exacerbation and recovery states.  This is contrary to the findings of Mak and 
colleagues who observed higher plasma MMP-9 during asthma exacerbation that 
reduced on recovery but remained higher than healthy controls (191).  One 
explanation might be our attempt to detect MMP in urine rather than plasma, 
however, MMPs have been detected due to other conditions not directly affecting 
the kidney or urinary tract (192).  In our study, analysis of MMP was limited to Part 
1 subjects, a more heterogeneous population in terms of asthma severity.  Exhaled 
MMP-9 levels are higher in severe asthma than in mild to moderate asthma (193) 
and differential MMP expression and activity is observed in different asthma 
inflammatory phenotypes (194).  This may account for our failure to observe a 
difference between exacerbation and recovery in the Part 1 population.  
Glucocorticosteroids and long-acting β2 agonists attenuate MMP-9 expression from 
human bronchial epithelial cells (195).  The majority of our population were 
receiving inhaled therapy with 1 or both of these drugs and a significant proportion 
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had received high dose nebulised β2 agonists and oral corticosteroids prior to urine 
collection.  This could well confound our ability to detect any significant difference. 
 
5.1.8 GAGs 
The glycosaminoglycans are involved in airway remodelling and inflammation in 
asthma.  In controlled asthma, circulating endogenous heparin is lower than 
healthy controls (65), possibly contributing to increased inflammation in asthma.  
Attempts to use heparin as a therapeutic agent in asthma have been made for 
many years with variable success (196, 197).  In both human (63) and murine 
studies (198), GAG deposition in asthmatic airways has been observed.  The effects 
of inhaled corticosteroids and LABA include counteracting the pathologic 
degradation of hyaluronic acid, reducing the pro-inflammatory potential of airway 
smooth muscle cells (199).  This is in line with the observation by Priftis and 
colleagues that urinary GAG excretion is increased in children with asthma taking 
ICS, but not those taking reliever medication alone (200).  Presumably this effect is 
due to the anti-inflammatory effects of steroids and reduction in bronchial 
hyperreactivity reducing airway deposition of GAGs and subsequent remodelling.  
Our finding that urine GAG excretion is increased during asthma exacerbation and 
reduces at 35 day follow up is in keeping with the observation of Shute and 
colleagues (201), who observed increased GAGs in urine during acute severe 
asthma and a return to normal levels over 28 day follow up.   
 
5.1.9 Cytokines and chemokines 
A multiplex panel of chemokines, cytokines and pro-inflammatory mediators was 
examined to explore the detectable inflammatory changes in the study population.  
The intention in performing this multiplex analysis was to aid characterisation of 
inflammatory phenotype in this cohort in response to the lack of sputum data 
obtained.  The results demonstrate a systemic inflammatory response, not limited 
to an individual phenotype.  When measured peripherally, eotaxin was observed to 
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be lower at exacerbation.  This could represent cellular migration to the airways 
and had sputum been successfully measured, a direct comparison could have been 
made.  This observation might also represent an effect of acute treatment with oral 
corticosteroids.  A relatively strong correlation between eosinophil count and 
eotaxin at admission was observed which would support this hypothesis.  
In Part 1, higher levels of IL-6, IFN-γ, IL-13, RANTES, IL-12P40, IL-17A and IL-5 were 
observed at exacerbation compared with follow up (mean 35 days), eotaxin was 
lower during exacerbation than recovery, and no difference was observed in IL-8 or 
TNF-α between timepoints.  Comparing exacerbation with clinical recovery, a 
statistically significant fall was observed in IFN-γ, IL-13, RANTES and IL-5, with a 
significant rise in eotaxin.  The subjects in this study are their own controls, and 
these observations imply a rise in plasma cytokine levels during exacerbation that 
returns to baseline at recovery, except eotaxin, which falls during exacerbation and 
rises on recovery.   
 
These findings demonstrate a systemic increase in Th1 cytokines (IFN-γ, IL-12P40), 
Th2 inflammatory (IL-5, IL-13) and regulatory (IL-17A, IL12P40) cytokines, pro-
inflammatory cytokines (IL-6), T cell/eosinophil chemokines (RANTES) and a 
decrease in the eosinophil chemokine Eotaxin.  These findings are consistent with 
the observations of other investigators.  Lee and colleagues observed increased 
serum IL-5, IL-13 and a trend towards increased IFN-γ during acute asthma 
exacerbation (202).  Zietkowski and colleagues observed increased RANTES in the 
airway during acute asthma exacerbation (203).  Kaminska observed IL-12, IL-13 
and IFN-γ in bronchial biopsies from asthmatic airways with fixed airflow 
obstruction and IL-17 and RANTES in those with intermittent obstruction (204).  
Kato observed increases in serum IL-5 and IL-6 during acute asthma exacerbation 
(205).  Elevations in sputum levels of Eotaxin have been observed during acute 
exacerbation of asthma (206). 
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In Part 2 of the study, no difference was observed in any marker comparing 
baseline with exacerbation or recovery.  It is likely that the small sample size limited 
the detection of any significant differences in this study arm. 
 
The observed differences in cytokines and chemokines between different clinical 
scenarios in asthma raise interesting questions and possible hypotheses.  It is 
important, however, to acknowledge that the intention of these analyses was to 
characterise disease phenotype, an objective that was unsuccessful, and no 
correction was made for multiple comparisons potential weakening the validity of 
the observed differences (207).  These parameters are not measured routinely in 
clinical practice and hence a normal range is not established to give reference to 
the measured values.  It is clear however, that while some of the measured changes 
may be statistically significant, any clinical significance must be questioned, for 
example the average decrease observed in IL-13 from 0.0 to 0.0 (table 5). 
 
5.2 Clinical parameters 
This study recruited patients with asthma who experienced an acute exacerbation 
requiring treatment with oral corticosteroids, and their treatment was provided by 
clinical teams according to standard practice and national guidelines (4).  The data 
collected has highlighted clinical observations that merit further discussion and 
prompt future research questions and important consideration for the design of 
subsequent studies. 
5.2.1 Asthma exacerbation 
The NHLBI define an asthma exacerbation as an “acute or subacute episode of 
progressively worsening shortness of breath, cough, wheezing, and chest tightness 
– or some combination of these symptoms.  Exacerbations are characterised by 
decreases in expiratory airflow that can be documented and quantified by simple 
measurement of lung function” (1).  GINA definitions are similar in description and 
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equally lacking in quantifiable measures defining presence or absence of 
exacerbation (5).  The BTS delineates the severity of an exacerbation into 
moderate, acute severe and life threatening based on a series of clinical parameters 
measured once exacerbation is diagnosed (4).  None of these definitions gives a 
clear objective definition that can be agreed on for the purposes of research, or for 
consistency in clinical practice, leaving a large part to the subjective experience of 
the patient combined with individual judgement of the treating clinician.  The 
ATS/ERS statement on asthma research gives a similar description as those 
described above but clarifies a severe exacerbation in terms of research should 
require treatment with systemic corticosteroids or require hospital admission (6). 
 
The present study defined exacerbation as requiring oral corticosteroids in line with 
a severe exacerbation.  It is a strength of this study that the decision to treat and 
admit was left to the discretion of the treating clinician in line with national 
guidelines (4).  Due to the rather nebulous definition outlined in national and 
international guidelines, it is an important point to consider when designing future 
studies how objective one can be when diagnosing asthma exacerbation. 
 
5.2.2 Recovery from exacerbation 
None of the national or international asthma guidelines define recovery from an 
exacerbation of asthma.  The BTS advise improved symptoms and PEFR rather than 
a return to normality should be used to guide decisions on discharge from the 
emergency department (4), GINA advises PEFR may be useful to monitor recovery 
(5), and the NHLBI do not refer to recovery in their guideline (1).  Recovery is not 
described by the ATS/ERS joint statement on asthma research (6). 
 
For the purposes of this study, the decision was taken to define recovery as a return 
to pre-exacerbation state defined subjectively by the patient.  If asthma control was 
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poor prior to exacerbation and a return to this level of control was achieved, this 
was considered a recovery.  The choice of 4 week initial follow up was based 
anecdotally on received wisdom that inflammatory changes occurring due to 
asthma exacerbation take approximately 6 weeks to return to normal, accepting 
symptoms may improve prior to this.  On subsequent literature review, no 
reference could be found to a 6 week figure, in fact there is a paucity of any studies 
commenting on recovery after asthma exacerbation. 
 
The consistency with real life practice is a strength of this study but once again, the 
definition of recovery from asthma exacerbation should be considered in future 
study design and is an area that merits further study. 
 
5.2.3 FeNO during acute exacerbation 
The use of sputum eosinophil counts to guide asthma management has been shown 
to reduce exacerbation frequency and reduce steroid doses used for treatment 
(32).  The use of FeNO as a surrogate marker of sputum eosinophilia has been less 
convincing in terms of outcome data (48).  However, recent ATS guidelines 
acknowledge the advantages and limitations to the test and recommend its use for 
the diagnosis of eosinophilic airway inflammation and assessing likelihood of 
steroid responsiveness (49).  There has been limited study of FeNO during acute 
exacerbation.  One ED study was discontinued as reproducibility of FeNO 
measurement acutely was considered unacceptable (208) a second paediatric study 
observed elevated levels of FeNO during asthma exacerbation, however no cut off 
level for exacerbation diagnosis could be established (209). 
 
FeNO was measured in Part 1 subjects at exacerbation and again on recovery.  No 
significant difference was observed in measured FeNO at exacerbation compared 
with recovery.  Even when this comparison was limited to those study participants 
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with an eosinophilic inflammatory phenotype, no difference in FeNO was observed 
between exacerbation and recovery.  While it is recognised that in this study, the 
total population who recovered with data recorded at both timepoints for 
comparison was small (54 subjects), and that the eosinophilic subgroup was smaller 
still (30 subjects), this remains one of the biggest cohorts to date examining FeNO 
during acute exacerbation of asthma and again at recovery.   
 
5.2.4 Eosinophilic phenotype 
As discussed in Chapter 2, sputum sampling was not successful in the majority of 
study participants.  The decision was taken, therefore, to categorise eosinophilic 
phenotype using the method described by Schleich and colleagues (160) utilising 
one or more of a raised peripheral eosinophil count, raised IgE or raised FeNO.  
Where sputum was obtained, a differential sputum eosinophil count of >3% was 
deemed significant.  If these criteria were met at any study timepoint, the subject 
was deemed to have an eosinophilic inflammatory phenotype. 
 
It is worthy of note that eosinophilic inflammation changed between timepoints for 
study subjects in no particular pattern.  Some had eosinophilia present through 
study visits, some present only at exacerbation and some only at recovery.  
Phenotypic lability such as this has been observed in children with asthma (210) and 
is unrelated to changes in steroid treatment.  This observation highlights the 
importance of careful characterisation of an individual’s asthma phenotype using all 
available information.  In terms of future study design and using phenotypes to 
guide therapy, there may be a need to examine parameters such as sputum, 
peripheral blood and FeNO in a longitudinal manner before an individual’s 
phenotype is determined. 
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5.2.5 Objective markers of recovery and exacerbation 
As discussed above the definition of asthma exacerbation has been described by 
guidelines and parameters are described that determine severity of exacerbation 
(4).  These require an individual to be deemed as having an asthma exacerbation to 
apply and in terms of research, it is important to try and define an exacerbation by 
clearly determined parameters.  This argument may seem pedantic, however, when 
attempting to confirm an asthma exacerbation in this study, it was determined that 
an exacerbation was based on a treating physician deeming it was occurring, due to 
an absence of accepted measurable parameters.  Those parameters that are 
described such as PEFR require knowledge of PEFR when well for comparison, a fact 
not known by a significant proportion of this population, or comparison with a 
predicted value, often different from best in those who did know.  Similar 
difficulties arose when defining recovery from exacerbation. 
 
In Part 1 of this study, a significant rise was observed in both FEV1 (mean 600 mls) 
and PEFR (mean 120 l/min) from exacerbation to recovery.  This provides objective 
measurement of improvement in airflow obstruction at recovery but is limited by a 
lack of baseline data to demonstrate a fall during exacerbation.   
 
Study participants were also asked to record the presence or absence of common 
asthma symptoms on a daily basis and the number of times a reliever was used, 
again in an attempt to provide a measurable distinction between exacerbation and 
recovery states.  A symptom score from 0-4 was derived from the presence or 
absence of wheeze, night wakening, chest tightness and breathlessness during a 24 
hour period.  Reliever use, either number of puffs of SABA and/or number of SABA 
nebulisers in 24 hours was also recorded and assigned a numerical value as outlined 
in table 32.  The composite score from 0-7 combines symptom score and reliever 
use. 
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Table 32 – Symptom and composite scores 
Parameter Score 
Wheeze 1 
Night waking 1 
Chest tightness 1 
Breathlessness 1 
Reliever use  
≤ 2 0 
3 – 9 1 
≥ 10 2 
 
This scoring system gives a score between zero and seven on any one day.  Other 
scoring systems have been described and validated for evaluating asthma control 
(75, 211), however the intention in our study was not to look at asthma control, 
rather to provide objective evidence of exacerbation.  It was intended that the 
simplicity of binary questions, i.e. presence or absence of each symptom, would 
remove some of the subjectivity present in numerical scales used in other scores. 
 
In the prospective Part 2 data, statistically significant rises were observed in 
symptom score and reliever use independently, and combined as a composite 
score.  When examined alone, reliever use was positively skewed requiring 
logarithmic data to be evaluated.  This makes it less practical as a tool to be used in 
clinical or research practice.  However, the symptom and composite scores are 
simple to record and have provided objective evidence of exacerbation.  
Consideration should be given to prospective evaluation of these scores in larger 
cohorts to validate their use.  They could be of particular benefit for future research 
studies to help define exacerbation and subsequent recovery.  The temporal 
relationship observed is that symptoms climb in the 10 days preceding exacerbation 
and peak just after, whereas reliever use begins to rise 7 days prior to exacerbation 
and peaks just before.  Both parameters fall after exacerbation. 
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The prospective PEFR data did not demonstrate a significant fall in mean PEFR prior 
to exacerbation, however there was a statistically significant fall in PEFR variability 
when compared with baseline.  Clinically the fall was only 20 l/min, a mean 7% fall 
for our population classed as below the threshold of normal variability for PEFR 
measurement and not regarded as a significant fall from baseline in terms of 
asthma exacerbation (4).  This contradicts the findings of Tattersfield and 
colleagues who observed falls in PEFR prior to exacerbation of up to 20% in the 
FACET study (75).  However, the present study examined 23 subjects, only 15 of 
whom had adequate PEFR data compared with 425 subjects in the FACET study, 
114 of whom were diagnosed as exacerbating by a fall in PEF of 30% or more from 
baseline.  Furthermore, the FACET trial examined mean morning and mean evening 
PEFR values where the present trial examined PEFR variability.  This could explain 
the smaller “sub-clinical” fall in PEFR for the present population.  
 
Symptom data from the FACET trial shows a rise in symptoms in the 10 days 
preceding exacerbation (75).  The present study demonstrated comparable 
significant increases in symptom score in the 10 days prior to exacerbation.  The 
symptom score used in the present study has the added benefit of simplicity in 
terms of data recording.  Other studies suggest a symptom diary may be a more 
sensitive tool for revealing acute exacerbation of asthma than measures such as 
PEFR (212).  It is worthy of note that the FACET trial found that for increased PEFR 
variability, increased symptoms or increased reliever use, the odds ratio of 
subsequent exacerbation was statistically significant, but did not exceed 1.1 for any 
of the variables.  In comparison, an odds ratio of between 4 and 6 for subsequent 
exacerbation following a positive urine FDP warrants further study. 
 
5.2.6 Who recovers quickly? 
Initial analysis looking at inflammatory phenotype defined by sputum differential 
cell count suggested that eosinophilic asthmatics in this cohort were more likely to 
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recover rapidly than neutrophilic asthmatics.  As discussed, the limited sputum data 
made such comparisons too small in terms of sample numbers to draw any firm 
conclusions.  Subsequent analysis of this cohort looking only at those who 
recovered and looking at the relationship between rate of recovery and presence of 
eosinophilic inflammation did not show any significant correlation. 
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5.3 Conclusions 
This is the largest study to date examining coagulation and fibrinolysis in acute 
exacerbation of asthma.  In individuals with moderate to severe asthma, urine FDPs 
were detected in the days preceding an asthma exacerbation, prior to patients 
developing symptoms sufficient to seek medical attention.  The detection of FDP in 
urine was associated with a significantly increased risk between 4 and 6 times more 
likely of subsequent asthma exacerbation in the following 7 to 14 days when 
compared with a negative urine FDP test.  Fibrin(ogen) degradation products are 
promising urinary biomarkers of asthma exacerbation that warrant future study 
and detecting FDPs in urine presents the realistic prospect of translating these 
findings into a practical and acceptable point-of-care test for patients with asthma.  
This is supported by the observation that prospectively D-dimer, a fibrin 
degradation product, was significantly increased in plasma at exacerbation 
compared with baseline. 
The present study examined plasma markers of fibrin turnover alongside cytokines, 
chemokines and blood cells.  Although various parameters significantly decreased 
from exacerbation to follow up, when comparing exacerbation and clinical 
recovery, no markers of fibrin turnover significantly changed in plasma.  A 
significant increase in eosinophils, eotaxin and PF4, alongside observed positive 
correlations at exacerbation between these parameters and platelets, supports the 
migration of eosinophils and platelets into the lung during asthma exacerbation.  
Future study of coagulation and fibrinolysis in asthma may benefit from focussing 
on airway samples in preference to plasma for this reason. 
Clinically, this study demonstrates that FeNO is not useful for distinguishing asthma 
exacerbation from baseline or recovery states.  The symptom and composite scores 
used in this study provide objective evidence of asthma exacerbation for use in 
future research studies and would benefit from prospective evaluation and 
validation in future larger cohorts. 
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Appendix 20 – Blood and urine tests by PHT laboratory 
Blood and urine tests performed by PHT laboratory 
Parameter Reference range Analyser Supplier 
Haematology 
Full blood count (FBC) 
Beckman Coulter LH 
750 
Beckman Coulter (UK) 
Ltd, 
Oakley Court, 
Kingsmead Business Park, 
London Road, 
High Wycombe, 
HP11 1JU, 
UK 
 
Haemoglobin (Hb) 12.0-16.0 g/dl 
White cell count (WCC) 4.0-11.0 x109/l 
Platelets (Plats) 150-400 x109/l 
Mean cell volume (MCV) 80.0-99.0 fl 
Neutrophils (Neut) 2.0-7.5 x109/l 
Eosinophils (Eosin) 0.0-0.4 x109/l 
Monocytes (Mono) 0.2-0.8 x109/l 
Clotting  
International normalised 
ratio (INR) 
0.8-1.2 
IL ACL Top 
Diamond Diagnostics, 
333 Fiske Street, 
Holliston, 
MA 01746, 
USA 
Activated partial 
thromboplastin ratio 
(APTR) 
0.8-1.2 
D-dimer 0-0.5 μgFEU/ml 
Fibrinogen 1.5-3.5 g/l 
Immunology 
Immunoglobulin E (IgE) 0-81 IU/ml 
Phadia 250 
Phadia AB, 
P.O. Box 6460, 
SE-751 37 UPPSALA, 
Sweden 
Biochemistry 
C-reactive protein (CRP) 0-5 mg/l 
DxC 800 Synchron 
Beckman Coulter (UK) 
Ltd, 
Oakley Court, 
Kingsmead Business Park, 
London Road, 
High Wycombe, 
HP11 1JU, 
UK 
 
Serum glucose (Gluc) 3.5-6.0 mmol/l 
Random urine 
creatinine (Urine creat) 
mmol/l 
Liver function tests (LFT) 
Bilirubin (Bili) 3-20 μmol/l 
Alkaline phosphatase 
(ALP) 
30-130 iu/l 
Aspartate transaminase 
(AST) 
12-40 iu/l 
Bone profile 
Albumin (Alb) 35-48 g/l 
Adjusted calcium 
(adjCa2+) 
2.15-2.60 mmol/l 
Urea and electrolytes (U+E) 
Sodium (Na+) 135-146 mmol/l 
Potassium (K+) 3.5-5.0 mmol/l 
Urea 2.9-7.1 mmol/l 
Creatinine (Creat) 40-90 μmol/l 
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Appendix 21 – Blood and urine tests by BNHFT laboratory 
Blood and urine tests performed by BNHFT laboratory 
Parameter Reference range Analyser Supplier 
Haematology 
Full blood count (FBC) 
Siemens Advia 2120 
Siemens Healthcare 
Diagnostics Inc. 
511 Benedict 
Avenue/Tarrytown, NY 
10591, 
USA 
 
Haemoglobin (Hb) 110-165 g/l 
White cell count (WCC) 4.0-11.0 x109/l 
Platelets (Plats) 150-500 x109/l 
Mean cell volume (MCV) 79-98 fl 
Neutrophils (Neut) 1.5-8 x109/l 
Eosinophils (Eosin) 0-0.8 x109/l 
Monocytes (Mono) 0.2-0.8 x109/l 
Clotting  
International 
normalised ratio (INR) 
0.8-1.2 
Diagnostica Stago – 
Destiny Max 
Diagnostica Stago UK Ltd, 
2 Theale Lakes Business 
Park, 
Moulden Way, 
Theale, 
RG7 4GB, 
UK 
Activated partial 
thromboplastin time 
(APTT) 
25.4-34.6s 
D-dimer 0-0.5 mg/l 
Fibrinogen 1.5-4 g/l 
Immunology 
Immunoglobulin E (IgE) Tested at PHT – see above 
Biochemistry 
C-reactive protein (CRP) <2 mg/l 
Siemens Advia 2400 
Siemens Healthcare 
Diagsnostics Inc. 
511 Benedict 
Avenue/Tarrytown, NY 
10591, 
USA 
Serum glucose (Gluc) 3.8-6 mmol/l 
Random urine 
creatinine (Urine creat) 
mmol/l 
Liver function tests (LFT) 
Bilirubin (Bili) 0-17 μmol/l 
Alkaline phosphatase 
(ALP) 
35-110 iu/l 
Alanine transaminase 
(ALT) 
0-60 iu/l 
Bone profile 
Albumin (Alb) 32-48 g/l 
Adjusted calcium 
(adjCa2+) 
2.12-2.62 mmol/l 
Urea and electrolytes (U+E) 
Sodium (Na+) 134-147 mmol/l 
Potassium (K+) 3.5-5 mmol/l 
Urea 2.6-6 mmol/l 
Creatinine (Creat) 62-124 μmol/l 
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Appendix 22 – TMB substrate solution for plasma ELISA 
Substrate buffer = 1.5g sodium acetate dissolved in 80ml de-ionised H2O, adjusted 
to pH 5.5 with glacial acetic acid.  Made up to 100ml with de-ionised H2O then 
refrigerate for up to 2 weeks at 4oc 
Tetramethylbenzidine (TMB) stock solution = 30mg TMB dissolved in 5ml DMSO, 
store up to 1 month at room temperature protected from sunlight 
Substrate solution (for each 96 well plate) = 12ml substrate buffer + 200μl TMB 
stock solution + 1.2μl H2O2 30% solution 
 
Appendix 23 – Sample standard curves 
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Appendix 24 – UPR16 
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